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ABSTRACT 
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to 
mediate VEGFR2 expression in breast cancer cells 
Neil Thomas Pfister 
 
 
 Mutant p53 impacts the expression of numerous genes at the level of 
transcription to mediate oncogenesis. To investigate how mutant p53 impacts 
transcription, we studied how mutant p53 regulates vascular endothelial growth 
factor receptor 2 (VEGFR2), one of its strongest target genes that we identified 
through global gene expression profiling in mutant p53-expressing MDA-468 
breast cancer cells. VEGFR2, the primary functional VEGF receptor and clinical 
target of bevacizumab, mediates endothelial cell neovascularization by promoting 
increased cellular proliferation, migration, and pro-survival signaling. In breast 
tumors, VEGFR2 is often aberrantly expressed on the breast tumor epithelia, 
which correlates with worse overall survival. 
 We identify VEGFR2 as a mutant p53 transcriptional target in multiple 
breast cancer cell lines. Mutant p53-mediated upregulation of VEGFR2 mediates 
mutant 53 gain of function including increased cellular growth and migration. In 
humans, breast tumors with TP53 hotspot mutants have elevated VEGFR2 levels 
compared to tumors with loss of function mutations. The same class of tumors has 
significantly upregulated HIF1A and VEGFA compared to TP53 wild-type tumors, 
indicating that mutant p53-containing breast tumors express a neoangiogenic 
gene signature that may intensify VEGFR2 autocrine signaling. A clinical trial 
suggests that TP53 mutated breast tumors may specifically respond to anti-VEGF 
therapy, while TP53 wild-type tumors may not respond. We suggest that mutant 
p53-containing breast tumors may be distinctively vulnerable to anti-VEGF 
therapies. 
 We investigated how mutant p53 impacts transcription of VEGFR2 using 
multiple techniques including scanning ChIP, micrococcal nuclease-PCR, and in 
vivo DNase I footprinting by ligation mediated PCR. Mutant p53 was found to bind 
near the VEGFR2 transcriptional start site, causing the promoter to adopt a 
transcriptionally active conformation. Using SILAC mass spectrometry, we 
identified subunits of the SWI/SNF chromatin remodeling complex as mutant p53 
interactors. Importantly, re-ChIP and immunodepletion ChIP demonstrate that 
mutant p53 and SWI/SNF co-occupy the VEGFR2 promoter. Depletion of multiple 
SWI/SNF subunits reduced VEGFR2 RNA expression, and SWI/SNF is required 
for maximal mutant p53 promoter occupancy.  
Using RNA sequencing, we report that approximately half of all mutant p53 
gene alteration requires the SWI/SNF complex. We surmise that mutant p53 
impacts transcription of VEGFR2 as well as myriad other target genes by promoter 
remodeling through interaction with the SWI/SNF chromatin remodeling complex. 
Therefore, not only might mutant p53 expressing tumors be uniquely susceptible 
to anti-VEGF therapies, but restoration of SWI/SNF tumor suppressor function by 
targeting mutant p53 may have therapeutic potential. Mutant p53 interaction with 
the SWI/SNF complex may explain how mutant p53 modulates the expression of 
such a diverse set of genes.  
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 TP53 is the most frequently mutated gene found in human cancers (Olivier et al., 
2010). Wild-type p53 is a sequence-specific transcription factor that when activated by 
various stresses such as DNA damage, oncogenic signaling or nutrient depletion, 
promotes cellular outcomes such as cell arrest, cell death, senescence, metabolic 
changes and others, depending on the extent and context of the stress (Vousden and 
Prives, 2009). In human cancer, p53 primarily sustains missense mutations in its 
conserved DNA binding domain. The small number of residues (~5-6) within this region 
that are mutated with extraordinarily high frequency are termed hotspot mutations. 
These mutations can be loosely divided into two categories, the contact mutants (e.g. 
R273H), which remain well folded but whose mutated residues fail to make specific 
contact with elements within the DNA binding site and conformational mutants (e.g. 
R175H) that are partly unfolded leading to loss of zinc coordination and general DNA 
binding. Evidence from sources as varied as human epidemiology studies, mouse 
models and cell-based experiments has shown that these hotspot missense mutant 
forms of p53, which often accumulate to high levels in the cells they inhabit, can acquire 
neomorphic properties such as increased metastases in mice and increased motility 
and invasive characteristics in cultured cells (Brosh and Rotter, 2009; Muller and 
Vousden, 2014). In Li-Fraumeni, patients missense mutation was reported to lead to 
earlier tumor onset than other forms of p53 loss (Bougeard et al., 2008). p53 hotspot 
mutant proteins have been reported to associate with chromatin and alter a cell’s 
transcriptional profile, leading to oncogenic cellular changes (Cooks et al., 2013; Di 
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Agostino et al., 2006; Do et al., 2012; Freed-Pastor et al., 2012; Stambolsky et al., 
2010). 
 
p53 Background and Discovery 
p53 was initially identified as a cellular oncogene that cooperates with simian 
virus 40 or H-Ras to transform cells (DeLeo et al., 1979; Eliyahu et al., 1984; Hinds et 
al., 1989; Lane and Crawford, 1979; Linzer and Levine, 1979; Parada et al., 1984). 
Histology supported the hypothesis that p53 is an oncogene, as high levels of p53 are 
observed in transformed cells while low levels of p53 are observed in normal tissues 
(Bartek et al., 1990a; Cattoretti et al., 1988; Rotter, 1983). However, p53 was soon 
identified as a tumor suppressor. Consistent with a tumor suppressor, the 17p13.1 
chromosomal region containing the TP53 gene is frequently lost in tumors that contain 
point mutations in the other allele (Baker et al., 1989; Baker et al., 1990; Nigro et al., 
1989). Mutant p53 is a dominant-negative inhibitor of wild-type p53 (Kern et al., 1992), 
and wild-type p53 confers G1 checkpoint control to cells lacking functional p53 (Yin et 
al., 1992) in a dose-dependent manner (Chen et al., 1996), which is mediated by p21 
(Waldman et al., 1995). Mechanistically, wild-type p53 binds DNA in a sequence-
specific manner to mediate its functions while mutant p53 fails to bind to a consensus 
sequence (Bargonetti et al., 1991; Bargonetti et al., 1993; el-Deiry et al., 1992; Funk et 
al., 1992; Kern et al., 1991b). Critically, p53 null mice are more tumor-prone than mice 
with wild-type p53, establishing p53 as a tumor suppressor (Donehower et al., 1992). 
These data provided a framework to understand Li-Fraumeni syndrome, where germline 
mutations in TP53 predispose affected individuals to breast cancer, sarcomas, 
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lymphomas, and other neoplasms (Malkin et al., 1990; Srivastava et al., 1990; Varley et 
al., 1997; Wong et al., 2006).  
 
TP53 Mutations in Human Cancers  
TP53 mutations are observed in nearly every type of human cancer with a wide 
range of frequencies ranging from approximately 1% in papillary thyroid cancer to 95% 
in serous ovarian cancer (Figure 1.1). TP53 is interesting for a tumor suppressor in that 
does not frequently sustain deletions (Figure 1.1). Instead, TP53 primarily sustains 
various other types of mutations, the most frequent of which are missense mutations in 
the p53 DNA binding domain (see Figure 1.2 for a specific example with breast cancer). 
Different datasets may have varying frequencies for TP53 mutation within the same 
cancer type. In breast cancer, published TP53 mutation rates range from 27.2% for 
breast cancers unstratified by subtype (Banerji et al., 2012) to 53.8% (35/65 samples) in 
triple negative breast cancer (Shah et al., 2012). The most comprehensive datasets 
report between 31.7% and 38.2% for two breast cancer TCGA datasets (Figure 1.1; 
Network, 2012). TP53 mutation is an independent prognostic indicator (correlating with 
worse prognosis) in breast cancer (Olivier et al., 2006; Petitjean et al., 2007a), lung 
cancer (Ahrendt et al., 2003), and with certain hotspot mutations in colon cancer 
(Samowitz et al., 2002). TP53 mutations occur at multiple stages in the progression of a 
tumor, and the stage in which TP53 mutation occurs may affect the malignancy of the 





Essential Selective Advantages of TP53 Mutations in Tumors 
TP53 is most frequently mutated in its DNA binding domain as mutations in this 
domain preclude interaction of p53 with its consensus DNA binding sequence (Kern et 
al., 1991a). The p53 consensus sequence is a feature in the promoter of canonical p53 
target genes such as MDM2 (Barak et al., 1993; Juven et al., 1993), NOXA (Oda et al., 
2000), PUMA (Nakano and Vousden, 2001), and p21 (CDKN1A)(el-Deiry et al., 1993). 
Abrogation of DNA binding by mutation in the p53 DNA binding domain (Kern et al., 
1991a) dysregulates the induction of p53-mediated cellular arrest (through p21) and 
apoptosis (through PUMA and NOXA), and leads to the accumulation of elevated levels 
of the mutant form of p53 in part due to the impairment of inducing p53’s primary 
negative regulator, the E3 ubiquitin ligase MDM2 (reviewed in Freed-Pastor and Prives, 
2012) . Loss of p53 function enables a cell to evade cell arrest mechanisms that would 
allow adequate repair of damaged DNA and allow a cell to evade apoptosis, which 
would have eliminated a cell that sustained DNA damage. Hence, abrogation in p53 
function is a critical step in oncogenesis (reviewed in Vousden and Prives, 2009). 
Indeed, even when TP53 is not directly affected, its negative regulators MDM2 and 
MDMX are often overexpressed (reviewed in Toledo and Wahl, 2006).  
It should be considered that deletion of part or all of the chromosome 17p arm is 
an understudied mechanism of p53 loss of function. Chromosome 17p deletions (the 
TP53 gene resides at chromosome 17p13.1 between base pairs chr17: 7,571,720 bp to 
7,590,868 bp of the hg19 assembly) are a frequent occurrence in a variety of cancers, 
including in around 75% of colorectal cancers (Vogelstein et al., 1988), which may 
account for a significant additional mechanism of loss of TP53 from a cell. A cell with a 
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17p deletion is not necessarily annotated to have a mutation in TP53, for instance. In 
addition to colorectal cancer, 17p loss has been reported in sarcomas (Mulligan et al., 
1990), primitive neuroectodermal tumors of childhood (Raffel et al., 1990), bladder 
cancer (Tsai et al., 1990), breast cancer (Mackay et al., 1988), and lung cancer (Yokota 
et al., 1987). While 17p loss of the homologous chromosome is known to occur 
following mutation in TP53 (Baker et al., 1989; Baker et al., 1990; Nigro et al., 1989), it 
should be appreciated that chromosome 17p alteration will invariably impact TP53 
status.  
 
TP53 Hotspot Mutations 
The spectrum of TP53 mutations is evidence for an oncogenic role of TP53 
mutations in promoting tumorigenesis. Six codons have been designated as ‘hotspots’ 
due to increased selection for these mutants: codons 175, 196, 213, 248, 273, and 282 
(Hollstein et al., 1991). Each of these codons occurs within the DNA binding domain of 
p53, the location of the overwhelming majority of p53 mutations, with no significant 
selection for mutations outside this domain (Petitjean et al., 2007a; Soussi et al., 2005). 
p53 hotspot mutants are classified as either a DNA contact mutant (eg: codon R248, 
codon R273) or a conformational mutant (eg: codon R175, codon G245) based on the 
mechanism of alteration of the DNA binding domain, with conformational mutants being 
more structurally abnormal, and each class leading to abrogation of sequence-specific 
DNA binding (Bartek et al., 1990b; Cho et al., 1994; Gannon et al., 1990; Legros et al., 




p53 in Breast Cancer 
As noted above, TP53 mutation in breast cancer occurs with an average 
frequency among human cancers, with reported mutation rates ranging from between 
27.2% for breast cancers unstratified by subtype (Banerji et al., 2012) to 53.8% (35/65 
samples) in triple negative breast cancer (Shah et al., 2012), with larger studies 
reporting TP53 mutation rates of around 32-38% (See Figure 1.1; Network, 2012). 
Mutations of p53 in breast cancer result in a point mutation in approximately 80% of 
cases, with a lower than expected ratio of nonsense, insertion, or deletion mutations 
(see Figure 1.2; Petitjean et al., 2007b). In breast cancer, somatic mutations occur in 
similar codon positions as in other tumors with a key difference being an increased 
frequency of mutations in residue Y220 (reviewed in Walerych et al., 2012). Another 
difference in the TP53 mutation spectrum in breast cancer is that codon R213, which is 
often a missense mutations in other cancers, frequently results in a nonsense mutation 
in breast cancer. For instance, in the TCGA Provisional dataset (accessed at 
www.cbioportal.org), mutation in R213 results in a nonsense mutation in 7 out of 7 
instances (also compare Figure 1.2 vs. Figure 1.3 for R213 from the IARC dataset). The 
R213>stop codon mutation has been previously reported in ovarian cancer (Schuyer et 
al., 1998), so there may be a similarity in the mechanism of R213 nonsense mutations 
between breast and ovarian cancer.  
Overall, R175, Y220, G245, R248, and R273 are the most frequently mutated 
residues in breast cancer that cause missense mutations and therefore should be 
considered hotspot mutations (see Figure 1.3; Feki and Irminger-Finger, 2004; 
Walerych et al., 2012). These genetic alterations are especially important to understand 
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in breast cancer, where it is clear that TP53 mutation significantly reduces overall 
survival (Elledge et al., 1993; Langerod et al., 2007). In breast cancer, specific TP53 
missense mutations are associated with worse outcomes (Alsner et al., 2008; Olivier et 
al., 2006; Petitjean et al., 2007a), and p53 missense mutants predicted to affect DNA 
binding confer worse survival than p53 null mutations (Alsner et al., 2008). 
 
Considerations for Mutant p53 Therapeutics in Breast Cancer 
p53 Y220C (Basse et al., 2010), in addition to the more well documented p53 
R175H mutation (Brown et al., 2011; Bykov et al., 2002; Goldstein et al., 2011; Muller 
and Vousden, 2014; Olivier et al., 2009), have been prime targets for mutant p53 
pharmacologics to ‘re-fold’ conformational mutants of p53 into a wild-type p53 
conformation that may be restored in tumor suppressive activities (reviewed in Muller 
and Vousden, 2014). The Y220C mutation (the most frequent mutation in this residue) 
is thermodynamically unstable (Bullock et al., 2000) and has been reported to retain 
some wild-type p53 activities such as binding to p21 promoter sequences and 
transcactivating a p21-containing promoter sequence at sub-physiological temperatures 
(Di Como and Prives, 1998). However, Y220C failed to transactivate the p21 reporter 
construct at physiological temperatures, suggesting that the Y220C mutant may be 
inactive in most tumor environments (Di Como and Prives, 1998). It is unlikely that 
DNA-contact mutants (mutations in R248, R273, R280) are candidates for reactivation 
of wild-type p53 function because the amino acids that interact with the p53 response 
element are altered. For the p53 contact mutants, other approaches (such as disrupting 
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mutant p53 interaction with a core transcriptional coactivator) may be feasible in the 
future. 
 
p53 Domain Structure 
This section describes the polypeptide structure of p53 with an emphasis on how 
the tertiary structure of p53 may be manipulated to investigate mutant p53 function. 
Structurally, p53 is composed of a bipartite N-terminal transactivation domain, a proline-
rich domain, a central DNA-binding domain, an oligomerization domain, and a C-
terminal regulatory domain (Figure 1.3; Joerger and Fersht, 2008). p53 is a dimer of 
dimers, composed of a dimer (formed with interactions within the DNA binding domain 
of the L2 and L3 loops) that homo-dimerizes through hydrophobic interactions between 
leucines 344 and 348 in the oligomerization domain to form the functional p53 tetramer 
(Jeffrey et al., 1995; Joerger and Fersht, 2008). The p53 protein is thus approximately 
200 kDa as a tetramer, which allows for four distinct binding sites for binding partners 
within each tetramer. 
The N-terminal transactivation domain is subdivided into two subdomains, TAD1 
within the first 40 amino acids and TAD2 within amino acids 41-61 (Chang et al., 1995; 
Walker and Levine, 1996). TAD1 functionally requires residues 22 (leucine) and 23 
(tryptophan) and TAD2 functionally requires residues 53 (tryptophan) and 54 
(phenylalanine). These residues can be mutated to polar amino acids (mTAD1 into 
L22Q/W23S and mTAD2 into W53Q/F54S), leading to abrogation or reduction in p53 
transactivation of many target genes (Candau et al., 1997; Lin et al., 1994; Lin et al., 
1995; Venot et al., 1999; Yan and Chen, 2010; Zhu et al., 1998). The proline-rich 
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domain (PRD, amino acids 64 to 92) is likely necessary for mutant p53 conformation as 
the Pin1 prolyl isomerase is required for optimal mutant p53 function (Girardini et al., 
2011), and this domain can be deleted to study PRD-dependent effects (Yan and Chen, 
2010). The carboxy-terminal regulatory domain (CTD, approximately residues 363 to 
393) has been shown to be necessary for certain mutant p53 target gene activation but 
dispensable or even inhibitory for mutant p53 pro-proliferation phenotypes, and this 
domain can be deleted to study CTD-dependent effects (Frazier et al., 1998; Yan and 
Chen, 2010).  
The N- and C-termini of p53 are involved in the majority of described protein-
protein interactions with p53 (Vousden and Prives, 2009). Additional specific interaction 
partners will be described in later sections. The CTD and oligimerization domain (OD, 
residues 326-356) are required for wild-type p53 interaction with Sp1 and Sp3 (Kamada 
et al., 2011; Koutsodontis et al., 2005). The CTD contains numerous lysines that are 
modified to regulate p53, and these residues can be mutated to investigate mutant p53 
CTD interactions with other proteins. TAD-independent mutant p53 interactions are 
thought to depend largely on p63 or p73 interaction, likely through the CTD, while the 
TAD-dependent functions are thought to depend on transcription factor interaction 
(Oren and Rotter, 2010). Indeed, specific mutant p53 domains are either required or 
dispensible to mutant p53 target gene activation, and the mechanisms of this regulation 
are incompletely defined (Table 1.1). It is imperative to investigate domain-specific p53 
interactions in order to understand mechanistically how p53 regulates various genes as 




Transcriptional Activation by Wild-Type p53 
 The following section describes the most well understood mechanisms of how 
wild-type p53 initiates transcription at genes containing a p53 response element 
(reviewed in Beckerman and Prives, 2010). It must be stated from the outset that the 
precise mechanisms in which p53 initiates transcription at its target genes are 
incompletely understood and undoubtedly more complex than will be discussed in this 
section. The basic model for activation of a p53 target gene from promoter engagement 
through transcription initiation occurs in two distinct phases: (1) p53 recognition and 
association with its DNA response element followed by (2) recruitment of transcriptional 
modifiers that culminate in the formation of the RNA polymerase II preinitiation complex 
(Laptenko and Prives, 2006). This section will focus on select p53-mediated 
transcriptional activation mechanisms that ostensibly occur following p53 binding to 
DNA. 
p53 mediates gene expression changes through complex interaction with 
multiple chromatin regulators (Laptenko and Prives, 2006). The potential for complex 
gene activation or regulatory mechanisms is especially complex when the tetrameric 
structure of p53 is considered. The functional p53 protein composed of four identical 
monomers allows for four distinct binding sites for binding partners within each tetramer. 
This allows for a high degree of complexity in the regulation of transcription, as a single 
tetramer could bind to multiple transcriptional modifiers at its N- or C-termini (or with its 
DNA binding domain); a single p53 tetramer could theoretically bind to four different 
transcriptional modifiers at a single binding site in its N-termini, for instance. 
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 p53 preferentially associates with genomic regions with a high degree of 
nucleosomal occupancy (Lidor Nili et al., 2010). Increased DNase I cleavage (termed 
hypersensitivity) is a hallmark of active genes, corresponding to an open promoter 
configuration in which nucleosomes are not present (reviewed in Krebs and Peterson, 
2000). DNase I hypersensitivity is a feature of multiple wild-type p53 target gene 
promoters including p21 (CDKN1A)(Braastad et al., 2003). Interestingly, the p53 binding 
site within these promoters occurs in regions that are resistant to DNase I (Braastad et 
al., 2003). These genomic regions where p53 is bound undergo nucleosomal 
displacement, which is specific to p53 recruitment as the nucleosomal displacement is 
reversible upon p53 inactivation using a temperature-sensitive p53 mutant (Lidor Nili et 
al., 2010).  
At the p21 promoter, which is the best studied p53 responsive gene, both distal 
and proximal p53 response elements contain high levels of nucleosomal occupancy 
(Laptenko et al., 2011). Upon p53 activation, nucleosomal occupancy is rapidly lost, for 
which it was predicted that two nucleosomes at the distal (5’) response element are 
displaced upon p53 activation (Laptenko et al., 2011). Nucleosomal displacement is 
most likely to occur subsequent to p53 DNA binding as it is unlikely that the alternative - 
that nucleosomes and p53 compete for the same site - occurs, especially considering 
that p53 can bind to its response element while the response element is engaged by a 
nucleosome (Laptenko et al., 2011). Interestingly, the ability of p53 to bend DNA within 
the p53-DNA complex is directly correlated with the stability of the p53-DNA interaction 
(Nagaich et al., 1997). It is conceivable that the intrinsic sequence of the p53 response 
element (which dictates the degree of DNA bending upon p53 activation) facilitates 
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nucleosomal repositioning and impacts subsequent steps in transcriptional activation 
and resetting of the promoter (promoter turnover)(Laptenko and Prives, 2006; Nagaich 
et al., 1997). As mutant p53 does not bind to DNA in a stable manner like wild-type p53, 
these steps of transcriptional activation likely differ.  
As summarized above, it is a common feature that p53 target gene promoters 
are in nucleosomal-enriched sites that undergo nucleosomsal remodeling following p53 
recruitment (Laptenko et al., 2011; Lidor Nili et al., 2010). p53 has been reported to 
cooperate with nucleosomal remodeling complexes including the Mi-2/NuRD complex 
(Luo et al., 2000) and multiple members of the SWI/SNF chromatin remodeling complex 
(discussed below; Lee et al., 2002). p53 has not yet been described to function with the 
INO80, SWR, or ISWI families of chromatin remodeling complexes.  
The Mi-2/NuRD complex is interesting because a component of this complex, 
PID (also known as metastasis-associated protein 2, MTA2), significantly restricts a p53 
response by preventing acetylation of p53. The Mi-2/NuRD complex is an atypical 
chromatin remodeling complex in that it has both histone deacetylase and chromatin 
remodeling activities in the same complex (Denslow and Wade, 2007). The Mi-2/NuRD 
complex is composed of the HDAC1 and HDAC2 histone deacetylases and the CHD3 
(Mi-2α) and CHD4 (Mi-2β) chromatin remodeling components, among other proteins 
(Denslow and Wade, 2007). The CHD3 and CHD4 ATPases are chromodomain-
containing proteins in the SNF2 family of proteins, which includes the SWI/SNF 
ATPases BRG1 and BRM (Denslow and Wade, 2007; Eisen et al., 1995; Woodage et 
al., 1997). The PID component of the Mi-2/NuRD complex binds to the p53 N-terminus 
between amino acids 1-80, and binding is abolished when the first transactivation 
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domain of p53 (amino acids 22, 23) is inactivated (Luo et al., 2000). This finding is 
further interesting because theoretically the Mi-2/NuRD complex could be recruited by 
p53 to remodel chromatin and then deacetylate p53 to terminate the p53 transcription 
activation cycle.  
p53 is known to direct transcription through interaction with the Mediator complex 
(Meyer et al., 2010; Zhang et al., 2005). The Mediator complex, initially identified in 
yeast (Kim et al., 1994) and later identified in humans as a group of thyroid hormone 
receptor associated-proteins (TRAPs), functions as a gene-specific transcriptional 
coactivator for RNA polymerase II (Fondell et al., 1996). The pre-initiation complex is 
composed of RNA polymerase II, the Mediator complex, and the general transcription 
factors TFII-A, -B, -D, -E, -F, and -H (Esnault et al., 2008; Roeder, 1996). The human 
Mediator complex interacts directly with TFIID in the process of forming the pre-initiation 
complex (Johnson et al., 2002). In yeast, Med11 is required to recruit TFIIH and TFIIE 
to the pre-initiation complex that leads to serine 5 phosphorylation of the RNA Pol II 
CTD (Esnault et al., 2008). Mediator has also been described to interact directly with the 
unmodified RNA Pol II CTD, which causes the Mediator complex to adopt a specific 
CTD-bound conformation (Naar et al., 2002). p53 has been reported to interact with 
various Mediator components (Gu et al., 1999), including Med17 (TRAP80)(Ito et al., 
1999) and Med1 (RB18A)(Drane et al., 1997; Meyer et al., 2010). Med17 interacts with 
p53 TAD1 (Ito et al., 1999) and Med1 interacts with the p53 CTD (mapped to residues 
363-393)(Meyer et al., 2010). Interestingly, increasing titrations of Med1 lead to 
decreased p53-dependent p21 expression and increased p53-dependent Bax 
expression (Frade et al., 2000) and increased MDM2 expression (Frade et al., 2002). 
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Notably, the D5 domain of Med1 has been reported to interact with mutant p53 in Raji 
lymphoma cells (R213Q, Y234H), although this interaction has not been reviewed by 
the mutant p53 literature nor subsequently reported on through this point in time (Lottin-
Divoux et al., 2005). 
Arginine methyltransferaes PRMT1 and CARM1 have been implicated in p53 
transcriptional activation (An et al., 2004). PRMT1 and CARM1 bind directly to the p53 
N-terminus in a region encompassing TAD1 and cooperate with p300 to stimulate 
transcription of the p53 target gene GADD45A (An et al., 2004). Histone methylation 
marks may serve dual roles to recruit co-activators that recognize those sequences and 
by indirectly enhancing acetylation by blocking histone deacetylases (Nishioka et al., 
2002) including the NuRD complex (Zegerman et al., 2002). PRMT1 has been 
described to modify histones in a manner that permits them to be subsequently modified 
to transcriptionally active modification modes (Huang et al., 2005), and PRMT1 is 
known to cooperate with CARM1 to mediate gene expression (Hassa et al., 2008). 
The N-terminus of p53 (involving the transactivation domain residues 22 and 23) 
interacts with p300 (Gu et al., 1997). p300 is a histone acetyltransferase that serves to 
regulate p53 through direct acetylation (Avantaggiati et al., 1997; Gu and Roeder, 1997; 
Lill et al., 1997). Acetylation of the p53 CTD correlates with increased acetylation of 
histones H3/H4 and increases the interaction of p53 with p300 as well as with the 
TAF10 subunit of TFIID (Barlev et al., 2001). Interestingly, at the p21 promoter it has 
been reported that p300 does not function in transcriptional co-activation through 
acetylation of p53 (Espinosa and Emerson, 2001). Rather, p53 was found to recruit 
p300 in order to acetylate nucleosomal histones to mediate transcriptional activation 
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(Espinosa and Emerson, 2001; see also An et al., 2004). Histone acetylation marks are 
known activating marks for other transcriptional components including SWI/SNF 
(Agalioti et al., 2002), which functions in an ATP-dependent manner to reorganize 
chromatin to allow the binding of transcription factors (Kwon et al., 1994).  
It can be surmised that at the p21 locus p53 binds to its response element, 
recruits p300 which acetylates key histone residues, which stimulates SWI/SNF 
recruitment and subsequent nucleosomal repositioning to facilitate the recruitment of 
other transcriptional components that culminate in the formation of the RNA pol II pre-
initiation complex. While this is a simplified model, these key ideas - specifically, that 
wild-type p53 binds to its response element, recruits chromatin modifying proteins that 
modify both p53 and neighboring histones and chromatin-associated proteins to 
stimulate subsequent transcriptional processes such as additional co-activator 
recruitment - will serve as a guide to understand mutant p53 gain of function whereby 
one of the most critical actions of mutant p53 may be the recruitment of transcriptional 
regulators to specific promoters to impact transcription.  
 
Mutant p53 Gain of Function 
 The initial reports that p53 is an oncogene are not entirely misleading as it is now 
firmly established that there is a pro-oncogenic gain of function role for mutant p53. Li-
Fraumeni patients with missense mutations are associated with a 9-year earlier tumor 
onset than patients with other mechanisms of p53 haploinsufficiency (Bougeard et al., 
2008). Mice engineered with haploinsufficient mutant p53 (p53+/mut) have accelerated 
tumor growth, increased tumor count, altered tumor spectrum, and increased 
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metastases than mice with true haploinsufficiency (p53+/-)(Caulin et al., 2007; Dittmer et 
al., 1993; Lang et al., 2004; Liu et al., 2000; Olive et al., 2004). Critically, p53mut/- mice 
spontaneously acquire a variety of additional carcinomas in addition to the normal 
tumors associated with p53-/- mice, defining an in vivo gain of function phenotype for 
mutant p53 (Olive et al., 2004).  
It is generally appreciated that the majority of mutant p53 gain of function effects 
derive from the ability of mutant p53 to affect transcription of a variety of genes. Indeed, 
mutant p53 transcriptional effects have been shown to lead to increased cell 
proliferation, decreased apoptosis, increased migration, increased invasion through 
Matrigel, increased tumor inflammation, and increased metastases (Adorno et al., 2009; 
Bossi et al., 2006; Bossi et al., 2008; Freed-Pastor et al., 2012; Haupt et al., 2009; 
Hsiao et al., 1994; Lim et al., 2009; Muller et al., 2009; Muller et al., 2013; Preuss et al., 
2000; Scian et al., 2005; Strano et al., 2002; Werner et al., 1996; Yan and Chen, 2009; 
Yan et al., 2008). These studies will be described below.  
In mouse models, mutant p53 is associated with increased rates of metastasis 
(Adorno et al., 2009; Heinlein et al., 2008; Hsiao et al., 1994; Pohl et al., 1988; 
Weissmueller et al., 2014). This effect was initially identified in 1988 (Pohl et al., 1988) 
and was defined to be missense mutant specific in 1994 by utilizing xenotransplants of 
leukemia cells expressing different missense p53 mutations (Hsiao et al., 1994). 
Leukemia cells (Be-13 cells) expressing p53 R175H, R248Q, and R213Q were able to 
disseminate to distant sites and induce further hematological disease, while the same 
cells expressing Y234H and R273C were unable to metastasize (Hsiao et al., 1994). 
The missense mutations that resulted in disseminated disease correlated with 
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decreased survival, and these mice underwent rapid death following the mutant p53-
mediated metastases (Hsiao et al., 1994). In a mouse model of invasive breast cancer, 
the mouse equivalent of p53 R273H (R270H) has also been found to increase the rate 
of lung metastasis (Heinlein et al., 2008). 
Two more recent studies describe how mutant p53 impedes p63 (Adorno et al., 
2009) or p73 function to promote metastasis (Weissmueller et al., 2014). Contact 
mutant p53 R280K (endogenously expressed in MDA-231 breast cancer cells) were 
studied in xenotransplants. 21 out of 22 mice with unaltered levels of mutant p53 had 
lymph node positivity, while 12 out of 22 mice exhibited lymph node positivity when 
mutant p53 was depleted (Adorno et al., 2009). This correlated with the number of 
micrometastases to the lung, as depletion of mutant p53 resulted in 75-90% (depending 
on the clone) reduction in micrometastases (Adorno et al., 2009). Furthermore, when 
R175H was overexpressed in the presence of depleted R280K, the number of lung 
micrometastases was rescued to normal levels (Adorno et al., 2009). This study further 
describes how Smad3 (a component of TGFβ signaling) cooperates with mutant p53 to 
oppose p63 action (which impedes metastatic spread to the lung)(Adorno et al., 2009). 
A second study defined how a p73/NF-Y complex repressed PDGFRβ expression in a 
mouse model of pancreatic cancer (Weissmueller et al., 2014). Pancreatic cancer cell 
lines were derived from mice engineered with the mouse equivalent of p53 R175H 
(R172H). These cell lines have been previously defined and also express constitutively 
active K-Ras under tissue specific control (Hingorani et al., 2005). These cells were 
analyzed in the presence and absence of p53 R172H. Following orthotopic injection into 
the pancreas, metastasis to the lung and liver were significantly reduced when mutant 
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p53 was depleted (Weissmueller et al., 2014). Mutant p53 interaction with p73 was 
found to inhibit p73 interaction with NF-YB, allowing NF-Y to activate PDGFRβ 
expression that is critical to the metastatic phenotype of mutant p53 in these cells 
(Weissmueller et al., 2014). Hence, it is well established that mutant p53 promotes 
metastasis in mouse models, which is consistent with the observations that mutant p53 
correlates with worse survival in human cancers (Alsner et al., 2008; Elledge et al., 
1993; Langerod et al., 2007; Olivier et al., 2006; Petitjean et al., 2007a) 
Hotspot p53 mutants have been reported to contribute to inflammation-
associated colorectal cancer by cooperation with NF-κB to affect inflammation-
associated genes (Cooks et al., 2013). This observation was especially interesting 
because mutant p53 is documented to affect the expression of genes in the NF-κB 
pathway that lead to increased cell growth and survival (Scian et al., 2005), not to say 
much about the multifaceted role of inflammation in cancer (reviewed in Grivennikov et 
al., 2010). Hotspot mutations of p53 are also well documented to lead to increased cell 
proliferation, (Bossi et al., 2006; Bossi et al., 2008; Freed-Pastor et al., 2012; Haupt et 
al., 2009; Preuss et al., 2000; Scian et al., 2004; Strano et al., 2002; Yan and Chen, 
2009; Yan et al., 2008), resistance to apoptosis (Bossi et al., 2008; Lim et al., 2009) 
which can be mediated through mutant p53 interaction with Ets-2 (Do et al., 2012), 
increased migration (Adorno et al., 2009; Weissmueller et al., 2014), and increased 
cellular invasion through Matrigel (Muller et al., 2009; Muller et al., 2013).  
These studies identify a variety of mechanisms through which mutant p53 
promotes oncogenesis. As each tumor is unique in its development, it should be 
considered at this point that mutant p53 may be a promiscuous transcription factor that 
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is utilized by the tumor cell - based on its specific mutations, dominant signaling 
pathways, and interaction with the microenvironment - in a manner that is selectively 
advantageous. The next section will summarize what is known about mutant p53-
mediated transcription with a focus on specific mutant p53 interacting partners and 
transcriptional targets. 
 
Transcriptional Activation by Mutant p53 
It remains to be understood how mutant p53 mechanistically affects transcription. 
Mutant p53 does not directly bind to a consensus DNA sequence (Bargonetti et al., 
1991; Bargonetti et al., 1993; el-Deiry et al., 1992). Rather, it is likely that mutant p53 
through its N-terminal transactivation domains or C-terminal regulatory domain 
associates with other transcription factors, histone-modifying machinery, or the 
transcription initiation complex to promote transcription (summarized in Table 1.2). Note 
that the majority of transcription factors that interact with mutant p53 also interact with 
wild-type p53.  
Mutant p53 has been demonstrated to interact with the following transcription 
factors: p53 homologues p63 and p73, Sp1, Smad2, Smad3, NF-Y, E2F1, Ets-1, Ets-2, 
and the Med1 component of the Mediator complex (see Table 1.2; Adorno et al., 2009; 
Bargonetti et al., 1997; Bensaad et al., 2003; Chicas et al., 2000; Davison et al., 1999; 
Di Agostino et al., 2008; Di Agostino et al., 2006; Do et al., 2012; Fontemaggi et al., 
2009; Frazier et al., 1998; Gaiddon et al., 2001; Lee et al., 2000; Lottin-Divoux et al., 
2005; Marin et al., 2000; Sampath et al., 2001; Strano et al., 2002; Yan et al., 2008). It 
is presumed that mutant p53 depends on these interactions (and others not yet 
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identified) to mediate the transcription of numerous genes to mediate its gain of function 
effects. A list of mutant p53-regulated genes is provided in Table 1.3.  
The list of mutant p53-regulated genes, most of which have demonstrated 
functional purpose, is extensive and includes ABCB1 (MDR)(Bush and Li, 2002; Chin et 
al., 1992; Lin et al., 1995; Sampath et al., 2001; Strauss and Haas, 1995), the GRO1 
chemokine (Yan and Chen, 2009), PCNA (Deb et al., 1992), the ID2 transcription 
regulator (Yan et al., 2008), the ID4 transcription regulator (Fontemaggi et al., 2009), 
the hsMAD1 mitotic spindle checkpoint protein (Iwanaga and Jeang, 2002), 15-
lipoxygenase (Kelavkar and Badr, 1999), the galectin-3 anti-apoptotic protein (Lavra et 
al., 2009), insulin-like growth factor II (Lee et al., 2000), insulin-like growth factor 
receptor I (Werner et al., 1996), epidermal growth factor receptor (Ludes-Meyers et al., 
1996), c-Fos (Preuss et al., 2000), NF-kappaB2 (Cooks et al., 2013; Scian et al., 2005; 
Weisz et al., 2007), c-Myc (Frazier et al., 1998), the EGR transcription factor (Weisz et 
al., 2004), mitogen-activated protein kinase kinase 3 (Gurtner et al., 2010) asparagine 
synthetase (Scian et al., 2004), human telomerase reverse transcriptase (Scian et al., 
2004), the stathmin microtubule-destabilizing protein (Singer et al., 2007), matrix 
metalloproteinase 13 (Sun et al., 2000), genes of the mevalonate pathway (Freed-
Pastor et al., 2012), as well as numerous others (Table 1.3).  
Mutant p53 regulation of these genes varies based on the specific p53 mutant 
and the cell line. Notably, many of these genes were studied by overexpressing mutant 
p53 in p53-null cell backgrounds (indicated in the table as Overexpression) and often 
with reporter assays (Table 1.3). Reporter assays are inadequate to study mutant p53-
dependent transcription because they lack the full complexity of chromatin and mutant 
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p53 does not bind to a DNA response element. Overexpressing mutant p53 in p53-null 
cell backgrounds is adequate to study mutant p53 gain of function effects because there 
is no impact of wild-type p53 yet imperfect because the cell lines underwent selective 
changes without regard to the selective advantages conferred by mutant p53. Such 
selective changes - the tumor evolving to harness and depend on mutant p53 for its pro-
proliferative or other capacities - impact how mutant p53 functions in a particular tumor. 
Therefore, we suggest that cell culture studies involving mutant p53 be performed using 
cell lines that express single point mutations in one allele of p53 and have underwent 
loss of heterozygosity (see Freed-Pastor et al., 2012 for examples). 
Tumor-specific genetic alterations, chromatin landscape, and the availability of 
specific transcription factors affect mutant p53 function (Adorno et al., 2009; Dell'Orso et 
al., 2011; Haupt et al., 2009; Kim and Deppert, 2003, 2004; Li et al., 2008; Strano et al., 
2007). It follows that one p53 mutant may be observed to behave differently than 
another p53 mutant based on changes in conformation, binding partners, cellular 
localization, and transactivation capability. Indeed, mutant p53 gain of function depends 
on cell and tumor context. Further note that there is significant evidence linking Ras-
pathway activation to enhanced mutant p53 gain of function (Solomon et al., 2012). 
Note that post-translational modifications, nucleosome state, quarter-site orientation and 
spacer length of the p53 response element, and cofactors affect wild-type p53 gene 
regulation (Riley et al., 2008). Post-translational modifications, nucleosome state, and 
cofactors likely impact mutant p53 transcription as well. 
These observations (in addition to the fact that mutant p53 does not bind to the 
p53 response element) may explain why wild-type p53 and mutant p53, despite binding 
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to many of the same transcription factors (Table 1.2) differentially affect gene 
expression. Mutant p53 can even lead to diametric outcomes of gene expression, even 
though mutant p53 can still cooperate with wild-type p53 co-activators, such as the 
histone acetyltransferase p300 (Avantaggiati et al., 1997; Di Agostino et al., 2006). For 
instance, mutant p53, when located at genes that wild-type p53 activates such as p21, 
GADD45, PERP, and PTEN, leads to their repression (Vikhanskaya et al., 2007). It is 
unclear why mutant p53 and wild-type p53 lead to diametric gene expression outcomes 
when they can interact with similar subsets of transcription factors and co-activators. 
One possibility is that wild-type p53 has interactions with the same transcription factors 
that mutant p53 binds, but when overexpressed or activated, wild-type p53 retains 
preference to its response element and therefore induces an appropriately timed, step-
wise transcriptional response while mutant p53 prevents a transcriptional response (or 
even actively suppresses a response) by being constitutively located at the gene, by 
failing to initiate a specific activation sequence, or by failing to recruit the appropriate 
transcription factors (such as by recruiting transcriptional co-repressors).  
Mutant p53 likely mediates transcription by co-opting sets of transcription factors 
to initiate gene activation at the transcription factor’s location. Co-activators recruited by 
the transcription factor or mutant p53 then stimulate gene expression. The extent that 
mutant p53 co-opts individual transcription factors for target gene activation is unclear 
and likely dependent on the specific mutation in p53 and the active cell signaling 
pathways leading to subsets of active transcription factors in the cell. It is also possible 
that mutant p53, following recruitment by a transcription factor or chromatin modulator, 
recruits additional factors that can stimulate the function of the initial recruiting factor 
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(discussed in Chapter 3). It is possible that there are mechanisms for mutant p53 to 
change the state of chromatin, and these mechanisms may rely on mutant p53 
recruitment to DNA through transcription factor binding followed by a change in 
chromatin architecture by known and unknown chromatin-modifying machinery that are 
recruited by the mutant p53-TF complex.  
Transcription factors may not need to be active to be recruited by mutant p53, 
although mutant p53 may need to be modified in a specific manner. Mutant p53 
engagement may lead to conformational change of an inactive transcription factor to a 
conformation that can bind DNA. In this mechanism, the presence of mutant p53 in a 
cell leads to transcription factor engagement by mutant p53. If these transcription 
factors were inactive and cytoplasmic, mutant p53 presence would shift their localization 
to the nucleus, forming a complex with mutant p53, the engaged transcription factor, 
and a co-activator such as p300. Indeed, cell context, perhaps through mutant p53 
modifications, can alter mutant p53-coactivator binding (Di Agostino et al., 2006). 
Promoters known to be engaged by NF-Y and mutant p53 shift from containing the 
repressive HDAC1 to the activating p300 upon DNA damage by doxorubicin (Di 
Agostino et al., 2006). Additionally, serine-6 and serine-9 phosphorylations are required 
for mutant p53-Smad binding (Adorno et al., 2009; Cordenonsi et al., 2007). Mutant p53 
contact mutants can cooperate through NF-κB signaling to increase mutant p53 target 
gene activation (Solomon et al., 2012). It should also be considered that mutant p53 
may refine transcription factor binding specificities, a process termed latent specificity (a 
cofactor-induced change in DNA recognition)(Slattery et al., 2011). 
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It must be emphasized that the mechanism of mutant p53-transcription factor and 
mutant p53-coactivator interaction is not understood, and it is these interactions 
culminating in transcriptional changes that likely represent the majority of mutant p53 
gain of function effects. To understand the mechanism of mutant p53 gain of function 
transcriptional effects, the mechanisms for mutant p53-transcription factor and mutant 
p53-coactivator (or mutant p53-chromatin regulator) interaction, culminating in gene 
expression changes, must be delineated. This will allow for investigation into the extent 
that different transcription factors function with mutant p53 by itself or coordinately with 
each other and mutant p53 to lead to gene expression changes. Moreover, novel co-
activators and co-repressors must be identified that could account for mutant p53 
transcriptional outcomes (see Chapter 3). Future drug discovery targets rely entirely on 
the previous point- if a factor is found that is required for mutant p53 gene 
transactivation, such as a novel co-activator, then a drug could be developed that would 
be highly specific for the mutant p53-coactivator complex that would only exist in cells 
expressing mutant p53 gain of function mutants. 
 
Mutant p53 Regulation of Receptor Tyrosine Kinases 
Mutant p53 has been reported to stimulate expression of multiple receptor 
tyrosine kinases and other signaling components. It is well described that receptor 
tyrosine kinases promote pro-proliferative signaling (Lemmon and Schlessinger, 2010). 
Common signaling nodes can be engaged by multiple receptor tyrosine kinases, even 
though the output is different, eg: the same signaling pathway can shift from promoting 
a differentiated state (common to normal cells) to a pro-proliferative state (Lemmon and 
26 
	  
Schlessinger, 2010; Marshall, 1995). It is conceivable that mutant p53 may affect cell 
signaling pathways to promote de-differentiation of tumor cells. Mutant p53 has been 
reported to stimulate additional receptor tyrosine kinases, including EGFR (Ludes-
Meyers et al., 1996), IGF1R (Werner et al., 1996), MET (Muller et al., 2013), and 
PDGFRβ (Weissmueller et al., 2014), all of which promote pro-proliferative signaling. 
This activation, in the case of EGFR and MET, is dependent on Rab-coupling protein, 
which increases recycling of these receptor tyrosine kinases to enhance their signaling 
outputs (Muller et al., 2009; Muller et al., 2013). It is worth considering that as a tumor 
forms, acquisition of a hotspot mutation in TP53 may facilitate transcriptional plasticity, 
whereby tumor cells increase capacity for gene expression changes and therefore 
undergo selection for the greatest pro-proliferative transcriptional program for the 
particular tumor context. This hypothesis explains, for instance, why such a wide array 
of genes and pathways has been reported to mediate mutant p53 gain of function. 
 
VEGFR2 Signaling 
The receptor tyrosine kinase VEGFR2 (KDR/FLK1) is of great clinical importance 
because it is the functional target of the humanized monoclonal antibody bevacizumab 
(Avastin®), which inhibits vascular endothelial growth factor A (VEGF) activation of 
VEGFR2 (Presta et al., 1997). Bevacizumab is approved for adjuvant use in the 
treatment of metastatic renal cell carcinoma, non-small cell lung cancer, glioblastoma 
multiforme, and metastatic colorectal cancer but in November 2011 lost FDA approval 
for the treatment of breast cancer. Despite the efficacy of bevacizumab in subsets of 
breast cancer patients, the lack of well-defined patient selection criteria meant that the 
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number needed to treat was far too high when cost and the limited side effect profile 
were considered (Bear et al., 2012; Cobleigh et al., 2003; Link et al., 2007; Miller et al., 
2007; Miller et al., 2005; Schneider et al., 2008; von Minckwitz et al., 2012; Wedam et 
al., 2006). There exists a critical demand for new knowledge to improve patient 
selection criteria for response to anti-VEGF pathway treatment, for which there are 
multiple treatments currently in phase II or III clinical trials (Saharinen et al., 2011). 
VEGFR2 is a receptor tyrosine kinase that under normal physiological conditions 
is only expressed on endothelial cells, which form the lining of blood vessels (Holmes et 
al., 2007; Millauer et al., 1993; Quinn et al., 1993; Shalaby et al., 1997; Terman et al., 
1992). Upon VEGF stimulation, VEGFR2 homo-dimerizes and trans-phosphorylates to 
initiate pro-migratory signaling to initiate endothelial cell chemotaxis toward the VEGF-
producing tissue and, once seeded, pro-proliferative signaling to promote 
neovascularization from existing blood vessels near the site (Holmes et al., 2007; 
Millauer et al., 1994; Zhang et al., 2002). Intriguingly, VEGFR2 is induced to varying 
extents on the tumor epithelium - the malignant cells - in the majority of epithelial tumor 
types, including breast, colon, lung, and kidney cancers (Guo et al., 2010; Nakopoulou 
et al., 2002; Speirs and Atkin, 1999; Wedam et al., 2006). VEGFR2 is postulated to lead 
to the same pro-migratory and pro-proliferative effects in tumor cells that occur in 
endothelial cells (Guo et al., 2010). Because malignant breast tumors invariably express 
VEGF, VEGFR2 expression on tumor epithelia led to the hypothesis of an autocrine 
loop, whereby the tumor epithelia expresses the ligand for its own receptor (Ghosh et 
al., 2008; Kranz et al., 1999; Ryden et al., 2003; Ryden et al., 2005; Weigand et al., 
2005). It follows that if certain tumors are addicted to the VEGF-VEGFR2 autocrine 
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loop, then anti-VEGF therapy will be more effective in tumors that express VEGFR2 
because the therapy will antagonize the tumor by direct repression of pro-proliferative 
signaling on the tumor cells in addition to atrophy of the vascular supply (Weigand et al., 
2005).  
Remarkably, VEGFR2 signaling affects endothelial cells in manner that could be 
pro-oncogenic if expressed on tumor cells by increasing proliferation, migration, and 
survival signaling (Azam et al., 2010; Grunewald et al., 2006; Holmes et al., 2007; 
Takahashi et al., 2001; Takahashi et al., 1995; Tugues et al., 2011). Blockade of VEGF-
VEGFR2 signaling by reducing VEGF expression, blocking VEGF-VEGFR2 interaction, 
inhibiting VEGFR2 with small molecules, expression of dominant negative VEGFR2 
mutants, or siRNA depletion of VEGFR2 each lead to tumor inhibition by antagonism of 
endothelial cell neovascularization (Gerber et al., 2000; Holash et al., 2002; Kuo et al., 
2001; Millauer et al., 1996; Millauer et al., 1994; Oku et al., 1998; Prewett et al., 1999; 
Saleh et al., 1996a; Saleh et al., 1996b; Strawn et al., 1996; Wedge et al., 2000; Wood 
et al., 2000). In cell culture, which allows the study of autocrine VEGF-VEGFR2 
signaling because there are no confounding vascular effects, breast cancer cells upon 
impaired VEGF signaling experience reduced cell proliferation, increased apoptosis, 
reduced migration, and reduced invasion through Matrigel (Bachelder et al., 2001; 
Beliveau et al., 2010; Ge et al., 2009a; Ge et al., 2009b; Lee et al., 2003; Liang et al., 
2006; Pidgeon et al., 2001; Price et al., 2001; Scherbakov et al., 2006; Timoshenko et 
al., 2007; Weigand et al., 2005).  
We postulate that VEGFR2 is a candidate receptor tyrosine kinase that can 
mediate mutant p53 gain of function because many mutant p53 gain of function effects 
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(discussed previously) overlap with known outcomes of VEGFR2 signaling. It is 
reasonable to hypothesize that if mutant p53 upregulates VEGFR2, then VEGFR2 
signaling accounts for a proportion of observed mutant p53 gain of function effects. The 
VEGFR2 promoter is known to be regulated by Sp1 (Meister et al., 1999), E2F1 (Pillai 
et al., 2010), and Ets-1 (Sato et al., 2000), and the VEGFR2 promoter also contains NF-
kappaB (Patterson et al., 1995) and p53-family member sequences motifs (Guo et al., 
2010). Each of these elements has a reported relationship with mutant p53 (discussed 
previously) that may account for potential regulation of mutant p53 at the VEGFR2 
promoter. Interestingly, VEGFR2 has been reported to translocate to the nucleus to 
regulate its own expression by functioning as its own transcription factor, similar in 
mechanism to the EGF Receptor, implying the existence of a positive feedback loop 
(Domingues et al., 2011; Lin et al., 2001). It is interesting to consider that a cell could 
reinforce pathways until they are dominant through positive feedback mechanisms. It is 
feasible that a cell with mutant p53 has multiple competing cell signaling pathways that 
culminate in a dominant signaling pathway.  
 
 
p53 and Angiogenesis 
p53 exerts tumor suppressive functions through multiple mechanisms in the 
parent cell, but p53 is also tumor suppressive in the context of the tissue. An incipient 
tumor invariably requires the elaboration of VEGF to initiate the angiogenic switch to 
promote growth beyond several millimeters (Bergers and Benjamin, 2003). Wild-type 
p53 prevents angiogenesis through multiple mechanisms: transcriptional suppression of 
VEGF expression (Mukhopadhyay et al., 1995; Pal et al., 2001; Zhang et al., 2000), 
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induction of thrombospondin-1 (Tsp1) and brain-specific angiogenesis inhibitor 1 
(Dameron et al., 1994a, b; Grossfeld et al., 1997; Nishimori et al., 1997), increased 
degradation of hypoxia inducible factor 1-α (Ravi et al., 2000), increased expression of 
anti-angiogenic collagen fragments (Assadian et al., 2012; Bian and Sun, 1997; 
Teodoro et al., 2006), downregulation of COX-2 (Subbaramaiah et al., 1999), 
upregulation of ephrin receptor A2 (Dohn et al., 2001), and suppression of bFGF-
binding protein expression (Hammond and Giaccia, 2002; Sherif et al., 2001; Van Meir 
et al., 1994). p53 may also limit angiogenesis through upregulation of miR34a (Chang et 
al., 2007). Furthermore, mutant p53 has been shown to cooperate with protein kinase C 
to stimulate VEGF expression (Kieser et al., 1994).  
In breast tumor cells, in which TP53 mutation is often (but not always) an early 
genetic lesion, VEGF is invariably overproduced, leading to neovascularization of the 
incipient tumor (Borresen-Dale, 2003; Done et al., 2001; Ghosh et al., 2008; Jerry et al., 
1993; Kranz et al., 1999; Ryden et al., 2003; Zhou et al., 2009). Indeed, p53 status 
impacts response to anti-angiogenic therapy (Yu et al., 2002). This may be because of 
a reduced dependence on the vascular supply in p53 null tumors, which undergo less 
apoptosis than wild-type p53 expressing tumors in hypoxic conditions (Yu et al., 2002). 
Mutant p53 and VEGF expression independently predict worse outcome in breast 
cancer (Linderholm et al., 2000; Linderholm et al., 1998), and the combined expression 
of both proteins allows for significant prognostic value as the expression of both 
correlate with poor outcomes (Linderholm et al., 2000; Linderholm et al., 2001). 
In Chapter 2, the hypothesis that certain hotspot p53 mutants are selected during 
the progression of breast cancer in part due to the selective advantages conferred by 
31 
	  
pro-proliferative, pro-migratory VEGFR2 autocrine signaling is explored. We speculate 
that hotspot mutation of p53 coincides with the angiogenic switch in this class of tumors 
(tumors with p53 hotspot mutations) because mutation of p53 will simultaneously de-
repress VEGF expression and stimulate VEGFR2 expression leading to increased 
tumor growth and thus additional elaboration of VEGF, forming a feed-forward system 
that further stimulates neovascularization and tumor proliferation. Chapter 3 explores 
how mutant p53 regulates the VEGFR2 promoter, which we find is mediated through 
interaction with the SWI/SNF chromatin remodeling complex. 
 
 
The Mammalian SWI/SNF Chromatin Remodeling Complex 
 The mammalian SWI/SNF complex associates genome-wide with transcription 
regulatory elements (Euskirchen et al., 2011) to regulate nucleosome occupancy 
(Tolstorukov et al., 2013). This complex is composed of either BRG1 or BRM ATPases, 
a set of core proteins, and other context-specific components (Narlikar et al., 2002; 
Wilson and Roberts, 2011). SWI/SNF complexes are subdivided into PBAF and BAF 
complexes based on the presence of BAF250A or BAF250B (BAF complex, contains 
either BRG1 or BRM ATPase) or BAF180 (PBAF complex contains only BRG1 
ATPase), although this distinction may not be absolute (Euskirchen et al., 2012; Ryme 
et al., 2009; Wilson and Roberts, 2011). 
 
 
The SWI/SNF Complex Functions as a Tumor Suppressor 
 Inactivating mutations in several SWI/SNF components are found at high 
frequency in a variety of cancers, including breast cancer, implicating SWI/SNF in tumor 
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suppression (Reisman et al., 2009; Weissman and Knudsen, 2009; Wilson and Roberts, 
2011). The frequency of SWI/SNF mutations in various cancers is depicted in Figure 
1.4. Note that in the largest breast cancer datasets, SWI/SNF genes undergo mutation 
at a similar rate to TP53 (Figure 1.1 and Figure 1.4; Figure 1.4 demonstrates the total 
percentage of tumors with any SWI/SNF mutation). Unlike TP53 and atypical of a tumor 
suppressor, SWI/SNF components are often found amplified in some tumors (although 
this is not well described in the literature). It may be informative to explore the genetic 
backgrounds of tumor-specific SWI/SNF components with amplification versus loss of 
function mutations to see if specific alterations correlate with mutational status of other 
genes such as TP53. The sum of TP53 and SWI/SNF subunit mutations in various 
cancers is depicted in Figure 1.5. Note that the addition of TP53 mutations to the 
SWI/SNF mutant tumors depicted in Figure 1.4 demonstrates a significant proportion of 
tumors that are TP53 mutated and wild-type for SWI/SNF (Figure 1.5). Note that for 
most tumors, there is a greater likelihood that there is a TP53 mutation or a SWI/SNF 
mutation (or both) than to be wild-type for TP53 and SWI/SNF (Figure 1.5). 
 In a small study of 12 patients with a small cell carcinoma of the ovary 
(hypercalcemic type) 12 patients had biallelic BRG1 mutations (Jelinic et al., 2014). 
Eleven of these patients for which TP53 status is known are wild-type for TP53 
(www.cbioportal.org; Jelinic et al., 2014). This observation is consistent with a much 
larger study where it was found that SWI/SNF mutations and TP53 mutations have a 
tendency toward mutual exclusivity in some cancer types including colorectal, clear cell 
ovarian, gastric, hepatocellular, and medulloblastoma cancers (Kadoch et al., 2013). 
This same tendency exists in breast cancer and suggests that loss of SWI/SNF function 
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may phenocopy p53 loss to mediate oncogenesis (Kadoch et al., 2013). This study 
specifically excluded amplifications in the analysis of SWI/SNF mutations (Kadoch et al., 
2013). 
SWI/SNF proteins are tumor suppressive in some specific contexts. For instance, 
BRG1 and SNF5 have also been described to mediate p53-dependent transcription of 
p21 (Lee et al., 2002), BRG1 is necessary for efficient RB-mediated cell cycle arrest 
(Bartlett et al., 2011; Strobeck et al., 2000), and BRG1 cooperates with ATM to promote 
the DNA damage response (Kwon et al., 2014). The Parsons laboratory has also 
defined a role for the PBAF subunit BAF180 in mediating p21 expression (causing G1 
arrest) in breast tumor cells in response to radiation or TGFβ signaling (Xia et al., 2008). 
The roles for SWI/SNF as a tumor suppressor are well described (Reisman et al., 2009; 
Weissman and Knudsen, 2009; Wilson and Roberts, 2011). Notably, BRG1 
heterozygous mice have increased frequency of mammary tumors (Bultman et al., 
2008). Moreover, targeted BRG1 homozygous deletion predisposes to ethyl carbamate-
induced lung tumors (Glaros et al., 2008).  
It is interesting to consider that the tumor suppressive functions of SWI/SNF may 
be counterbalanced by the dependence of a cancer cell to utilize SWI/SNF function for 
its own pro-survival purposes. It is conceivable that alteration of specific SWI/SNF 
subunits or interacting partners may obviate SWI/SNF tumor suppressor function and 
allow the complex to function more as an oncogene. This may explain, for instance, why 
SWI/SNF components are frequently amplified in multiple tumor types (see Figure 1.4). 
Interestingly, in tumors with mutated SWI/SNF residues, other functional SWI/SNF 
components can retain oncogenic potential for the cell. This has been described for 
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BRG1 and BRM (the ATPases of the SWI/SNF complex). When BRG1 is mutated, 
intact SWI/SNF complex is still present in tumor cells (Wilson et al., 2014). This is 
thought to be because BRM may substitute for BRG1 (Wilson et al., 2014). This 
hypothesis led to the discovery using an shRNA screen that in BRG1 mutant tumors, 
BRM is the most important genetic vulnerability that can be targeted (Hoffman et al., 
2014; Wilson et al., 2014). The authors describe the concept of cancer-selective paralog 
dependency, whereby loss of one genetic paralog (BRG1) reveals dependence to the 
paralogous gene (BRM)(Hoffman et al., 2014). 
 
 
SWI/SNF Functions with p53 
 
The genetic and physical interactions between SWI/SNF components and p53 
have been well described. Multiple components of the SWI/SNF complex have been 
identified as wild-type p53 binding partners including BRG1 (Lee et al., 2002; Naidu et 
al., 2009), SNF5 (Lee et al., 2002), BAF60A and BAF155 (Oh et al., 2008), ARID1A 
(Guan et al., 2011), and BRD7 (Burrows et al., 2010). BAF60A interaction with p53 has 
been mapped to the oligomerization domain, which suggests that p53 must be in its 
tetrameric form for interaction with SWI/SNF (Oh et al., 2008). BRG1 depletion has 
been reported to activate p53 signaling (Naidu et al., 2009), while SNF5 depletion has 
been reported to lead to loss of p53 expression (Xu et al., 2010). A proline-rich region of 
BRG1 is necessary for interaction with p53 (Naidu et al., 2009). CBP (which is closely 
related to p300) has been reported to dissociate from BRG1 upon DNA damage, 
correlating with decreased CBP and BRG1 levels at the p21 promoter and increased 
p300 and p53 levels at the p21 promoter (Naidu et al., 2009). As previously mentioned, 
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the p21 promoter undergoes nucleosomal remodeling upon p53 binding (Laptenko et 
al., 2011) and SWI/SNF complex components including BAF180 (Xia et al., 2008), 
SNF5 (Lee et al., 2002), and BRG1 (Lee et al., 2002) are required for p21 expression, 
so the relationship with p53 and SWI/SNF components is complex.  
As mutant p53 and wild-type p53 often mediate opposing effects on their 
interacting partners, in theory mutant p53 could dysregulate normal SWI/SNF complex 
function that wild-type 53 requires for transcriptional activities (Lee et al., 2002; Xu et 
al., 2007) by affecting its activity, interaction with other proteins, or chromosomal 
positioning. Mutant p53 has been proposed to facilitate transcriptional plasticity (Quante 
et al., 2012), and functional interaction of mutant p53 with a chromatin remodeling 
complex like SWI/SNF that has broad genomic distribution (Euskirchen et al., 2011) 
may explain the ability of mutant p53 to mediate gene expression at multiple loci. 
Because nucleosomal positioning is a critical factor in gene regulation, promoting or 
inhibiting transcription by regulating access to DNA-binding proteins (Wilson and 
Roberts, 2011), mutant p53 could theoretically co-opt SWI/SNF activity to mediate both 
gene activation and repression.  
 
 
Three-dimensional (3D) Cell Culture 
This section describes the use of three-dimensional culture to study cell culture 
models of breast cancer. Three-dimensional (3D) cell culture more faithfully 
recapitulates the cell-cell and cell-extracellular matrix (ECM) interactions that exist in a 
tumor (Kenny et al., 2007). In 3D culture, breast cancer cells are grown on a laminin-
rich extracellular matrix (Matrigel®) to form defined structures based on the extent of 
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dysplasia of the parent cell (Kenny et al., 2007). 3D culture is an improved method to 
study signaling pathways, which are affected by the ECM through multiple mechanisms 
(Beliveau et al., 2010; Boudreau et al., 1995; Guo et al., 2006; Hansen and Bissell, 
2000; Koch et al., 2011; Liu et al., 2004; Muller et al., 2009; Schatzmann et al., 2003; 
Wang et al., 1998; Weaver et al., 2002; Weaver et al., 1997; Zachary and Gliki, 2001; 
Zhang et al., 2009). These cell-matrix interactions have striking effects on global gene 
expression, with the implication that 3D culture provides more reliable gene expression 
and phenotypic data than 2D culture (Bissell, 2007; Bissell et al., 1982; Carrio et al., 
2005; Fournier et al., 2009; Fournier and Martin, 2006; Fournier et al., 2006; Freed-
Pastor et al., 2012; Petersen et al., 1992; Roskelley et al., 1994; Wang et al., 2002; 
Weaver et al., 1997; Zutter et al., 1995). Moreover, phenotypic reversion can be 
modeled in 3D, whereby a single change or group of changes to a malignant breast 
cancer cell may cause reversion to a normal-appearing, non-malignant acinus (Carrio et 
al., 2005; Freed-Pastor et al., 2012; Wang et al., 2002; Weaver et al., 1997; Zutter et al., 
1995). In 3D culture, mutant p53 is required for the optimal growth and invasive 
properties of breast cancer cells, and reduction of mutant p53 results in significant loss 
of invasive properties in MDA-MB-231 cells and phenotypic reversion to normal-
appearing acini in MDA-MB-468 cells (Freed-Pastor et al., 2012). Defining the molecular 
mechanisms for mutant p53 gain of function in a physiologically relevant system is 







Oncology is headed toward highly adaptable treatment regimens based on the 
particular genetic alterations of a tumor. Defining the contributions of mutant p53 to 
breast cancer tumorigenicity is a critical step toward identifying specific tumor 
alterations that can be therapeutically harnessed. It is our hope that this work will lead to 
insight into the molecular biology of cancer specifically pertaining to gene regulation in 
cancer cells. We hope to identify novel drug targets that can be targeted to mutant p53-
containing tumors. We also hope to identify signaling pathways that may cooperate with 
mutant p53 to enhance tumorigenicity. Defining the transcriptional changes mediated by 
mutant p53 in breast tumors is fundamental to the classification and treatment of breast 
tumors harboring mutant p53 and provides fundamental understanding to the 
mechanism of mutant p53 target gene activation. Ultimately we hope this work furthers 
the goal to define common vulnerabilities in mutant p53-expressing tumors that are 
common to multiple types of p53 alterations (so treatment options are simplified) that 
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Figure 1.1 TP53 Mutations in Human Cancers 
Histogram for TP53 mutation frequency in human cancers organized by frequency of 
alteration per study. The type of TP53 mutational status is indicated by color coding. 
Multiple alterations (listed in grey) indicates the presence of a copy number aberration 
(eg: amplification of 17p with homozygous loss of TP53) in conjunction with a mutation 
in the other allele (eg: point mutation) or the amplification of a mutant allele in that tumor 
sample. Breast cancer studies are indicated by arrows. Two of The Cancer Genome 
Atlas (TCGA) studies are detailed including the TCGA Provisional Breast Invasive 
Carcinoma Dataset and the Nature 2012 Breast Invasive Carcinoma Dataset (Network, 
2012). Data accessed and reproduced from the cBioPortal (http://www.cbioportal.org) in 
December, 2014.  
 
Figure 1.2 TP53 Somatic Mutations in Breast Cancer 
(A) Histogram for TP53 somatic mutations in breast cancer organized by affected codon 
from the IARC TP53 Database R17 Release. Mutations with greater than 1.75% 
mutation frequency are enumerated. 
 
(B) Circle chart representing TP53 somatic mutation categories in breast cancer from 
the entire IARC TP53 Database R17 Release. The ‘Other’ category includes in-frame 
deletions or insertions. The NA category refers to TP53 mutations in which the outcome 




(C) Circle chart representing TP53 point mutation categories in breast cancer from the 
IARC TP53 Database R17 Release.  
 
Figure 1.3 TP53 Missense Mutations in Breast Cancer 
Histogram for TP53 missense mutations in breast cancer from the IARC TP53 
Database R17 Release. Missense mutations with greater than 2.25% mutation 
frequency are enumerated. The p53 secondary structure is defined as follows: 
Transactivation domain (TAD, composed of transactivation subdomains TAD1 and 
TAD2), Proline-Rich Domain (PRD), DNA-Binding Domain, Oligomerization 
(Tetramerization) Domain (OD), and Carboxy-Terminal Domain (CTD). The p53 protein 
domains are demonstrated by amino acid position as previously described (Joerger and 
Fersht, 2008) with the codon missense mutation frequency demonstrated above. 
 
Figure 1.4 SWI/SNF Mutations in Human Cancers 
Histogram for SWI/SNF mutation frequency in human cancers organized by frequency 
of alteration per study. The type of SWI/SNF mutational status is indicated by color 
coding. Multiple alterations (listed in grey) typically indicates the presence of two or 
more SWI/SNF mutations in that tumor sample. Breast cancer studies are indicated by 
arrows. Two of The Cancer Genome Atlas (TCGA) studies are detailed including the 
TCGA Provisional Breast Invasive Carcinoma Dataset and the Nature 2012 Breast 
Invasive Carcinoma Dataset (Network, 2012). The SWI/SNF input list included the 
following genes: ARID1A, ARID1B, ARID2, PBRM1, SMARCA2, SMARCA4, 
SMARCB1, SMARCC1, SMARCC2, SMARCD1, SMARCD2, SMARCD3, SMARCE1, 
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ACTL6A, PHF10, DPF1, DPF3, and DPF2. Data accessed and reproduced from the 
cBioPortal (http://www.cbioportal.org) in December, 2014.  
 
Figure 1.5 TP53 and SWI/SNF Mutations in Human Cancers 
Histogram for TP53 and SWI/SNF combined mutation frequency in human cancers 
organized by frequency of alteration per study. The type of SWI/SNF mutational status 
is indicated by color coding. Multiple alterations (listed in grey) typically indicates the 
presence of two or more SWI/SNF mutations or a TP53 and a SWI/SNF mutation in that 
tumor sample. Breast cancer studies are indicated by arrows. Two of The Cancer 
Genome Atlas (TCGA) studies are detailed including the TCGA Provisional Breast 
Invasive Carcinoma Dataset and the Nature 2012 Breast Invasive Carcinoma Dataset 
(Network, 2012). The SWI/SNF input list included the following genes: TP53, ARID1A, 
ARID1B, ARID2, PBRM1, SMARCA2, SMARCA4, SMARCB1, SMARCC1, SMARCC2, 
SMARCD1, SMARCD2, SMARCD3, SMARCE1, ACTL6A, PHF10, DPF1, DPF3, and 
DPF2. Data accessed and reproduced from the cBioPortal (http://www.cbioportal.org) in 
December, 2014.  
 
Table 1.1 Studies Exploring Mutant p53 Domain-Specific Effects on Gene 
Expression 
The table summarizes known studies that have investigated domain-specific effects of 
mutant p53 on transcription. The cell lines in which the stated gene was found to be 
regulated, the p53 mutants that were utilized, the experiment system that was 
employed, and the associated references are listed.  
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Table 1.2 Transcription Factors that Interact with Mutant p53 
The table summarizes known transcription factors or chromatin modifers for which there 
is a reported interaction with mutant p53. Whether or not wild-type p53 is known to 
interaction with the same factor is listed. Known domain-specific TF interactions with 
wild-type p53 may predict domain interactions with mutant p53. Note that NF-κB may 
interact with mutant p53 (Solomon, Buganim et al. 2012). The table is an extension of a 
similar table prepared by Freed-Pastor and Prives (Freed-Pastor and Prives, 2012) 
 
Table 1.3 Known Mutant p53 Target Genes 
The table summarizes known mutant p53-regulated genes (primarily resulting in 
increased expression), the cell lines in which the gene was found to be regulated, the 
p53 mutants that were utilized, the experiment system that was employed, and the 
associated references. Note mutant p53 represses other genes, such as CD95 (Fas 
Receptor)(Gurova et al., 2003; Zalcenstein et al., 2003), ATF3 (a CREB TF family 
protein)(Buganim et al., 2006), TGF-Beta Receptor 2 (Kalo et al., 2007), Caspase 3 
(Wong et al., 2007), Id2 (Yan et al., 2008), and wild-type p53 target genes p21, 





















Pfister et al., Table 1.1 
GENE CELL LINE MUTANT METHOD STUDY 
MDR1 NIH3T3, Saos-2, Caco-2, BHK 
175H but not wild-type p53, 281G, 
requires TAD residues 
14/19.Requires ETS-1 site; Del22/23 
blocks Ets binding, Del360CTD still 
have Ets binding to 281G, and also 
Ets binding to 143A, 175H, 248W, 
273H; 213Q and 234H no effect on 
MDR1; 281G mTAD1 ineffective 
Overexpression- CAT 
reporter assay, Reporter 
assay 
(Candau et al., 
1997; Chin et al., 
1992; Lin et al., 
1995; Sampath et 
al., 2001; Strauss 
and Haas, 1995) 





 TIM50 (ets-1, CREB 
ChIP) 
 1299, SKBR3, MDA-
MB-468, Saos-2 
175H, 273H, 281G, mTAD1 281G 
ineffective 
Overexpression, siRNA, 
reporter assay, ChIP 
(Sankala et al., 
2011) 
 NF-kB2 H1299, 21PT, Saos-2 
175H, 273H,281G, but not mTAD1-
281G (mTAD = partial). 175H= 
increased NF-kB activity 
Gene Expression Array 
w ectopic expression, 
qPCR, Reporter assay, 
EMSA 
(Scian et al., 
2005) 
EBAG9, ITGA6, 
E2F5, MCM6, C-SYN H1299 281G, but not mTAD1-281G 
Gene Expression Array 
w ectopic expression, 
qPCR, 
(Scian et al., 
2005) 
VDR gene (protein), 





175H (VDR motif over-represented), 






(Scian et al., 
2005) 
 EGR1 H1299, PC3, SKBR3, HeLa 
175H, 248W, 273H, 281G, but not 
mTAD1-175H or 179E or wtp53 
Overexpression,Gene 
Expression Array, ChIP, 
Reporter assay, VEGF-
induction by EGR1 
(Weisz et al., 
2004) 
 CXCL1 (GRO1) SW480, MIA-PaCa-2, HCT116 
273H/309S, 248W, 175H but not 
wtp53, mTAD1, mTAD2, PRD 
required in 245S and 248W, CTD 
inhibitory 248W, no effect 245S 
siRNA, ectopic 
expression, ChIP,  
(Yan and Chen, 
2009, 2010) 




273H/309S, 248W, 175H but not 
wtp53, TAD1, TAD2, PRD required 
in 245S and 248W, CTD not required 
& perhaps inhibitory 
siRNA, ectopic 
expression, ChIP,  
(Yan and Chen, 
2010; Yan et al., 
2008) 
c-Myc (mTAD1 & 
CTD required) 
Cx3Ras (rat), 10(1) 
mouse cells, Saos-
2,SK-OV-3 and 10 (1) 
143A, 281G, 175H, 273H, 248; 
mTAD1 & CTD = intermediate 
phenotype with 281G; 175H, 248W, 





(Frazier et al., 
1998; Pugacheva 
et al., 2002) 
c-Myc, apoptosis 
suppression M1/2 myeloid cells 
143A, mTAD1 required for c-myc 
and apoptosis suppression Overexpression 






H1299  175H, 273H, TAD not required for transactivation Overexpression 
(Adorno et al., 
2009; Oren and 
Rotter, 2010) 




 281G, TAD not required for 
transactivation Overexpression 





M1/2 myeloid cells 135V, CTD required for apoptosis suppression Overexpression 
(Sigal et al., 
2001) 
CXCL1 WI-38, Ras expressing 175H, 179R, TAD1 not required Overexpression 
(Solomon et al., 
2012) 
IL-1 beta WI-38, Ras expressing 175H, 179R, TAD1 not required Overexpression 
(Solomon et al., 
2012) 
MMP3 WI-38, Ras expressing 175H, 179R, TAD1 not required Overexpression 




175H, mTAD1 required for TGF-
Beta Receptor 2 repression 
Overexpression, 










MUTANT INTERACTION STUDY 
Ets-1 Yes V143A, D281G, CTD may be 
required 
(Do et al., 2012; Kim and Deppert, 
2007; Kim et al., 2003; Sampath et al., 
2001; Strano et al., 2007) 
Ets-2 Yes R175H (interaction requires part of 
mutant p53 containing the 
oligomerization domain), 248W 
(Do et al., 2012) 
Sp1 Yes V134A, R175H, R249S, R273H, 
CTD/OD required for wtp53 
interaction 
(Bargonetti et al., 1997; Chicas et al., 
2000; Gualberto and Baldwin, 1995; 
Hwang et al., 2011; Koutsodontis et al., 
2005; Lee et al., 2000; Torgeman et al., 
2001) 
NF-Y Yes R175H, R273H, R273C, CTD 
required for binding to wtp53 
(Di Agostino et al., 2006; Imbriano et 
al., 2005; Liu et al., 2011) 
VDR Yes R175H, interaction does not occur in 
1-292 amino acid mutant 
(Stambolsky et al., 2010) 
SMADs (2/3, 
maybe 4) 
Unclear 175H, 273H, TAD likely required (Adorno et al., 2009; Wilkinson et al., 
2008) 
E2F1 Yes E2F1 binds wtp53 C-terminus, 175H 
and perhaps 280K recruit E2F1 to 
CDE consensus sequence 
(Fogal et al., 2005; Fontemaggi et al., 
2009) 
TBP Yes mTAD1&2 required for wtp53 (Chang et al., 1995; Lee et al., 2000; 
Ragimov et al., 1993; Seto et al., 1992) 
p63 No R175H, Y220C, R248W, R273H (not 
D281G), interaction may not require 
TAD 
(Adorno et al., 2009; Davison et al., 
1999; Gaiddon et al., 2001; Strano et 
al., 2002) 
p73 No R175H, Y220C, V143A, R248W (not 
R273H), interaction may not require 
TAD 
(Bensaad et al., 2003; Davison et al., 
1999; Di Agostino et al., 2008; Di Como 
et al., 1999; Gaiddon et al., 2001; Marin 
et al., 2000; Oren and Rotter, 2010) 
Med1 Yes R213Q and/or Y234H (cell line 
contains both) 
(Lottin-Divoux et al., 2005); (Drane et 
al., 1997; Meyer et al., 2010) 
 
p300 Yes R175H (note p53 mutants R175H, 
R273H were found to interact with 
NF-YA and NF-YB as well) 
(Avantaggiati et al., 1997; Di Agostino 








Pfister et al., Table 1.3 
GENE CELL LINE MUTANT METHOD STUDY 
RhoGDI alpha H1299, SKBR3, HT29 175H, 175H, 273H Overexpression, qPCR, siRNA (Bossi et al., 2008) 
RANGAP1 H1299, SKBR3, HT29 175H, 175H, 273H Overexpression, qPCR, siRNA (Bossi et al., 2008) 
RAB6KIFL H1299, SKBR3, HT29 175H, 175H, 273H Overexpression, qPCR, siRNA (Bossi et al., 2008) 
Seladin1 (DHCR24) H1299, SKBR3, HT29, MDA-MB-468 175H, 175H, 273H Overexpression, qPCR, siRNA 
(Bossi et al., 2008; 
Freed-Pastor et al., 
2012) 
MAP2K3 (no TATA) 
H1299, SKBR3, HT29 
/ also MDA-MB-468, 
MDA-MB-231 
175H, 175H, 273H/ 280K, 
reg by NF-κB, NFY 
Overexpression, qPCR, siRNA/ 
Overexpression (175/273), reporter 
assay, siRNA, ChIP 
(Bossi et al., 2008; 
Gurtner et al., 2010) 
IGFR1 
H1299, SKBR3, 
HT29, Saos-2, RD, 
HeLa 
175H, 175H, 273H,143A, 
but wtp53 suppresses 
Overexpression, qPCR, siRNA, 
Reporter assay 
(Bossi et al., 2008; 
Werner et al., 1996) 
Paxillin Beta SKBR3, HT29 175H, 273H qPCR, siRNA (Bossi et al., 2008) 
BCL2L1 SKBR3, HT29 175H, 273H qPCR, siRNA (Bossi et al., 2008) 
MDR1 NIH3T3, Saos-2, Caco-2, BHK 
175H but not wild-type 




site; Del22/23 block Ets 
binding, Del360CTD still 
have Ets binding to 281G, 
and also Ets binding to 
143A, 175H, 248W, 
273H; 213Q and 234H no 
effect on MDR1; 281G 
mTAD1 ineffective 
Overexpression- CAT reporter 
assay, Reporter assay 
(Candau et al., 1997; 
Chin et al., 1992; Lin et 
al., 1995; Sampath et 
al., 2001; Strauss and 
Haas, 1995) 
 
PCNA HeLa, Saos-2 
V143A, R175H, R248W, 
R273H, D281G but not 
wild-type p53 
Overexpression- CAT reporter assay (Deb et al., 1992) 
CCNA2  SKBR3, HT29, SW480, H1299 
175H, 273H, 273H/309S, 
induction by adriamycin 
inhibited 
WB, ChIP, Reporter Assay (Di Agostino et al., 2006) 
CCNB1 SKBR3, HT29, SW480 
175H, 273H, 273H/309S, 
induction by adriamycin 
inhibited 
WB, ChIP (Di Agostino et al., 2006) 
CCNB2 SKBR3, HT29, SW480, H1299-281G 
175H, 273H, 273H/309S, 
281G, induction by 
adriamycin inhibited 
WB, ChIP, Overexpression, 
Reporter Assay 
(Di Agostino et al., 
2006) 
CDK1 SKBR3, HT29, SW480 
175H, 273H, 273H/309S, 
induction by adriamycin 
inhibited 
WB, ChIP (Di Agostino et al., 2006) 
CDC25C SKBR3, HT29, SW480, H1299-281G 
175H, 273H, 273H/309S, 
281G, induction by 
adriamycin inhibited 
WB, ChIP, Overexpression, 
Reporter Assay 
(Di Agostino et al., 
2006) 
ID4  H1299, SKBR3 175H, 273H, Sp1 and NF-kB implicated 
Overexpression, gene array, ChIP, 
EMSA 
(Fontemaggi et al., 
2009) 
c-Myc  Cx3Ras(rat), (10)1 mouse, Saos-2,  
143A, 281G, 175H, 273H, 
248(W?); mTAD1 & CTD 
= intermediate phenotype 
with 281G 
Overexpression, Reporter assay (Frazier et al., 1998) 
ACAT2, HMGCS1, 
HMGCR, PMVK, 








MB-231 273H, 280K siRNA, qPCR, +/-ChIP 






175H, mTAD1 required 
for TGF-Beta Receptor 2 
repression 







MB-468 280K, 273H siRNA, qPCR, ChIP (Girardini et al., 2011) 
CPSF6, WDR67 MDA-MB-231 280K  siRNA, qPCR, ChIP (Girardini et al., 2011) 
hsMAD1 
 HeLa, HCT116 281G but not 143A Overexpression, Reporter assay 
(Iwanaga and Jeang, 
2002) 
Galectin-3 Saos-2, SW-1736, ARO 273H Overexpression (Lavra et al., 2009) 
EGFR Saos-2 
V143A, R175H, R248W, 
R273H, D281G and also 
wild-type p53 
Overeexpression, Reporter assay (Ludes-Meyers et al., 1996) 
Fos Saos-2  C174Y (fails to transactivate MDR1) Reporter assay (Preuss et al., 2000) 
dUTPase (DUT) 
(TAD1 required) 
SK-OV-3 and  
10 (1) 
175H, 248W (273H 
weak/failed, mTAD1 175H 
failed). 175H, 248W, 
273H activated c-Myc but 
mTAD1 does not 




MB-468, Saos-2 175H, 273H, 281G 
Overexpression, siRNA, reporter 
assay (mTAD1 281G = maybe no 
activation), ChIP 
(Sankala et al., 2011) 
Asparagine 
synthetase H1299, 10 (3), Saos-2 
143A, 157F, 163C, 175H, 
179Y, 194R, 273H, 281G, 
282W 
Overexpression, Reporter assay, 
ChIP-273H (Scian et al., 2004) 
hTERT H1299, 10 (3), Saos-2 
143A, 157F, 163C, 175H, 
179Y, 194R,273H, 281G, 
not 282W 
Overexpression, Reporter assay, 
ChIP-273H (Scian et al., 2004) 
NF-kB2 H1299, 21PT, Saos-2 
175H, 273H,281G, but 
not mTAD1-281G (some 
mTAD = partial). 175H= 
increased NF-κB activity 
Gene Expression Array w ectopic 
expression, qPCR, Reporter assay, 
EMSA 
(Scian et al., 2005) 
EBAG9, ITGA6, 
E2F5, MCM6,  
C-SYN 
H1299 281G, but not mTAD1-281G 
Gene Expression Array w ectopic 
expression, qPCR, (Scian et al., 2005) 
Stathmin Huh-7, HepG2, U138-MG 
213Q, 220C but not 






175H (VDR motif over-
represented), 273H, 
mTAD1-175H no effect on 
reporter assay 
ChIP-on-chip, overexpression, 
southwestern blot, reporter assay 
(Stambolsky et al., 
2010) 
hMMP-13 Saos-2 175H, 281G Overexpression, WB, reporter assay (Sun et al., 2000) 
EGR1 H1299, PC3, SKBR3, HeLa 
175H, 248W, 273H, 
281G, but not mTAD1-
175H or 179E or wtp53 
Overexpression,Gene Expression 
Array, ChIP, Reporter assay, VEGF-
induction by EGR1 
(Weisz et al., 2004) 
CXCL1 (GRO1) SW480, MIA-PaCa-2, HCT116 
273H/309S, 248W, 175H 
but not wtp53, mTAD1, 
mTAD2, PRD required in 
245S and 248W, CTD 
inhibitory 248W, no effect 
245S 
siRNA, ectopic expression, ChIP,  (Yan and Chen, 2009, 2010) 




273H/309S, 248W, 175H 
but not wtp53, mTAD1, 
mTAD2, PRD required in 
245S and 248W, CTD not 
required 
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Mutant p53 impacts the expression of numerous genes at the level of transcription to 
mediate oncogenesis. We identified vascular endothelial growth factor receptor 2 
(VEGFR2), the primary functional VEGF receptor that mediates endothelial cell 
vascularization, as a mutant p53 transcriptional target in multiple breast cancer cell 
lines. By making use of 3D cell culture and other techniques, we demonstrate that 
mutant p53-mediated upregulation of VEGFR2 mediates mutant p53 gain of function by 
enhancing cellular growth and migration. We find that breast tumors with p53 hotspot 
mutants have elevated VEGFR2 levels compared to tumors lacking p53 and elevated 
VEGFA and HIF1A levels compared to wild-type p53-expressing tumors. Importantly, a 
clinical trial suggests that TP53 mutated breast tumors may specifically respond to anti-
VEGFR2 therapy, while TP53 wild-type tumors may not respond. These data suggest 


















 TP53 is the most frequently mutated gene found in human cancers (Olivier et al., 
2010). Wild-type p53 is a sequence-specific transcription factor that when activated by 
various stresses such as DNA damage, oncogenic signaling or nutrient depletion, 
promotes cellular outcomes such as cell arrest, cell death, senescence, metabolic 
changes and others, depending on the extent and context of the stress (Vousden and 
Prives, 2009). In human cancer p53 primarily sustains missense mutations in its 
conserved DNA binding domain. The small number of residues (~5-6) within this region 
that are mutated with extraordinarily high frequency are termed hotspot mutations. 
These mutations can be loosely divided into two categories, the contact mutants (e.g. 
R273H), which remain well folded but whose mutated residues fail to make specific 
contact with elements within the DNA binding site and conformational mutants (e.g. 
R175H) that are partly unfolded leading to loss of zinc coordination and general DNA 
binding. Evidence from sources as varied as human epidemiology studies, mouse 
models and cell-based experiments has shown that these hotspot missense mutant 
forms of p53, which often accumulate to high levels in the cells they inhabit, can acquire 
neomorphic properties such as increased metastases in mice and increased motility 
and invasive characteristics in cultured cells (Brosh and Rotter, 2009; Muller and 
Vousden, 2014). In Li-Fraumeni patients, missense mutation was reported to lead to 
earlier tumor onset than other forms of p53 loss (Bougeard et al., 2008). p53 hotspot 
mutant proteins have been reported to associate with chromatin and alter a cell’s 




Agostino et al., 2006; Do et al., 2012; Freed-Pastor et al., 2012; Stambolsky et al., 
2010). 
 By examining an array-based data set comparing MDA-468 cells with normal vs. 
reduced levels of mutant p53 we discovered that mutant p53 activates the mevalonate 
pathway to promote invasive properties of breast cancer cells (Freed-Pastor et al., 
2012). When we reanalyzed the global gene expression analysis from these data, 
vascular endothelial growth receptor 2 (VEGFR2/KDR/FLK1) was identified as a gene 
strongly induced by mutant p53. VEGFR2 is a receptor tyrosine kinase that is activated 
upon VEGF ligand binding and, under normal physiological conditions, mediates 
angiogenesis (Ferrara, 2004). VEGFR2 is the key receptor for endothelial cell 
neovascularization and mediates increased cellular proliferation, migration, and pro-
survival signaling (Ferrara, 2004).  
In addition to the breast tumor vasculature, VEGFR2 is often aberrantly 
expressed on the breast tumor epithelia (Ryden et al., 2003). Increased VEGF or 
VEGFR2 expression on breast tumor cells each correlate with decreased survival 
(Ghosh et al., 2008). The VEGFR2 ligand VEGF is the clinical target of anti-VEGF 
therapies including bevacizumab, which in 2011 lost FDA approval for metastatic breast 
cancer, revocation of which may have been due to inability to distinguish the candidates 
who would respond to treatment. Interestingly, wild-type p53 is a canonical repressor of 
the VEGF pathway through multiple mechanisms including transcriptional repression of 
VEGFA (Mukhopadhyay et al., 1995) and MDM2-induced degradation of HIF1A (Ravi et 
al., 2000). Loss of wild-type p53 function promotes the angiogenic switch by 




al., 2000). We propose that hotspot mutation in p53 provides additional oncogenic 
potential to breast cancer cells compared to simple loss of p53 function due to the 
induction of VEGFR2 expression. 
 
RESULTS 
Mutant p53 Promotes VEGFR2 Expression in Breast Cancer Cell Lines 
 Using a 3D tissue culture system, global gene expression profiling was 
performed in MDA-468 breast cancer cells that contain a doxycycline-inducible short 
hairpin RNA (shRNA) to the 3’-untranslated region of the p53 messenger RNA (MDA-
468.shp53 cells) (Freed-Pastor et al., 2012). MDA-468 cells express only the R273H 
p53 hotspot mutant from the endogenous TP53 locus. Upon re-analysis of the gene 
expression profiling datasets from our earlier study, VEGFR2 was identified as the 
number 8 overall most upregulated gene by mutant p53 and in the top percentile of 
upregulated genes (Table 2.S1). VEGFR2 was chosen for further study because it is a 
clinically important gene that is known to mediate tumor neovascularization and in 
breast cancer cells can mediate pro-oncogenic signaling through autocrine activation 
(Guo et al., 2010). 
 Using quantitative RT-PCR (qRT-PCR), we confirmed that VEGFR2 RNA levels 
are strongly correlated with mutant p53 protein levels in MDA-468.shp53 cells in 3D 
culture conditions (Figure 2.1A). We also observed decreased VEGFR2 expression in 
2D culture conditions (Figure 2.S1A), although to a lesser extent than was observed in 
3D culture (75% depletion to 90% depletion of VEGFR2 transcript in 2D and 3D 




transcription, as we detected reduced expression of intronic VEGFR2 transcript to the 
same extent as total VEGFR2 RNA (Figure 2.S1B). Stepwise depletion of mutant p53 
led to increasing reductions in VEGFR2 levels (Figure 2.S1C). Reduction of VEGFR2 
RNA corresponded to depletion of VEGFR2 protein isoforms, which differ in migration 
pattern based on varying post-translational modifications (Figures 2.1A, 2.S1A, 
2.S1C)(Bruns et al., 2010). Mutant p53 regulated VEGFR2 in two additional breast 
cancer cell lines that express endogenous p53 hotspot mutants. Using MDA-231 cells 
(p53 R280K), we found that p53 depletion by two different siRNAs (Figure 2.1B) or 
using doxycycline to induce p53 shRNA in MDA-231.shp53 cells (see Figure 2.3B) 
resulted in significant reduction in VEGFR2 expression. Depletion of mutant p53 by two 
different siRNAs in SK-BR-3 cells (p53 R175H) grown in 2D cultures also led to 
reduction in VEGFR2 transcript (Figure 2.S1D). Thus, mutant p53 is a regulator of 
VEGFR2 expression in multiple breast cancer cell lines endogenously expressing both 
conformational and contact p53 hotspot mutations. 
 To determine whether different p53 hotspot mutants activate expression of 
VEGFR2, we engineered MDA-468.shp53 cells to express hotspot p53 mutants R175H, 
G245S, and R248W that lack the targeting region of the inducible p53 shRNA in these 
cells (Freed-Pastor et al., 2012). In this situation endogenous p53 R273H was depleted 
upon addition of doxycyline, so the great majority of the remaining p53 isoform in each 
cell was the respective ectopic hotspot mutant (Figure 2.1C). We found that p53 R175H 
fully rescued and p53 G245S partially rescued the ability of the depleted endogenous 
mutant p53 to transactivate the VEGFR2 promoter as compared to VEGFR2 expression 




hotspot mutant, failed to increase VEGFR2 expression (Figure 2.1C). With the caveat 
that these ectopically expression proteins were overexpressed when compared to the 
endogenously expressed p53, these data indicate that at least three different hotspot 
mutants can activate VEGFR2 expression, including a contact mutant (endogenous p53 
R273H) and conformational mutants (p53 R175H and p53 G245S) in the MDA-468 cell 
line. These data also suggest that different p53 hotspot mutants possess intrinsically 
different capacities to activate VEGFR2 transcription. 
 
Mutant p53 Status Correlates with Increased VEGFR2 in Human Breast Cancer 
Samples 
 A fundamental question is whether mutant p53 impacts VEGFR2 expression in 
human breast tumors. To address this, we sorted the Breast Invasive Carcinoma TCGA 
Provisional dataset into TP53 mutation classes including wild-type, hotspot missense 
mutation, non-hotspot missense mutation, and truncation mutation, which includes 
nonsense, frameshift, in-frame deletion, and in-frame insertion mutations that are 
predicted to alter wild-type p53 activities such as ability to repress VEGF; Table 2.S2). 
To extend our query to other angiogenesis related genes known to be affected by p53 
status, we analyzed normalized RNA-Seq expression values for VEGFR2, VEGFA, and 
HIF1A. Five hotspot mutants of p53 observed in breast cancer (Walerych et al., 2012) 
were selected prior to analysis and are present in 49 out of 969 tumors in the dataset 
(R175, Y220, G245, R248, R273; Table 2.S3). Comparing expression levels of 
VEGFR2 to tumors that contain truncation mutations in p53, hotspot mutant tumors 




compared to wild-type p53, hotspot mutants of p53 express elevated levels of VEGFA 
and HIF1A, which are potent pro-angiogenic factors that potentiate VEGFR2 activation 
(Figure 2.1E-F)(Ferrara, 2004). All classes of inactivating p53 mutations (hotspot, non-
hotspot missense and truncation mutants) correlated with significantly increased levels 
of VEGFA and HIF1A (p < .05 in each case), suggesting that upregulation of VEGFA 
and HIF1A is due to de-repression of wild-type p53 rather than activation by mutant p53 
(Figure 2.1E-F). We speculate that hotspot mutant p53-containing breast tumors are 
unique in being able to regulate a pattern of pro-angiogenic gene expression that may 
preferentially potentiate VEGFR2 autocrine signaling compared to tumors with wild-type 
p53 or other forms of loss of p53 function.  
 
Cell-Autonomous VEGFR2 Expression Mediates Mutant p53 Gain of Function 
 Mutant p53 has been reported to promote cell growth and invasiveness in 3D 
culture models of breast cancer (Freed-Pastor et al., 2012; Muller et al., 2009). To 
investigate whether VEGFR2 mediates downstream effects of mutant p53, including 
increased cellular growth and invasive characteristics, we pharmacologically inhibited 
VEGFR2 with semaxanib (SU5416), a potent inhibitor of VEGFR2 autophosphorylation 
with an IC50 of 1.23 µM (Fong et al., 1999). In 3D cultures, inhibition of VEGFR2 with 
semaxanib prevented growth of MDA-231 and MDA-468 breast cancer cells but not of  
MCF10A immortal breast cells or MCF7 breast cancer cells that express wild-type p53 
(Figure 2.S2A-D).  
To further define VEGFR2 as an oncogene that can mediate mutant p53 gain of 




3D culture. MDA-231 and MDA-468 cells were significantly inhibited in 3D growth upon 
depletion of VEGFR2 with siRNA, recapitulating the effect of depletion of mutant p53 
(Figure 2.2A-B with corresponding immunoblots in Figure 2.S2E-F). Furthermore, we 
observed that the MDA-231 cells, which in 3D cultures form stellate-appearing clusters, 
had mostly lost their characteristic invasive-appearing processes (Figure 2.2A)(Kenny et 
al., 2007). These data indicate that, with respect to 3D culture gross morphology, loss of 
VEGFR2 phenocopies loss of mutant p53 and suggest that VEGFR2 is required for 
efficient growth of mutant p53-containing breast cancer cells. They also suggest that 
cell-autonomous VEGFR2 signaling is required for cell growth in cell lines that contain 
mutant p53.  
 To determine whether VEGFR2 expression can rescue loss of mutant p53, MDA-
231.shp53 cells expressing a doxycycline-inducible short hairpin RNA to p53 (Freed-
Pastor et al., 2012) were engineered to stably express VEGFR2 or a phosphorylation-
defective VEGFR2 mutant (VEGFR2-Y1059F)(Jinnin et al., 2008). As expected, loss of 
mutant p53 led to dramatic reduction in size of the invasive, stellate-shaped clusters of 
MDA-231.shp53 cells (top panels of Figure 2.3A). Remarkably, when VEGFR2 was 
expressed in cells with reduced endogenous mutant p53, the growth properties and 
morphological characteristics of the cell clusters were restored (p < 0.001, Figure 2.3A-
C). Further, cells expressing phosphorylation-defective VEGFR2-Y1059F failed to 
rescue the loss of mutant p53, indicating that the rescue with VEGFR2 is due to pro-
oncogenic signaling properties mediated by this receptor tyrosine kinase (Figure 2.3A-
C). Furthermore, using a wound closure assay in MDA-231 cells our data indicated that 




2.S3A). Note that MDA-468 cells do not migrate efficiently and are not amenable to 
such measurements. These data implicate VEGFR2 as a proto-oncogene in breast 
cancer cells that, when transactivated by mutant p53, functions as an oncogene that 
can mediate mutant p53 gain of function effects that are consistent with characteristic 
growth and invasive properties of tumor cells. 
 
Mutant p53 Breast Tumors Preferentially Respond to Bevacizumab 
To determine whether mutant p53-expressing breast tumors preferentially 
respond to anti-VEGF therapy, we analyzed the response in tumors with wild-type TP53 
vs. mutated TP53 from the NeoAva study (Figure 2.3E-F; see Methods for further 
description). Interestingly, across all patients, response ratios were higher in patients 
with TP53 mutated tumors (Figure 2.S3B-D). Most relevantly, among patients who 
received chemotherapy+bevacizumab, the pathological complete response (pCR) was 
33.3% vs. 17.1% in TP53 mutated vs. wild-type tumors (Figure 2.S3C). A higher pCR 
rate in TP53 mutated tumors compared to wild-type tumors (27.7% vs. 4.5%) was also 
observed among patients receiving chemotherapy alone, so a benefit of bevacizumab 
cannot be concluded based on pCR in this patient cohort (Figure 2.S3C). When 
treatment response was analyzed as a continuous variable, however, a greater 
reduction in tumor volume was observed when bevacizumab was combined with 
chemotherapy in TP53 mutated tumors compared to tumors with wild-type TP53 (Figure 
2.3E-F). The p-value of this observation, p = 0.28, suggests that a larger sample size is 
necessary to confirm a therapeutic effect of bevacizumab on p53 mutated breast 









 VEGFR2 is a candidate proto-oncogene (Ding et al., 2008) that is correlated with 
decreased survival in breast cancer patients (Ghosh et al., 2008). Here we identified 
VEGFR2 as a transcriptional target of mutant p53 in breast cancer cells (Figure 2.1). In 
human tumors, hotspot mutation in TP53 correlates with increased VEGFR2 expression 
and elevated HIF1A and VEGFA levels, which are repressed in tumors with wild-type 
p53 (Figure 2.1D-F). Wild-type p53 is known to inhibit the VEGF pathway by multiple 
mechanisms including repression of VEGF expression and reduced HIF1A, so mutation 
in TP53 leading to loss of such activities will promote VEGF pathway signaling (Bergers 
and Benjamin, 2003). In our experiments mutant p53-stimulated VEGFR2 expression is 
necessary and sufficient for increased growth and migration of cultured breast cancer 
cell lines due to cell-autonomous VEGFR2 signaling. That tumors containing mutant 
p53 are likely to be more susceptible to anti-angiogenic therapy is supported by clinical 
data shown in Figure 2.3E-F.  
Interestingly, mutant p53 has been reported to stimulate additional receptor 
tyrosine kinases including EGFR (Ludes-Meyers et al., 1996), IGF1R (Werner et al., 
1996), MET (Muller et al., 2013), and PDGFRB (Weissmueller et al., 2014), all of which, 
along with VEGFR2, promote pro-proliferative signaling. As a tumor forms, acquisition 
of a hotspot mutation in TP53 may facilitate transcriptional plasticity, whereby tumor 




the greatest pro-proliferative transcriptional program for the particular tumor context. 
This hypothesis explains, for instance, why such a wide array of genes and pathways 
has been reported to mediate mutant p53 gain of function.  
Mutant p53 is associated with decreased overall survival in breast cancer 
(Langerod et al., 2007), which is most likely due to increased rate of metastases, a 
known phenotype in mutant p53 mouse models (Adorno et al., 2009; Lang et al., 2004; 
Olive et al., 2004; Weissmueller et al., 2014). TP53 mutation facilitates the angiogenic 
switch by de-repressing HIF1A and VEGFA expression (Mukhopadhyay et al., 1995; 
Ravi et al., 2000), promoting expression of pro-angiogenic factors that enhance tumor 
angiogenesis, growth, and metastatic potential (Folkman, 2002). Our data suggest that 
p53 hotspot mutants may be selected over loss of function p53 mutants during the 
progression of breast cancer in part due to the advantages conferred by cell-
autonomous VEGFR2 signaling.  
We point out that the mevalonate pathway previously shown to be regulated by 
mutant p53 (Freed-Pastor et al., 2012) and VEGFR2 pathways are not mutually 
exclusive. VEGFR2 requires multiple products of the mevalonate pathway to function 
including plasma membrane components as well as post-translational lipid modifications 
to signaling mediators (Guo et al., 2010; Mo and Elson, 2004). Indeed, multiple 
pathways may be altered by mutant p53 within an individual tumor, or even due to 
mutual interactions among tumor cells in the microenvironment, to promote pro-
proliferative capacities.  
We have reported on a mutant p53 transcriptional target that could lead to clinical 




can independently mediate the pro-proliferative and pro-migratory effects of mutant p53 
(Figures 2.1-3). TP53 loss of function mutations correlate with increased angiogenic 
potential in breast tumors (Figure 2.1E-F), while TP53 hotspot mutations correlate with 
increased VEGFR2 levels (Figure 2.1D). We suggest that classifying breast tumors by 
TP53 mutational status could improve response rates to anti-VEGF therapy (Figure 
2.3E-F). Because VEGFR2 functions as an oncogene in mutant p53-expressing cells, 
we postulate that breast tumors expressing hotspot mutants of p53 will be especially 
sensitive to anti-VEGF therapy due to the combined effect of inhibiting mutant p53-
induced pro-proliferative VEGFR2 signaling compounded with antagonistic effects on 
tumor vasculature. Oncology is headed toward highly adaptable treatment regimens 
based on the particular genetic alterations of a tumor. Defining the contributions of 
mutant p53 and VEGFR2 to breast cancer tumorigenicity are likely to be critical steps 
toward identifying specific tumor alterations that can be therapeutically harnessed. 
Future work should define whether patients with mutant p53-expressing breast tumors 





pLNCX-Flag-p53-R175H, -G245S, -R248W and doxycycline-inducible shp53 
plasmids were generated as previously described (Freed-Pastor et al., 2012). 




Claesson-Welsh and Dr. Bjorn Olsen, respectively (Jinnin et al., 2008). Constructs were 
verified by sequencing using primers listed in Table 2.S4. 
siRNAs 
For siRNA knockdown experiments, Silencer® Select siRNAs were purchased 
from Life Technologies and are the following: siRNA to TP53 (s605 and s606) and 
VEGFR2 (s7822 and s7823). Silencer® Select Negative Control #1 siRNA (Life 
Technologies) was used as control siRNA. DharmaFECT 1 (Thermo Scientific) was 
used as the transfection reagent for all siRNA knockdown experiments. siRNA 
sequences are listed in Table 2.S4.  
Antibodies 
p53 was detected using a combination of mAb 1801/mAb DO-1 (both in-house 
purified from hybridoma supernatants) or with polyclonal FL393 (sc-6243, Santa Cruz 
Biotechnology). Anti-Actin (A2066) antibodies were purchased from Sigma. Anti-
VEGFR2 (55B11) rabbit mAb was purchased from Cell Signaling Technology. 
Drugs 
The following drugs were purchased from Sigma Aldrich: SU5416 (semaxanib, 
S8442), Hydrocortisone (H4001), Insulin (I1882), Doxycycline (D9891), DMSO (D5879), 
and Mitomycin C (Sigma M4287). EGF was purchased from Peprotech (AF-100-15). 
For drug treatment experiments doxycyline was dissolved in H2O and utilized at a final 
concentration of 10 µg/mL, which was determined to generate maximal depletion of 
endogenous mutant p53. SU5416 (semaxanib) was dissolved in DMSO and added to 
cell cultures 48 hours post-plating at the listed experimental concentrations. DMSO was 





Cell Lines and Generation of Stable Cell Lines 
MDA-468, MDA-231, SK-BR-3, and MCF7 cells were maintained in DMEM + 
10% Fetal Bovine Serum (FBS, Gemini Bio-Products). MCF10A cells were maintained 
in DMEM/F12 supplemented with 5% horse serum (Life Technologies), 10 µg/ml Insulin, 
0.5 µg/ml Hydrocortisone and 20 ng/ml Epidermal Growth Factor (EGF). All cells were 
maintained at 37oC in 5% CO2. Unless otherwise stated we refer to these growth 
conditions as two-dimensional (2D) cultures to distinguish them from three-dimensional 
(3D) culture conditions described below.  
Clonal MDA-468.shp53 and clonal MDA-231.shp53 cells, as well as MDA-
468.shp53-175H, -245S, -248W derivative cell lines are previously described (Freed-
Pastor et al., 2012). Stable MDA-231.shp53 cell lines were developed to overexpress 
control vector (pcDNA3.1-GFP), pcDNA3.1-VEGFR2, and pcDNA3.1-VEGFR2-Y1059F 
by transfection of linearized pcDNA3.1 vector. Stable clones were selected with G418 
(Gemini Bio-Products). To induce shRNA expression, cells were treated with 10 µg/ml 
doxycycline from day 0 for time periods indicated in the figure legends. When 
overexpressing VEGFR2 or mutant p53 derivatives, MDA-468.shp53 and MDA-
231.shp53 cells lines were maintained in doxycycline to deplete endogenous mutant 
p53. For siRNA knockdown experiments, cells were seeded 24 hours prior to 
transfection. 
3D Cultures 
The 3D cell culture protocol was performed as previously described (Debnath et 




factor reduced Matrigel (356231, BD Biosciences). Cells were seeded at 5,000 
cells/well in assay medium (DMEM/F12 + 2% Horse Serum + 10 µg/mL Insulin + 0.5 
µg/mL Hydrocortisone + 2% Matrigel), with 5 ng/ml EGF supplemented to MCF10A 
cultures. For RNA, protein, or chromatin analyses from 3D cultures, 35 mm plates were 
lined with 475 µl Matrigel and cells were seeded at a density of 175,000 to 225,000 
cells/plate in assay medium + 2% Matrigel. Cells were re-fed with assay medium on day 
4 and imaged or collected for analysis on day 8. When siRNA was utilized, cells grown 
in 2D conditions were transfected with 50 nM of siRNA and 24 hours later cells were 
plated in 3D culture conditions. Cells were harvested using Cell Recovery Solution (BD 
Biosciences). Where indicated drug concentrations in 3D cultures were maintained 
when refreshing media. Differential interference contrast images were acquired by live 
imaging at 10X magnification using a LSM 700 confocal microscope with ZEN 2011 
software (ZEISS). Multiple fields of each imaged were obtained and representative 
images were chosen for presentation. Where needed the Colony Blob Count Tool 
(Baecker, 2012) program was utilized within ImageJ (Schneider et al., 2012) to calculate 
the area of cells grown in 3D culture conditions. Areas of each independent replicate 
were quantitated using settings to control for background lighting. Incorrect program 
measurements, determined by counting an area of greater than one cell cluster as an 
individual colony or by counting an area in which no cell cluster exists were manually 
excluded. 
Migration Assay 
Cell culture inserts (Ibidi #80209) were place in 35 mm tissue culture dishes to 




were transfected with 50 nM of siRNA to deplete mutant p53 or VEGFR2 24 hours 
earlier were trypsinized, quantitated by MOXI Z automated cell counter (ORFLO 
Technologies), and added to each side of the cell culture insert gap. Approximately 36 
hours after the cells were seeded (60 hours with siRNA), the cell culture insert was 
removed with sterile forceps. Fresh media was added that was supplemented with 5 
µg/mL mitomycin C (Sigma M4287) to prevent cell proliferation. Cell were imaged at 0 
and 48 hours, which approximated wound closure for the control sample, using 
differential interference contrast images acquired by live imaging at 10X magnification 
using a LSM 700 confocal microscope with ZEN 2011 software (Carl Zeiss AG). Total 
migration was calculated by measuring with Adobe Photoshop ruler tool the total 





For most experiments, RNA was isolated from cells using the Qiagen RNeasy 
Mini Kit. Complementary DNA was generated using the Qiagen Quantitect reverse 
transcription kit using 1 µg of input RNA as measured by NanoDrop Spectrophotometer 
(Thermo Scientific). Real-time PCR was carried out on an ABI StepOne Plus machine 
using SYBR green dye. Transcript levels were assayed in triplicate and normalized to 
RPL32 mRNA expression. Relative changes in cDNA levels were calculated using the 
Comparative-Ct Method (ΔΔCT method). All qRT-PCR primers were designed with 




Human Genome Browser hg19 assembly. Primer targeting was confirmed with the 
UCSC Human Genome Browser in silico PCR tool. All primer sequences were validated 
for amplification efficiency by comparison to a genomic DNA standard curve and amplify 
single targets as determined by melting curve analysis. Primer sequences are listed in 
Table 2.S4. All primers were purchased from Life Technologies. 
	  
	  
Breast Cancer Patient Datasets 
Breast Tumor Analysis from TCGA Provisional Breast Cancer Dataset 
The Cancer Genome Atlas (TCGA) datasets (Network, 2012) were downloaded 
directly from the TCGA data portal (February 2014). The Breast Invasive Carcinoma 
(BRCA) TCGA Provisional dataset was used for analysis. The datasets were imported 
into Matlab and data analysis was performed using Matlab scripts (Sobie, 2011). First, 
the somatic mutations dataset was analyzed to determine tumor samples that had 
mutations in TP53. We stratified the tumor samples based on their TP53 mutational 
status. The tumor samples that were sequenced for somatic mutations but did not report 
any mutations in the TP53 locus are assumed to be wild-type for TP53. This dataset 
included information on the type of mutations in TP53 such as missense, nonsense, in-
frame deletion, in-frame insertion, frameshift and silent mutations. The nonsense, 
frameshift, in-frame deletion, and in-frame insertion mutations generally produce a 
truncated, nonfunctional transcript and by this justification were pooled into one group 
and labeled as truncation mutations. For the purposes of our analysis, missense 
mutations in residues R175, Y220, G245, R248, and R273 were classified a priori as 




(Table 2.S3)(Feki and Irminger-Finger, 2004; Walerych et al., 2012). All other missense 
mutations were classified as non-hotspot missense mutations. Tumor samples with 
silent mutations were not considered for the purpose of our analysis. Thus, all tumor 
samples were stratified on the basis of TP53 mutational status. Then, the RNA-
sequence V2 (RNA-SeqV2) dataset was downloaded and analyzed to determine the 
expression levels of genes of interest. In the TCGA portal, the RNA-SeqV2 dataset 
includes the normalized gene expression of all genes as estimated by upper quartile 
normalization procedure using the RSEM software package. RNA expression values 
were analyzed as upper quartile normalized RNA-Seq by Expectation-Maximization 
(RSEM) of reads. This data was imported into Matlab and used for analysis. The 
median gene expression was calculated for each gene of interest following tumor 
sample stratification based on TP53 status and plotted using the box plots function. The 
statistical significance of the findings was determined by Welch’s t-test (Jeanmougin et 
al., 2010). In the case of VEGFR2 gene, we hypothesized that the gene expression (as 
determined by RNA sequencing) of tumor samples with hotspot mutations in TP53 
would be higher than other samples. Hence, the one tailed t-test was used in this case. 
We then extended our analysis to other genes that are also involved in the angiogenic 
pathway. In this case, we used the two-tailed t-test and corrected for multiple testing by 
using the false discovery rate procedure (FDR) of Benjamini and Hochberg to obtain the 
adjusted p-values (Hochberg and Benjamini, 1990). The box plots in the figure were 
plotted in Matlab and are standard box plots with the notch to show the confidence 
intervals of the median of gene expression. For the sake of visual clarity, the outliers are 




significance (p-value < 0.05). The accuracy of the analytical procedure was verified by 
corroborating multiple samples to the results obtained from the cBioPortal website (Gao 
et al., 2013). 
The NeoAva Study  
Patients with HER2 negative mammary carcinomas (> 2.5 cm; stage T2, T3 or 
T4) previously untreated for the current disease were included in the NeoAva study. The 
study was approved by the institutional protocol review board, the regional ethics 
committee, the Norwegian Medicines Agency and was carried out in accordance with 
the Declaration of Helsinki and ICH guidelines for Good Clinical Practice. The study was 
registered in the ClinicalTrials.gov database with the identifier NCT00773695. The 
patients were recruited into the study at 3 sites in Norway (The Norwegian Radium 
Hospital, Ullevål University Hospital and St. Olav’s hospital). Written informed consents 
were obtained from all the patients prior to inclusion. While 132 patients received 
neoadjuvant chemotherapy, 12 patients (not reported here) were allocated to an 
endocrine treatment arm. The patients were further randomized to receive or not to 
receive bevacizumab in addition to chemotherapy. Pathological complete response 
(pCR) was the primary endpoint and was defined as complete eradication of all invasive 
and non-invasive forms of cancer from breast and lymph nodes. Percentage of tumor 
shrinkage was determined by taking ratio of the size of the tumor at surgery to the size 
of the tumor at inclusion (termed ‘response ratio’), giving a continuous scale of response 
to treatment.  
TP53 mutational status was assessed by sequencing the entire coding region 




Technologies). The samples were run on a 3730 DNA Analyzer (Life Technologies), a 
capillary electrophoresis-based automated DNA sequencer. TP53 mutational status was 
successfully obtained for 124 of the total 132 patients in the chemotherapy cohort. 
Response ratio data is missing and thus not included for 7 out of 124 samples with 
TP53 status available due to unavailability of post-treatment tumor measurements. P-
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Figure 2.1 Mutant p53 Promotes VEGFR2 Expression in Breast Cancer Cells 
(A) MDA-468.shp53 cells were grown in 3D culture conditions for 8 days with (+ DOX) 
and without (-DOX) doxycycline to induce an shRNA targeting mutant p53. Total 
VEGFR2 transcript was assayed by qRT-PCR and normalized to -DOX condition. **p < 
0.001 by one tailed t-test. Below is the related immunoblot showing levels of the 
indicated proteins.  
 
(B) MDA-231 cells were grown in 3D culture conditions and assayed for VEGFR2 
expression following depletion of mutant p53 with two different siRNAs as described in 
Methods. Expression is normalized to control siRNA. *p < 0.05, **p < 0.01 by one tailed 
t-test. Immunoblot at right shows indicated protein levels with control or p53 siRNAs.  
 
(C) MDA-468.shp53 cells were selected to stably  express mutant p53 hotspot mutants 
R175H, R245S, or R248W that lack the short hairpin sequence used  target 
endogenous mutant p53 R273H. A control cell line containing empty vector or the cells 
expressing the indicated p53 hotspot mutants were grown in 3D culture in the presence 
of doxycycline to deplete the endogenous mutant p53 R273H. Total VEGFR2 
messenger RNA was analyzed by qRT-PCR and normalized to -DOX control condition. 
Corresponding immunoblot of p53 proteins with actin loading control is shown below. In 
panels A-C error bars represent standard error. In each experiment, at least three 




VEGFR2 antibody, and mutant p53 was identified with a mixture of mABs 1801 and DO-
1.  
 
(D-F) TCGA breast cancer RNA-Seq V2 dataset analysis stratified by TP53 mutational 
status (wild-type, truncation mutation, hotspot missense mutation, or non-hotspot 
missense mutation as indicated). RNA expression of (D) VEGFR2 (E) VEGFA and (F) 
HIF1A is presented as a boxplot, where the box contains the interquartile range. The 
central line represents the median gene expression. Median expression values are 
delineated for the truncation mutant category in (D) and for TP53 wild-type category in 
(E-F). RNA expression values were analyzed as upper quartile normalized RNA-Seq by 
Expectation-Maximization (RSEM) of reads. *p < 0.05 by Welch’s one-tailed t-test in (D). 
 
Figure 2.2 VEGFR2 Inhibition Phenocopies Loss of Mutant p53  
(A) MDA-231 cells and (B) MDA-468 cells were transfected with two independent 
siRNAs to deplete mutant p53 or VEGFR2 and then grown in 3D culture conditions for 8 
days. Representative differential interference contrast images were acquired at 10X 
magnification on live imaging. Relative cell areas of an average of at least 95 colonies 
per condition for 3 independent replicates was calculated and shown in the 
corresponding bar graphs. Error bars represent standard deviation. Scale bar, 100 µm. 







Figure 2.3 Mutant p53 Gain of Function is Mediated by VEGFR2 and May Predict 
Response to Bevacizumab 
(A) MDA-231.shp53 cells were engineered to express control vector, VEGFR2, or 
VEGFR2 tyrosine phosphorylation mutant Y1059F as described in Methods and then 
grown in 3D culture conditions for up to 8 days. Where indicated, cells were grown in 
the presence of doxycycline (DOX, low Mut p53) to deplete endogenous mutant p53. 
DIC images were acquired at 10X magnification on live imaging. Scale bar, 100 µm.  
 
(B) Immunoblot of indicated proteins from panel A. The black line adjoins non-adjacent 
lanes from the same immunoblot.  
 
(C) Relative cell area of an average of at least 85 colonies per condition among 4 
independent replicates was analyzed. Error bars represent standard deviation. *p < 
0.001 calculated by one-tailed t-test.  
 
(D) For wound migration analysis, MDA-231 cells were transfected with control siRNA 
and two independent siRNAs each to deplete mutant p53 or VEGFR2 and then seeded 
to confluency in a tissue culture plates containing inserts. Representative differential 
interference contrast images (Supplemental Figure 2.3A) were acquired immediately 
upon removal of the insert (0 hours) and 48 hours later. Relative migration was 
calculated by dividing the total distance migrated of each sample to the total migration in 




average of four biological replicates. Error bars represent standard deviation. *p < 0.01, 
**p < 0.001 by two-sided t-test. 
 
(E-F) Response ratio showing reduction in tumor volume in (E) TP53 wild-type tumors 
and (F) TP53 mutated tumors treated with chemotherapy alone (Chemo) or 
chemotherapy plus bevacizumab (Chemo + Bev). Each data point represents one 
patient’s response to the indicated treatment which was calculated as the tumor volume 
of residual tumor divided by the initial tumor volume. Data are plotted as a boxplot and 
the sample size is indicated by ‘n’. P-value is derived from the Kruskal-Wallis test. 
Median values of the chemotherapy-only cohorts are delineated. 
 
Figure 2.S1 Mutant p53 Promotes VEGFR2 Expression in Breast Cancer Cells, 
(Related to Figure 2.1) 
(A) MDA-468.shp53 cells were grown in 2D culture condition for 5 days with and without 
doxycycline (DOX). Total VEGFR2 transcript was assayed by qRT-PCR and normalized 
to -DOX condition. Immunoblot at right shows VEGFR2 and mutant p53 protein levels.  
 
(B) MDA-468.shp53 cells were grown in 3D culture for 8 days with and without 
doxycycline (DOX). VEGFR2 transcript from intron 1 was assayed by qRT-PCR and 
normalized to -DOX condition.  
 
(C) Immunoblot from MDA-468.shp53 cells grown in 3D culture for 8 days with 0, 5, and 




(D) SK-BR-3 cells were grown in 2D culture and assayed for VEGFR2 expression 
following depletion of mutant p53 with two different siRNAs. Expression is normalized to 
control siRNA. In each experiment, at least three biological replicates were performed, 
and the same cell lysates for the extracted RNA were used for immunoblots. Error bars 
represent standard error. *p < 0.01, **p < 0.001 by one-tailed t-test. 
	  
Figure 2.S2 VEGFR2 Inhibition Phenocopies Loss of Mutant p53, (Related to 
Figure 2.2) 
MDA-468.shp53 (A), MDA-231 (B), MCF10A (C) and MCF7 (D) cells were grown in 3D 
culture conditions. After 2 days of growth, DMSO vehicle or 5 µM of semaxanib were 
supplemented to the media. Cells were refed with fresh media and DMSO or semaxanib 
at day 4. Cells were imaged at day 8. Representative differential interference contrast 
images were acquired at 10X magnification on live imaging. Scale bar, 100 µm.  
 
(E) Immunoblot corresponds to cells shown in Figure 2.2A. MDA-231 cells were 
transfected with two independent siRNAs to mutant p53 or VEGFR2 and then grown in 
3D culture conditions for up to 8 days. VEGFR2, mutant p53, and actin loading controls 
are demonstrated.  
	  
	  
(F) Immunoblot corresponds to cells shown in Figure 2.2B. MDA-468 cells were 
transfected with two independent siRNAs to mutant p53 or VEGFR2 and then grown in 





Figure 2.S3 Mutant p53 Gain of Function is Mediated by VEGFR2 and Mutant p53 
Tumors Respond Better to Cancer Therapy than Wild-Type p53 Tumors, (Related 
to Figure 2.3) 
(A) MDA-231 cells were transfected with control siRNA and two independent siRNAs 
each to deplete mutant p53 or VEGFR2. After trypsinization, approximately 25,000 cells 
were seeded into culture dishes with Ibidi cell culture-inserts for wound migration, which 
leaves an approximately 500 µm space where no cells are seeded. 60 hours post-
transfection, cells were confluent, and the tissue culture insert was removed. 
Representative differential interference contrast images were acquired at 10X 
magnification on live imaging immediately upon removal of the tissue culture insert (0 
hours) and at 48 hours. Scale bar, 200 µm. Images correspond to Figure 2.3D.  
 
(B) NeoAva clinical trial results stratified by TP53 status. 79 breast cancer patients with 
TP53 wild-type tumors and 38 breast cancer patients with TP53 mutated tumors were 
imaged to establish tumor size prior to treatment. Patients were stratified to receive 
chemotherapy alone or chemotherapy plus bevacizumab. Following treatment, tumor 
size was analyzed. Each datapoint represents one patient’s response to the indicated 
treatment plotted as the remaining tumor volume divided by the initial tumor volume 
(which is the response ratio). Data are plotted as a boxplot. The sample size (n) and 
median response are indicated. P-value was derived from the Kruskal-Wallis test.  
	  
	  
(C) Table summarizing the total number of tumors that had pathological Complete 




a mutant p53-containing tumor that received chemotherapy did not have tumor 
measurements before therapy and were excluded from analysis in (B) and Figure 2.3E-
F; these patients are included in (C) because pCR status is known.   
 
(D) Average change in tumor volume (response ratio) was plotted by TP53 status (blue, 
wild-type TP53; red, mutant TP53) for patients in the NeoAva study. Response is shown 
as a continuous variable (ranging from 0-2.34). 
 
Table 2.S1 Gene Expression Profiling Identifies VEGFR2 as a Potential Mutant p53 
Regulated Gene 
Using a 3D tissue culture system, global gene expression profiling was performed in 
MDA-468.shp53 breast cancer cells that contain a doxycycline-inducible short hairpin 
RNA (shRNA) to TP53 (Freed-Pastor et al., 2012). Three independent experiments 
were averaged, and the top 10 genes that were downregulated upon mutant p53 
depletion (and thus are genes mutant p53 may upregulate) at 5% significance are listed 
with the log2 expression values.  IGFBP5, Ceruloplasmin (CP), and Mammaglobin-A 
(SCGB2A2) were verified as mutant p53 target genes and investigated in Chapter 3 
(see Figure 3.S3E). 
	  
	  
Table 2.S2 TP53 Mutation Categories in the Breast Invasive Carcinoma TCGA 
Provisional Dataset 
TP53 mutation classes were categorized from the Breast Invasive Carcinoma TCGA 




RNA-sequencing data were included in the analysis. TP53 mutations were 
characterized as wild-type, hotspot missense, non-hotspot missense, or truncation 
mutations (which includes in-frame deletion, in-frame insertion, frameshift, and 
nonsense mutations). The frequency of each type of TP53 mutation is listed.  
	  
	  
Table 2.S3 TP53 Missense Mutation Categories in the Breast Invasive Carcinoma 
TCGA Provisional Dataset 
TP53 mutations was categorized from the Breast Invasive Carcinoma TCGA Provisional 
dataset. The frequency of missense mutation in TP53 codons are listed for every 
occurrence greater than 5 times in the dataset (middle column). Codon 245 is provided 
separately as it is a hotspot mutant (Feki and Irminger-Finger, 2004; Walerych et al., 
2012). Not every sample had RNA-sequencing data, so the frequency of missense 
mutations with RNA-sequencing data is provided in the rightmost column. Missense 
mutations in codons R175, Y220, G245, R248, and R273 were classified a priori for 
analysis as hotspot mutations, as these are reported to be the most frequently mutated 
residues in breast cancer (Feki and Irminger-Finger, 2004; Walerych et al., 2012). 
These codons are underlined in the top part of the table and shown separately in the 
bottom section of the table. The sum total of non-hotspot missense and hotspot 
missense mutations with RNA-seq data is 126 and 49, respectively (Table 2.S2). 
	  
	  
Table 2.S4 Primer, Oligonucleotide, and siRNA List 
Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
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Mutant p53 impacts the expression of numerous genes at the level of transcription to 
mediate oncogenesis. We previously identified vascular endothelial growth factor 
receptor 2 (VEGFR2), the primary functional VEGF receptor that mediates 
endothelial cell vascularization, as a mutant p53 transcriptional target in multiple 
breast cancer cell lines (Chapter 2). Up-regulation of VEGFR2 mediates the role of 
mutant p53 in increasing cellular growth and migration in 2D and 3D culture 
conditions (Chapter 2). We extend these findings in this study by investigating how 
mutant p53 impacts transcription of VEGFR2 using multiple techniques including 
scanning ChIP, micrococcal nuclease-PCR, and in vivo DNase I footprinting by 
ligation-mediated PCR. Mutant p53 was found to bind near the VEGFR2 
transcriptional start site, causing the promoter to adopt a transcriptionally active 
conformation. Relatedly, mutant p53 interacts with the SWI/SNF chromatin 
remodeling complex which is required for remodeling the VEGFR2 promoter. Our 
results indicate that approximately half of all mutant p53 regulated genes are 
mediated by SWI/SNF. We suggest that mutant p53 co-opts SWI/SNF function to 
mediate gene expression changes across a wide variety of genes that allow mutant 
p53-expressing cells to generate transcriptional plasticity that serves as a selective 










 TP53 is the most frequently mutated gene found in human cancers (Olivier et 
al., 2010). Wild-type p53 is a sequence-specific transcription factor that when 
activated by various stresses such as DNA damage, oncogenic signaling or nutrient 
depletion, promotes cellular outcomes such as cell arrest, cell death, senescence, 
metabolic changes and others,  depending on the extent and context of the stress 
(Vousden and Prives, 2009). In human cancer p53 primarily sustains missense 
mutations in its conserved DNA binding domain. The small number of residues (~5-6) 
within this region that are mutated with extraordinarily high frequency are termed 
hotspot mutations. These mutations can be loosely divided into two categories, the 
contact mutants (e.g. R273H), which remain well folded but whose mutated residues 
fail to make specific contact with elements within the DNA binding site and 
conformational mutants (e.g. R175H) that are partly unfolded leading to loss of zinc 
coordination and general DNA binding. Evidence from sources as varied as human 
epidemiology studies, mouse models and cell-based experiments has shown that 
these hotspot missense mutant forms of p53, which often accumulate to high levels 
in the cells they inhabit, can acquire neomorphic properties such as increased 
metastases in mice and increased motility and invasive characteristics in cultured 
cells (Brosh and Rotter, 2009; Muller and Vousden, 2014). In Li-Fraumeni patients, 
missense mutation was reported to lead to earlier tumor onset than other forms of 
p53 loss (Bougeard et al., 2008). p53 hotspot mutant proteins have been reported to 





cellular changes (Cooks et al., 2013; Di Agostino et al., 2006; Do et al., 2012; Freed-
Pastor et al., 2012; Stambolsky et al., 2010). 
 We previously identified VEGFR2 as a mutant p53 transcriptional target that 
mediates mutant p53-dependent functions including increased growth and migration 
in breast cancer cells (Chapter 2). Here, we additionally report that mutant p53 
regulates the chromatin architecture of the VEGFR2 promoter by mediating 
nucleosomal displacement through the SWI/SNF chromatin remodeling complex. The 
SWI/SNF complex associates genome-wide with transcription regulatory elements 
(Euskirchen et al., 2011) to regulate nucleosome occupancy (Tolstorukov et al., 
2013). This complex is composed of either BRG1 or BRM ATPases, a set of core 
proteins, and other context-specific components (Narlikar et al., 2002; Wilson and 
Roberts, 2011). SWI/SNF complexes are subdivided into PBAF and BAF complexes 
based on the presence of BAF250A or BAF250B (BAF complex, contains either 
BRG1 or BRM ATPase) or BAF180 (PBAF complex contains only BRG1 ATPase), 
although this distinction may not be absolute (Euskirchen et al., 2012; Ryme et al., 
2009; Wilson and Roberts, 2011). Importantly, inactivating mutations in several 
SWI/SNF components are found at high frequency in a variety of cancers, including 
breast cancer, implicating SWI/SNF in tumor suppression (Reisman et al., 2009; 
Wilson and Roberts, 2011). 
 We found that the mammalian SWI/SNF complex, previously reported as a 
wild-type p53 interactor and regulator of wild-type p53 gene expression at the 
CDKN1A (p21/WAF1) locus (Lee et al., 2002), is a novel mutant p53 interactor that is 





multiple other mutant p53-regulated genes. We hypothesize that mutant p53 co-opts 
SWI/SNF complex function to mediate its gain-of-function transcriptional effects. A 
model is proposed whereby mutant p53 expression imparts transcriptional plasticity 
to a tumor that is mediated through interaction with the SWI/SNF chromatin 
remodeling complex.  
 
RESULTS 
Mutant p53 Mediates Chromatin Remodeling at the VEGFR2 Promoter 
 Because VEGFR2 expression was one of the genes most strongly activated 
by mutant p53 in MDA-468.shp53 cells, we sought to define how mutant p53 
regulates the VEGFR2 promoter using this clonal cell line. We utilized quantitative 
promoter scanning chromatin immunoprecipitation (ChIP) along 4 kb of the VEGFR2 
promoter using 9 primer sets. Mutant p53 was associated with the VEGFR2 
promoter, with peak binding at the proximal promoter (primer set -150 bp, Figure 
3.1A). Peak binding was ~5-fold higher than background levels (normalized to 
percent input) at the -150 site and 3-fold above the lowest mutant p53 signal, located 
at the -2350 site (Figure 3.1A). The binding signal was specific, in that it was 
consistently significantly decreased when mutant p53 was depleted (Figure 3.1A and 
Figure S3.1A-C). Mutant p53 could be detected along at least 1.5 kb of the VEGFR2 
promoter, even though peak binding was in the vicinity of the transcriptional start site. 
This broad binding pattern is consistent with the view that mutant p53 is not likely to 
bind to a specific DNA sequence. Rather, the p53 binding distribution observed is 





region predicted to be associated with a complex array of transcription factors, 
chromatin regulators, transcriptional machinery, nucleosomes, and other factors.  
As wild-type p53 mediates gene expression changes through complex 
interaction with multiple chromatin regulators (Laptenko and Prives, 2006), many of 
which are known mutant p53 binding partners (Freed-Pastor and Prives, 2012), and 
because wild-type p53 binding to DNA leads to nucleosome displacement (Laptenko 
et al., 2011; Lidor Nili et al., 2010), we sought to characterize mutant p53-dependent 
changes in chromatin architecture. The VEGFR2 promoter is a GC-rich, TATA-less 
promoter that is tightly regulated and under tissue-specific control (Patterson et al., 
1997). We postulated that mutant p53 could either mediate a step preceding 
promoter activation in which mutant p53 would initiate or facilitate changes in 
chromatin architecture such as by promoting nucleosomal displacement, or mutant 
p53 could be recruited to active promoters and augment transcription subsequent to 
and without affecting promoter remodeling. 
 To distinguish between these two possibilities we characterized the chromatin 
architecture of the VEGFR2 promoter using micrococcal nuclease (MNase) digestion 
followed by promoter-scanning qPCR (MNase-PCR). MNase eliminates DNA that is 
not allosterically protected from digestion by association with DNA-binding proteins 
and, specifically, core nucleosomes (Noll and Kornberg, 1977). MNase-PCR primers 
were designed to span the VEGFR2 promoter from -390 bp to +56 bp relative to the 
transcriptional start site with an average amplicon length of 66 bp and average 
overlap of 2.5 bp (Table 3.S1). Unfortunately primers could not be developed for the 





region has high GC content and homology to other genomic regions. The average 
amplicon was 66 bp, so each amplicon is less than half the length of DNA associated 
with a core nucleosome (which coordinates ~147 bp of DNA). Thus, observed 
changes were much more defined than would be by ChIP that typically has resolution 
of approximately 300-500 bp (Laptenko et al., 2011). Using crosslinked chromatin, 
MNase digestion was performed on isolated nuclear fractions with full or reduced 
expression of mutant p53. MNase-treated chromatin were separated via agarose gel 
electrophoresis, and mononucleosomal-length DNA was excised, purified, and PCR 
amplified using the described MNase primer sets (Figure 3.1B). Indeed, in the 
presence of mutant p53, there was increased chromatin digestion by MNase that was 
localized to the proximal promoter region between amplicons 3-6, corresponding to -
261 bp to -10 bp from the transcriptional start site, but not amplicons 1, 2, or 7 that 
correspond to flanking regions, suggestive of a relaxed, transcriptionally permissible, 
open-chromatin state in the region where mutant p53 was localized (Figure 3.1B). 
Note that amplicon 4 uses the same primer set as the -150 bp site where peak 
mutant p53 binding was observed in Figure 3.1A. Because depletion of mutant p53 
leads to localized resistance to MNase digestion, these data signify that mutant p53 
is associated with remodeled chromatin at the proximal VEGFR2 promoter and loss 
of mutant p53 leads to promoter closure (Figure 3.1B) consistent with the dramatic 
decrease in VEGFR2 expression (see Figure 2.1A). 
  To confirm and extend these observations with an independent enzymatic 
technique, in vivo DNase I footprinting by ligation-mediated PCR (LM-PCR) was 





in the genomic DNA region being queried. Increased DNase I cleavage (termed 
hypersensitivity) is a hallmark of  active genes, corresponding to an open promoter 
configuration (reviewed in (Krebs and Peterson, 2000)), and  is a feature of wild-type 
p53 target genes including p21 (CDKN1A)(Braastad et al., 2003), for which it is 
known that the area surrounding the p53 response element undergoes nucleosomal 
remodeling subsequent to p53 recruitment (Laptenko et al., 2011). In the presence 
and absence of mutant p53, crosslinked chromatin was subjected to DNase I 
digestion. We found increased DNase I hypersensitivity at the proximal promoter 
between nucleotides -160 bp to +5 bp, corresponding to MNase amplicon 6 as well 
as the area that would theoretically be amplified by MNase primer set 5, in the 
presence of mutant p53 (Figure 3.1C, red). There were no detectable changes in 
DNase I hypersensitivity downstream of the transcriptional start site using a separate 
set of nested primers corresponding to VEGFR2 exon 1 (Figure S3.1D). These 
experiments reveal that mutant p53 mediates promoter remodeling at the VEGFR2 
promoter and is required to sustain an open chromatin conformation.  
 
Mutant p53 Interacts with the SWI/SNF Chromatin Remodeling Complex 
 In order to screen for the protein partners that may cooperate with mutant p53 
to mediate changes in chromatin architecture, SILAC-based mass spectrometry was 
performed using H1299 cells expressing inducible the p53 R282W hotspot mutant. In 
this screen some subunits of the SWI/SNF chromatin remodeling complex were 
identified as mutant p53 interactors, namely BAF53A (ACTL6A) and a peptide 





other transcriptional machinery were identified in this screen. This is relevant to our 
study for a number of reasons: First, the SWI/SNF complex is a well-characterized 
ATP-dependent nucleosomal remodeler. Second, multiple components of the 
SWI/SNF complex have been identified as wild-type p53 binding partners including 
BRG1 (Lee et al., 2002; Naidu et al., 2009), INI1 (Lee et al., 2002), BAF60A and 
BAF155 (Oh et al., 2008), ARID1A (Guan et al., 2011), and BRD7 (Burrows et al., 
2010). Third, TP53 and SWI/SNF mutations have a tendency toward mutual 
exclusivity in cancers (Kadoch et al., 2013). Fourth, mutant p53 has many 
overlapping interacting partners with SWI/SNF components (Table 3.S3). Finally, 
mutant p53 and wild-type p53 often mediate opposing effects on their interacting 
partners, so in theory mutant p53 could dysregulate normal SWI/SNF complex 
function that wild-type 53 requires for transcriptional activities (Lee et al., 2002; Xu et 
al., 2007) by affecting its activity, interaction with other proteins, or chromosomal 
location. 
 Using immunoprecipitation experiments, we were able to co-
immunoprecipitate SWI/SNF components with mutant p53 in several cell lines (Figure 
3.2 and Figure S3.2). SWI/SNF core subunit BAF53A was co-immunoprecipitated by 
p53 R273H in MDA-468 cells and p53 R175H in SK-BR-3 cells (Figure 3.2A and 
3.2B, respectively). SWI/SNF core subunit BAF155 was co-immunoprecipitated by 
p53 R273H in MDA-468 cells and p53 R280K in MDA-231 cells (Figure S3.2A and 
S3.2B, respectively). Reciprocal immunoprecipitation was performed for BAF155, 
which co-immunoprecipitated mutant p53 in MDA-468 and MDA-231 cells (Figure 





immunoprecipitated with p53 R273H in HT29 cells (Figure S3.2C). Hence, mutant 
p53 associates with multiple SWI/SNF subunits, including core components BAF155, 
BAF170, and BAF53A that are present in both BAF and PBAF SWI/SNF complexes 
as well as core ATPases BRG1 (present in PBAF and BAF complex subclasses) and 
BRM (present in BAF complex subclasses)(Euskirchen et al., 2012). While at this 
point we cannot conclude that their association is direct, the fact that multiple 
SWI/SNF subunits were co-immunoprecipitated with mutant p53 suggests that their 
interaction is functional. This point is supported by the results described below. 
 
SWI/SNF Chromatin Remodeling Complex Mediates Nucleosome Occupancy of 
VEGFR2 Promoter and is Required for Optimal Mutant p53-Associated VEGFR2 
Expression 
  As mutant p53 association with the VEGFR2 promoter mediated promoter 
remodeling and mutant p53 interacted with the SWI/SNF chromatin remodeling 
complex, it is plausible that the SWI/SNF complex facilitates remodeling of the 
VEGFR2 promoter via nucleosomal repositioning. We first determined that mutant 
p53 and the SWI/SNF complex co-exist at the VEGFR2 promoter. Two techniques 
were used to ascertain their co-occupation of this region: sequential chromatin 
immunoprecipitation (re-ChIP) and immunodepletion chromatin immunoprecipitation 
(ID-ChIP) using MDA-468.shp53 cells. Schematics for these procedures are depicted 
in Figure S3.2D and S3.2E. For the re-ChIP, the first immunoprecipitation was 
performed with IgG control or anti-p53 antibodies. The pellet was washed, eluted, 





antibodies. We found that ChIP-p53-ChIP-BAF170 was significantly elevated over 
ChIP-p53-ChIP-IgG and ChIP-IgG-ChIP-BAF170 signals, formally demonstrating that 
core SWI/SNF subunit BAF170 and mutant p53 co-localize at the VEGFR2 promoter 
(Figure 3.2E). For the immunodepletion-ChIP, lysates were immunodepleted with IgG 
control antibodies or with p53 monoclonal antibodies to remove chromatin-bound p53 
(see Figure S3.2E). Mutant p53 immunodepletion was confirmed in total cell extract 
(Figure 3.2H) and at the VEGFR2 locus (Figure S3.2F). Each lysate was then 
immunoprecipitated with anti-BAF155, -BAF170, or IgG control antibodies. BAF155 
and BAF170 were chosen because they are core SWI/SNF subunits for which ChIP-
grade antibodies are available (Euskirchen et al., 2011). Both anti-BAF170 (Figure 
3.2F) and anti-BAF155 (Figure 3.2G) signals were significantly reduced in the mutant 
p53 chromatin depleted samples, confirming that mutant p53 and BAF155, and 
mutant p53 and BAF170, are simultaneously present at the VEGFR2 promoter. 
We next queried whether mutant p53 recruits the SWI/SNF complex to the 
VEGFR2 promoter. Using quantitative chromatin immunoprecipitation to determine 
the abundance of SWI/SNF core components BAF170 and BAF155 at the proximal (-
150 bp site) and distal (-2350 bp site) VEGFR2 promoter, corresponding to high and 
low mutant p53 sites, we found that BAF155 and BAF170 were enriched at the 
proximal promoter relative to the distal promoter (Figure 3.3A-B). Figure 3.S3A 
shows that mutant p53 signal was depleted at the -150 bp site in the experimental 
conditions. Since BAF155 and BAF170 signals did not change when mutant p53 was 
depleted, this indicated that mutant p53 does not affect the recruitment of the 





intragenic sites as well as one site 30 kb downstream of the 3’UTR were also 
analyzed, as the SWI/SNF complex has been shown to affect transcriptional 
efficiency by assisting with the RNA polymerase complex, but again no change was 
observed in the presence or absence of mutant p53 (Figure 3.3A-B, 3.S3A). 
Since SWI/SNF localization to the VEGFR2 promoter was unaffected by 
mutant p53, we considered the possibility that SWI/SNF recruits mutant p53 to the 
VEGFR2 promoter to cooperate in the initiation of promoter remodeling. As we found 
that a greater impact of depletion of BRG1 and BRM together on VEGFR2 
expression than siRNA-mediated reduction of either alone (see below) the two 
SWI/SNF ATPase components were co-depleted for this experiment. In fact, co-
reduction of BRG1 and BRM significantly reduced occupancy of mutant p53 at its 
peak binding region in the VEGFR2 promoter (at -150 bp) (Figure 3.3D, p < .01) 
while p53 binding to a control site 30 kb downstream of the 3’-UTR was not 
significantly affected (Figure 3.3D). The decrease in mutant p53 binding with 
SWI/SNF knockdown should be contextualized by comparison to the maximal 
reduction of mutant p53 observed at the same -150 bp site when mutant p53 is 
depleted with shRNA (~30% to ~50%; Figures 3.3D to 3.1A, 3.1A-C, 3.S3A). Since 
mutant p53 levels were unchanged upon BRG1 and BRM co-depletion (Figure 3.3J), 
the reduction of mutant p53 presence at the VEGFR2 promoter was due to reduced 
presence of SWI/SNF complex.  
To formally demonstrate that the SWI/SNF complex mediates nucleosomal 
displacement at the VEGFR2 promoter, we performed MNase digestion followed by 





was chosen for depletion because it is a core SWI/SNF subunit, present in both 
BRG1- and BRM-containing SWI/SNF complexes (Euskirchen et al., 2012). Upon 
BAF170 depletion, there was a significant increase in histone H3 occupancy at the 
VEGFR2 proximal promoter (MNase Amplicon 6; -78 to -10 bp) relative to the distal 
control site (MNase Amplicon 1; -390 to -330 bp) while no significant change between 
these sites in the control sample was detected (Figure 3.3E). Because depletion of a 
core SWI/SNF component resulted in increased nucleosome density at the VEGFR2 
promoter and decreased VEGFR2 expression, we conclude that the SWI/SNF 
complex is required to sustain an open promoter conformation at a mutant p53 target 
gene. 
 
The SWI/SNF Chromatin Remodeling Complex is Required to Activate Multiple 
Mutant p53-Dependent Genes 
 We hypothesized that mutant p53 enhances expression of additional genes 
that are also regulated by SWI/SNF complexes. We first determined whether 
VEGFR2 expression requires SWI/SNF activity, employing an RNAi approach to 
deplete multiple SWI/SNF components including the BRM and BRG1 ATPases, of 
which only one is present per SWI/SNF complex (BRG1-containing or BRM-
containing) and BAF155 and BAF170, which are components of all SWI/SNF 
complexes (Euskirchen et al., 2012). Upon depletion of all four of these SWI/SNF 
components, we observed significant reduction in VEGFR2 RNA expression (Figure 
3.3F-I). Interestingly, both BRM (Figure 3.3F) and BRG1 (Figure 3.3G) independently 





complexes mediate VEGFR2 expression (suggesting that mutant p53 may cooperate 
with both PBAF and BAF complexes). We next determined whether co-depletion of 
BRG1 and BRM resulted in greater depletion of VEGFR2 levels than depletion of 
either component individually. Compared to individual depletion of BRG1 or BRM, co-
depletion resulted in even more dramatic reduction in VEGFR2 levels of up to 60% 
(Figure 3.3J-K). Note that in these 2D culture conditions, for which we observe 
approximately 75% depletion of VEGFR2 transcript on mutant p53 knockdown 
(Figure S1A), there may exist residual mutant p53-dependent transcriptional 
activation. This difference may be due to residual SWI/SNF complex, retained open 
promoter conformation, or unidentified factors. Because SWI/SNF recruits mutant 
p53 and because mutant p53 and SWI/SNF are both required to sustain VEGFR2 
promoter conformation and gene expression, our data indicate that mutant p53 
enhances SWI/SNF-dependent VEGFR2 expression. 
 We next sought to generalize the extent that mutant p53 relies on SWI/SNF 
complex function to mediate its transcriptional activities. Utilizing individual depletion 
of BRG1 or BRM, three of the top mutant p53 target genes from the global gene 
expression analysis were tested for impact of SWI/SNF on their gene expression 
(see Table 2.S1). Depletion of BRM (Figure 3.S3B) and BRG1 (Figure 3.S3C) 
caused a reduction in the expression of IGFBP5, ceruloplasmin (CP), and 
mammaglobin-A (SCGB2A2), which we verified as mutant p53 target genes (Figure 
3.S3E). Co-depletion of both BRG1 and BRM led to greater reduction in the 
expression these genes (Figure 3.3L-N). Interestingly, when we examined expression 





mevalonate pathway (Freed-Pastor et al., 2012), depletion of the SWI/SNF complex 
had no significant effect on their expression (Figure 3.S3F). 
 To extend our findings more globally, we performed RNA-Sequencing on 
MDA-468 cells grown with siRNA to deplete mutant p53 (Mut p53 knockdown, KD) or 
siRNAs to co-deplete BRG1 and BRM (SWI/SNF KD). From a combined analysis of 
two biological replicates where the top 3000 affected genes were analyzed, 1785 
genes were significantly upregulated and 1215 downregulated upon mutant p53 
depletion, while 1902 genes were significantly upregulated and 1098 downregulated 
upon SWI/SNF depletion (Figure 3.4A-B). 1105 genes were co-upregulated by 
depletion of SWI/SNF or mutant p53, representing 61.9% of genes impacted by 
mutant p53 (Figure 3.4A-B). 531 genes were co-downregulated by depletion of 
SWI/SNF or mutant p53, representing 43.7% of genes impacted by mutant p53 
(Figure 3.4A-B). Of 3000 genes affected by mutant p53, SWI/SNF depletion impacted 
1636 (54.5%) of these genes in the same direction (Figure 3.4A-B). Each replicate is 
presented individually at a 1.67-fold expression cutoff in Supplemental Figure 3.4. 
Notably, fewer than about 1.5% of genes that were upregulated by SWI/SNF were 
downregulated by mutant p53, and fewer than about 1.5% of genes that were 
downregulated by SWI/SNF were upregulated by mutant p53, indicating that the 
SWI/SNF complex and mutant p53 are finely tuned to each other (Figure 3.S4B and 
S4D). We conclude that a common feature of numerous mutant p53-dependent 
genes is their requirement for SWI/SNF complex activity for maximal mutant p53-





activates by harnessing SWI/SNF chromatin remodeling complex function to remodel 
promoters into transcriptionally active conformations. 
 
DISCUSSION 
 We have reported two aspects of mutant p53 function that could lead to 
clinical interventions: (1) classifying breast tumors by TP53 mutational status could 
improve response to anti-VEGF therapy due to the combined effect of inhibiting 
mutant p53-induced pro-proliferative VEGFR2 signaling compounded with 
antagonistic effects on tumor vasculature (see Chapter 2) and (2) targeting the 
SWI/SNF complex in mutant p53 tumors could impede mutant p53 transcriptional 
gain of function effects.  
 In this study, we investigated how mutant p53 impacts transcription of 
VEGFR2 (which we identified as one of its strongest target genes; see Chapter 2). 
Mutant p53 was found to bind near the VEGFR2 transcriptional start site, causing the 
promoter to adopt a transcriptionally active conformation. We identified subunits of 
the SWI/SNF chromatin remodeling complex as mutant p53 interactors that co-
occupy the VEGFR2 promoter along with mutant p53. SWI/SNF is required for 
maximal mutant p53 promoter occupancy, as depletion of SWI/SNF both reduces 
mutant p53 association with the VEGFR2 promoter and results in significantly 
reduced VEGFR2 expression. Using RNA sequencing, we report that approximately 
half of all mutant p53-dependent gene alteration requires the SWI/SNF complex. We 





target genes by promoter remodeling through interaction with the SWI/SNF chromatin 
remodeling complex. 
Mutant p53 mediates pro-oncogenic transcriptional profiles (reviewed in 
(Brosh and Rotter, 2009)). Interestingly, mutant p53 has been reported to stimulate 
additional receptor tyrosine kinases, including EGFR (Ludes-Meyers et al., 1996), 
IGF1R (Werner et al., 1996), MET (Muller et al., 2013), and PDGFRB (Weissmueller 
et al., 2014), all of which, along with VEGFR2, promote pro-proliferative signaling. As 
a tumor forms, acquisition of a hotspot mutation in TP53 may facilitate transcriptional 
plasticity, whereby tumor cells increase capacity for gene expression changes and 
therefore undergo selection for the greatest pro-proliferative transcriptional program 
for the particular tumor context. This hypothesis explains, for instance, why such a 
wide array of genes and pathways has been reported to mediate mutant p53 gain of 
function.  
Mutant p53 is associated with decreased overall survival in breast cancer 
(Langerod et al., 2007), which is most likely due to increased rate of metastases, a 
known phenotype in mutant p53 mouse models (Adorno et al., 2009; Lang et al., 
2004; Olive et al., 2004; Weissmueller et al., 2014). TP53 mutation facilitates the 
angiogenic switch by de-repressing HIF1A and VEGFA expression (Mukhopadhyay 
et al., 1995; Ravi et al., 2000), promoting expression of pro-angiogenic factors that 
enhance tumor angiogenesis, growth, and metastatic potential (Folkman, 2002). Our 
data suggest that p53 hotspot mutants may be selected over loss of function p53 
mutants during the progression of breast cancer in part due to the advantages 





mutant p53 cooperation with the SWI/SNF complex is critical to mediating VEGFR2 
expression. 
The SWI/SNF complex associates genome-wide with transcription regulatory 
elements (Euskirchen et al., 2011) to regulate nucleosome occupancy (Tolstorukov et 
al., 2013). We observed SWI/SNF-dependent recruitment of mutant p53 to the 
VEGFR2 promoter (Figure 3.3D). Since mutant p53 and SWI/SNF complexes are 
required to mediate chromatin remodeling at the VEGFR2 proximal promoter, we 
propose that mutant p53 stimulates SWI/SNF-mediated nucleosomal displacement, 
possibly by facilitating recruitment of one or more transcriptional activators or histone 
modifiers that interact with mutant p53 (reviewed in (Freed-Pastor and Prives, 2012); 
Table 3.S3). SWI/SNF function is required at multiple mutant p53 target genes 
(Figure 3.3K-N). BRG1- and BRM-containing SWI/SNF complexes each are required 
for maximal expression of these mutant p53 target genes, as depletion of either 
ATPase decreases expression while co-depletion results in the greatest repression 
(Figure 3.3F-N, Figure 3.S3B-C). Our data define a model whereby mutant p53 
facilitates gene activation via SWI/SNF-mediated promoter remodeling (Figure 3.4C).  
Mutant p53 has been proposed to facilitate transcriptional plasticity (Quante et 
al., 2012), and our data supply a mechanism whereby mutant p53 may mediate 
genome-wide transcriptional changes by SWI/SNF-mediated nucleosomal 
remodeling. Because nucleosomal positioning is a critical factor in gene regulation, 
promoting or inhibiting transcription by regulating access to DNA, mutant p53 may 
co-opt SWI/SNF activity to mediate both gene activation and repression. As the 





regulators as mutant p53 (Table 3.S3), regulation of mutant p53 target genes could 
be extraordinarily complex, and protein recruitment patterns among loci or even at an 
individual locus may vary.  
SWI/SNF proteins are tumor suppressive in some contexts. For instance, 
PBAF subunit BAF180 mediates p21 expression in breast tumor cells to suppress 
tumorigenesis (Xia et al., 2008), BRG1 is necessary for efficient RB-mediated cell 
cycle arrest (Strobeck et al., 2000), and BRG1 cooperates with ATM to promote the 
DNA damage response (Kwon et al., 2014). Moreover, mutations in SWI/SNF 
subunits and TP53 have a tendency toward mutual exclusivity in multiple cancer 
types including breast cancer, suggesting that loss of SWI/SNF function may 
phenocopy p53 loss to mediate oncogenesis (Kadoch et al., 2013). It is possible that 
mutant p53 impedes tumor suppressive activities of the SWI/SNF complex, such as 
in the DNA damage response, which mutant p53 deregulates leading to genetic 
instability (Song et al., 2007). Therefore, in conjunction with chemotherapy or 
radiotherapy, restoration of SWI/SNF tumor suppressor function by targeting mutant 
p53 may be a therapeutic option in cancers expressing hotspot mutants of p53.  
Oncology is headed toward highly adaptable treatment regimens based on the 
particular genetic alterations of a tumor. Defining the contributions of mutant p53 and 
VEGFR2 to breast cancer tumorigenicity are likely to be critical steps toward 
identifying specific tumor alterations that can be therapeutically harnessed. 
Outstanding questions include how SWI/SNF and mutant p53 positively regulate 
each other via recruitment of p53 to promoters and how the ensuing functional 





feasibility of development of small molecules to interrupt the mutant p53-SWI/SNF 
interaction to impede mutant p53 gain of function activities. Finally, whether patients 
with mutant p53-expressing breast tumors demonstrate improved survival with anti-
VEGF treatment or such newly developed small molecules that impede mutant p53-





Doxycycline-inducible shp53 plasmids were generated as previously described 
(Freed-Pastor et al., 2012). 
siRNAs 
For siRNA knockdown experiments, Silencer® Select siRNAs were purchased 
from Life Technologies and are the following: siRNA to TP53 (s605 and s606), 
SMARCA4 (Brg1, s13139 and s13140), SMARCA2 (BRM, s13133 and s13134), 
SMARCC1 (BAF155, s13145 and s13146), and SMARCC2 (BAF170, s13148 and 
s13149). Silencer® Select Negative Control #1 siRNA (Life Technologies) was used 
as control siRNA. DharmaFECT 1 (Thermo Scientific) was used as the transfection 
reagent for all siRNA knockdown experiments. siRNA sequences are listed in Table 
3.S1.  
Antibodies 
p53 was detected using a combination of mAb 1801/mAb DO-1 (both in-house 





Biotechnology). Anti-p53 PAb421 (in-house purified) was used along with mAb 
1801/mAb DO-1 to deplete p53 in the immunodepletion ChIP. Anti-Actin (A2066), 
mouse IgG (I5381) and rabbit IgG (I5006) antibodies were purchased from Sigma. 
Anti-VEGFR2 (55B11) rabbit mAb was purchased from Cell Signaling Technology. 
Anti-BAF53A (ab131272), anti-Histone H3 (ab1791) and anti-Histone H2 antibodies 
(ab18255) were purchased from Abcam. Anti-BRG1 (G-7, sc-17796), BRM (N-19, sc-
6450), BAF170 (H-116, sc-10757), and BAF155 (H-76, sc-10756) antibodies were 
purchased from Santa Cruz Biotechnology.  
Drugs 
Doxycycline (D9891) was purchased from Sigma Aldrich. For drug treatment 
experiments doxycyline was dissolved in H2O and utilized at a final concentration of 




Cell Lines and Generation of Stable Cell Lines 
MDA-468, MDA-231, SK-BR-3, HT29, and H1299 cells were maintained in 
DMEM + 10% Fetal Bovine Serum (FBS, Gemini Bio-Products). All cells were 
maintained at 37oC in 5% CO2. Unless otherwise stated we refer to these growth 
conditions as two-dimensional (2D) cultures to distinguish them from three-
dimensional (3D) culture conditions described below.  
Clonal MDA-468.shp53 cells are previously described (Freed-Pastor et al., 





from day 0 for time periods indicated in the figure legends. For siRNA knockdown 
experiments, cells were seeded 24 hours prior to transfection. 
3D Cultures 
The 3D cell culture protocol was performed as previously described (Debnath 
et al., 2003). For routine imaging, 8-well chamber slides were lined with 45 µL of 
growth factor reduced Matrigel (356231, BD Biosciences). Cells were seeded at 
5,000 cells/well in assay medium (DMEM/F12 + 2% Horse Serum + 10 µg/mL Insulin 
+ 0.5 µg/mL Hydrocortisone + 2% Matrigel), with 5 ng/ml EGF supplemented to 
MCF10A cultures. For RNA, protein, or chromatin analyses from 3D cultures, 35 mm 
plates were lined with 475 µl Matrigel and cells were seeded at a density of 175,000 
to 225,000 cells/plate in assay medium + 2% Matrigel. Cells were re-fed with assay 
medium on day 4 and imaged or collected for analysis on day 8. When siRNA was 
utilized, cells grown in 2D conditions were transfected with 50 nM of siRNA and 24 
hours later cells were plated in 3D culture conditions. Cells were harvested using Cell 
Recovery Solution (BD Biosciences). Where indicated drug concentrations in 3D 




For most experiments, RNA was isolated from cells using the Qiagen RNeasy 
Mini Kit. For RNA-Seq, RNA was isolated using the MagJET RNA Kit (Thermo 
Scientific). Complementary DNA was generated using the Qiagen Quantitect reverse 





Spectrophotometer (Thermo Scientific). Real-time PCR was carried out on an ABI 
StepOne Plus machine using SYBR green dye. Transcript levels were assayed in 
triplicate and normalized to RPL32 mRNA expression. Relative changes in cDNA 
levels were calculated using the Comparative-Ct Method (ΔΔCT method). All qRT-
PCR primers were designed with Primer Express (Applied Biosystems) from genomic 
DNA sequence from the UCSC Human Genome Browser hg19 assembly. Primer 
targeting was confirmed with the UCSC Human Genome Browser in silico PCR tool. 
All primer sequences were validated for amplification efficiency by comparison to a 
genomic DNA standard curve and amplify single targets as determined by melting 
curve analysis. Primer sequences are listed in Table 3.S1. All primers were 
purchased from Life Technologies. 
Preparation and Sequencing of RNA-Seq Libraries 
Total RNA extracted using MagJET RNA Kit (Thermo Scientific) was first 
checked for integrity on an Agilent Bioanalyzer 2100; samples with RNA integrity 
number (RIN) > 9.0 were used for subsequence processing. Total RNA was 
subjected to two rounds of poly(A) selection using oligo-d(T)25 magnetic beads (New 
England Biolabs, NEB). A single read cDNA library was prepared following the 
Illumina TrueSeq small RNA protocol for strand-specific RNA sequencing with minor 
modifications (Hoque et al., 2013). Briefly, poly(A)+ RNA was fragmented in an 
alkaline buffer (NaHCO3, pH 9.3) at 94oC for 2 min, followed by dephosphorylation 
with recombinant shrimp alkaline phosphatase (NEB) and then phosphorylation with 
T4 polynucleotide kinase (NEB). After addition of 3’ adapter (5’ adenylated) and 5’ 





respectively, RNA was reverse transcribed (RT) using 3’ adapter-specific primer. 
cDNA was then amplified by PCR for 15 cycles with a universal forward primer and a 
reverse primer with bar code. The cDNA libraries were purified from an 8% 
polyacrylamide gel and quantified on an Agilent Bioanalyzer. 
Analysis of RNA-Seq Libraries 
RNA-sequencing was performed using an Illumina HiSeq 2000 v3 instrument. 
At least 68 million reads per sample were acquired using 100 bp single end reads. 
HTSeq (Anders et al., 2014) was used to convert reads mapped with MapSplice in 
SAM format to gene read counts. Reads were converted to gene counts using hg19 
genome as a reference. Differential gene expression was analyzed using EdgeR 
(Robinson et al., 2010). Gene expression counts were corrected for batch effect 
exactly as described in the EdgeR manual. The 3000 most affected genes (false 
discovery rate corrected values) in knockdown conditions as compared to control 
were selected. A Venn diagram program 
(http://bioinformatics.psb.ugent.be/webtools/Venn/) was used to identify genes that 
change between knockdown conditions. 
For RNA-Seq expression change analysis of individual biological replicates, 
reads (in FASTQ formatted files) were received from the JP Sulzberg Columbia 
Genome Center and were processed by trimming barcodes and removing primers 
using FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit). Reads were than 
mapped by MapSplice (Wang et al., 2010) to the hg19 reference genome with default 
settings. Mapped reads were then filtered by quality scores (higher than 10) using 





reads (using default settings) with quality scores of 10 and higher. GFOLD was also 
used to find differentially expressed genes compared to control condition using the 
count files (using default settings). We defined significant genes as having a GFOLD 
number of 1.667 fold or more in each direction. A Venn diagram program 
(http://bioinformatics.psb.ugent.be/webtools/Venn/) was used to identify and 
represent genes that change between knockdown conditions. 
	  
Protein Analysis  
 Co-immunoprecipitations were performed based on a previously described 
method (Noll et al., 2012). Briefly, sub-confluent cultures of MDA-468 or SK-BR-3 
(1×106 cells) were harvested, lysed in 500 µL of lysis buffer (20 mM Tris–HCl pH 8, 1 
mM EDTA, 0.5% NP-40, 150 mM NaCl, 10% glycerol and protease inhibitors 
(Roche)), sonicated and centrifuged at 16,100 x g for 15 minutes at 4°C. Clarified 
lysates were incubated with 200 ng of either anti-p53 antibody (DO-1, Santa Cruz 
Biotechnology) or mouse IgG for 2 hours at 4°C with agitation followed by the 
addition of 10 µL of Protein-G–Sepharose beads (GE Healthcare) and incubation at 
4°C for an additional 2 hours. Beads were washed three times with 400 µL of lysis 
buffer and protein complexes were eluted with SDS loading buffer at 95°C for 5 
minutes. Western blot analysis of inputs and co-immunoprecipitated protein 
complexes was performed as described previously (Pishas et al., 2011). Where 
indicated, co-immunoprecipitations were performed as described in the Quantitative 






SILAC Mass Spectrometry 
Cell Culture 
In stable isotope labeling by amino acids in cell culture (SILAC) experiments, 
inducible p53 R282W mutant and wild-type p53 expressing H1299 cells were 
differentially labeled to incorporate isotopic forms of lysine and arginine present in the 
DMEM media. For triple labeling experiments, the mutant cells were grown in media 
containing normal (or ‘light’ (L)) isotopes of L-lysine-(12C614N2) (143 µg/ml, Sigma) 
and L-arginine- (12C614N4) (83 µg/ml, Sigma) and media containing ‘heavy’ (H) 
isotopes of L-lysine-(13C615N2) and L-arginine-(13C615N4) (Cambridge Isotope 
Laboratory), respectively. The inducible wild-type p53-expressing cells were grown in 
media containing an intermediate isotopes (or ‘medium’ (M)) of L-lysine-(4,4,5,5-2H) 
and L-arginine-(13C6) (Cambridge Isotope Laboratory). Cells were grown in SILAC 
media for at least 5-6 cell doublings to ensure complete incorporation of labeled 
amino acids. Cells grown in M and H media were then induced with 2.5 µg/ml of 
Ponasterone A (Invitrogen) for 24 hours before harvesting to induce the expression 
of p53 R282W and wild-type p53 respectively. 
Immunoaffinity Purification of Protein Complexes 
Cell pellets were lysed in ice-cold modified RIPA buffer (50mM Tris-HCl, pH 
7.5-8, 150mM NaCl, 1% NP-40, Complete, Mini, EDTA-free Protease Inhibitor 
Cocktail Tablet (Roche) and PhosSTOP Phosphatase Inhibitor Cocktail Tablet 
(Roche) and centrifuged at 20,000 x g for 20 min at 4ºC. Total protein concentrations 
were measured using a bicinchoninic acid (BCA) protein assay (Thermo Scientific). 





differentially labeled cell line were affinity purified separately by overnight incubation 
at 4ºC with equal amount of anti-p53 (DO-1) conjugated to agarose beads (Santa 
Cruz Biotechnology). The beads were combined carefully after one wash step in 
RIPA buffer and were washed for additional three times with RIPA buffer thereafter. 
To elute the bound proteins from the anti-p53 (DO-1) agarose beads, a 1.5x bead-
volume of 2x lithium dodecyl sulfate sample buffer with reducing agent was added 
and the matrix was boiled for 5 min. The proteins were separated on NuPAGE 4-12% 
Bis-Tris gels (Invitrogen) that were then stained with Colloidal Blue (Invitrogen) and 
destained overnight before being processed for mass spectrometry (see below). 
Mass Spectrometry and Data Analysis 
Eluted protein complexes were separated by 1D SDS-PAGE and digested with 
trypsin using published procedures (Shevchenko et al., 2006). Samples were 
analysed on an Orbitrap or Orbitrap XL (Thermo Fisher) coupled to a Proxeon Easy-
nLC. Survey full scan MS spectra (m/z 300 – 1400) were acquired with a resolution of 
R=60,000 at m/z 400, an AGC target of 1e6 ions, and a maximum injection time of 
500 ms. The ten most intense peptide ions in each survey scan with an ion intensity 
above 2000 counts and a charge state ≥ 2 were sequentially isolated to a target 
value of 1e4 and fragmented in the linear ion trap by collisionally induced dissociation 
(CID/CAD) using a normalized collision energy of 35%. A dynamic exclusion was 
applied using a maximum exclusion list of 500 with one repeat count, repeat and 








Identification and Quantification of Peptides and Proteins 
Proteins were searched using Mascot version 2.2 (Matrix Science, London, 
UK) against a concatenated target/decoy database prepared by sequence reversing 
the human International Protein Index (IPI) (version 3.68) with addition of common 
contaminants such as human keratins, porcine trypsin and proteases. Cysteine 
carbamidomethylation was searched as a fixed modification, N-acetylation and 
oxidized methionine were searched as variable modifications. Labeled arginine and 
lysine were specified as fixed or variable modifications, depending on the prior 
knowledge about the parent ion. SILAC peptide and protein quantification was 
performed automatically with MaxQuant version 1.0.13.13 (Cox and Mann, 2008) 
using default parameter settings. Maximum false discovery rates (FDR) were set to 
0.01 for both protein and peptide. 
 
Chromatin Analysis 
Quantitative Chromatin Immunoprecipitation (ChIP)  
Quantitative chromatin ChIP experiments were carried out as previously 
described (Gomes et al., 2006). Briefly, MDA-468 cells were lysed in RIPA Buffer 
(150 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 
mM Tris pH 8.0, 0.5 mM phenylmethyl sulfonyl fluoride, 1 µM benzamidine, 3 µg/mL 
leupeptin, 100 ng/mL bacitracin, and 200 ng/mL a2-macroglobulin) and sonicated to 
yield ~500 bp fragments. Protein A/G Sepharose beads were conjugated to anti-p53 
antibodies (1801/DO-1) which were used subsequently to immunoprecipitate p53 





ABI StepOne Plus using SYBR green dye versus genomic standard DNA and input 
DNA. ChIP primers designed with Primer Express (Applied Biosystems) were derived 
from the USCS Human Genome Browser hg19 assembly. Primer sequence 
specificity was confirmed with the UCSC Human Genome Browser in silico PCR tool. 
All primer sequences were validated for amplification efficiency and amplify single 
targets as determined by melt curve analysis. ChIP primer sequences are provided in 
Table 3.S1. Samples were normalized to each other and to other amplicons using 
percent input DNA. 
Micrococcal Nuclease-PCR  
Approximately 1.5 million MDA-468.shp53 cells grown in 3D culture conditions 
were cross-linked for 10 minutes with 1% formaldehyde/PBS at room temperature 
followed by addition of 2.5 M glycine/PBS to 125 mM final concentration for 5 
minutes. Cells were washed in PBS and harvested by scraping and nuclei were 
collected via extraction in 10 mL of hypotonic nuclei preparation buffer (300 mM 
sucrose, 10 mM Tris-HCl, pH 7.5, 15 mM NaCl, 60 mM KCl, 5 mM MgCl2, 0.1 mM 
EDTA, 0.15 mM spermine, 0.5 mM spermidine, 0.1% Nonidet-P40, 0.5 mM 
phenylmethyl sulfonyl fluoride) supplemented with 3mM CaCl2 and were pelleted by 
centrifugation at 500 x g for 5 minutes. Nuclei were resuspended in 350 µL nuclei 
digestion buffer (300 mM sucrose, 10 mM Tris-HCl, pH 7.5, 15 mM NaCl, 60 mM KCl, 
5 mM MgCl2, 0.1 mM EDTA, 0.15 mM spermine, 0.5 mM spermidine, 0.5 mM 
phenylmethyl sulfonyl fluoride) supplemented with 3mM CaCl2. 0.5 units of 
micrococcal nuclease (Sigma N3755) diluted in 10 µL of nuclei digestion buffer were 





primarily mononucleosomal length DNA fragments as determined by agarose gel 
electrophoresis. MNase activity was stopped by the addition of EGTA to a final 
concentration of 20 mM to chelate calcium ions. Chromatin was incubated at 65oC for 
5 hours with proteinase K (40 µg proteinase K in 40 µL of Tris-EDTA buffer with 0.5% 
SDS) to reverse crosslinking and remove protein followed by 1 hour incubation with 
RNase A (100 units) at 37oC to remove RNA. DNA was extracted with phenol-
chloroform-isoamyl alcohol extraction followed by isopropanol precipitation. DNA was 
resuspended in 40 µL 1X DNA loading dye, and 10 µL of resuspended material was 
separated via 2% agarose gel electrophoresis. DNA bands were visualized by 
ethidium bromide staining, and DNA bands corresponding to mononucleosomal-
length (~147bp) fragments were excised. DNA was purified with QIAquick Gel 
Extraction Kit (Qiagen). qRT-PCR was utilized to determine ratio of MNase-resistant 
DNA between sample conditions. qPCR signal at the VEGFR2 TSS -390 to -330 bp 
site (amplicon 1) was used to normalize -DOX (+Mut p53) and +DOX (-Mut p53) 
sample qPCR signal. Primers sequences were individually designed and tested for 
amplification efficiency (Table 3.S1). 
Micrococcal Nuclease-ChIP 
Approximately 10 million sub-confluent MDA-468.shp53 cells were cross-
linked for 10 minutes with 1% formaldehyde/PBS at room temperature followed by 
addition of 2.5 M glycine/PBS to 125 mM final concentration for 5 minutes. Cells were 
washed in PBS and harvested by cell scraper. Nuclei were collected via extraction in 
10 mL of hypotonic nuclei preparation buffer (300 mM sucrose, 10 mM Tris-HCl, pH 





ethylenediaminetetraacetic acid, 0.15 mM spermine, 0.5 mM spermidine, 0.1% 
Nonidet-P40, 0.5 mM phenylmethyl sulfonyl fluoride) and were pelleted by 
centrifugation at 500 x gravity for 5 minutes. Nuclei were resuspended in 350 µL 
nuclei digestion buffer (300 mM sucrose, 10 mM Tris-HCl, pH 7.5, 15 mM NaCl, 60 
mM KCl, 5 mM MgCl2, 3mM CaCl2, 0.1 mM ethylenediaminetetraacetic acid, 0.15 
mM spermine, 0.5 mM spermidine, 0.5 mM phenylmethyl sulfonyl fluoride). 0.5 units 
of micrococcal nuclease (Sigma N3755) diluted in 10 µL of nuclei digestion buffer 
were added to the sample. Incubation was performed for 10 minutes at 37oC to 
generate primarily mononucleosomal length DNA fragments. MNase activity was 
stopped by the addition of EGTA to a final concentration of 20 mM to chelate calcium 
ions. Nuclei were disrupted via sonication, cell debris was cleared by centrifugation, 
and supernatant was collected. Samples were diluted in RIPA buffer and normalized 
by DNA content using a NanoDrop Spectrophotometer (Thermo Scientific). 
Chromatin immunoprecipitation was performed as previously explained using ChIP-
grade antibody to Histone H3 (Abcam) or rabbit IgG (Sigma). Following final wash 
steps, immunoprecipitated chromatin was incubated at 65oC for 5 hours with 
proteinase K (40 µg proteinase K in 40 µL of Tris-EDTA buffer with 0.5% SDS) to 
reverse crosslinking and remove protein followed by 1 hour incubation with RNase A 
(100 units) at 37oC to remove RNA. DNA was extracted with phenol-chloroform-
isoamyl alcohol extraction followed by isopropanol precipitation. DNA was 
resuspended in 30 µL of 1X DNA loading dye. 25 µL of resuspended material was 
separated via 2% agarose gel electrophoresis. DNA bands were visualized by 





length (~147bp) fragments were excised. DNA was purified with QIAquick Gel 
Extraction Kit (Qiagen). qPCR was utilized to determine ratio of MNase-resistant 
DNA between sample conditions. A standard curve of genomic DNA was utilized to 
determine nanograms (ng) of DNA immunoprecipitated. IP for Histone H3 in the 
siControl condition at the VEGFR2 TSS -390 to -330 bp site (amplicon 1) was utilized 
to normalize samples for the VEGFR2 TSS -78 to -10 bp site (amplicon 6).  
In vivo DNase I Footprinting by Ligation-Mediated PCR (LM-PCR) 
Approximately 1.5 million MDA-468.shp53 cells grown in 3D culture conditions 
were cross-linked for 10 minutes with 1% formaldehyde/PBS at room temperature 
followed by addition of 2.5 M glycine/PBS to 125 mM final concentration for 5 
minutes. Cells were washed in PBS and harvested by scraping and nuclei were 
collected via extraction in 10 mL of hypotonic nuclei preparation buffer (300 mM 
sucrose, 10 mM Tris-HCl, pH 7.5, 15 mM NaCl, 60 mM KCl, 5 mM MgCl2, 0.1 mM 
EDTA, 0.15 mM spermine, 0.5 mM spermidine, 0.1% Nonidet-P40, 0.5 mM 
phenylmethyl sulfonyl fluoride) and were pelleted by centrifugation at 500 x g for 5 
minutes. Nuclei were resuspended in 225 µL nuclei digestion buffer (300 mM 
sucrose, 10 mM Tris-HCl, pH 7.5, 15 mM NaCl, 60 mM KCl, 5 mM MgCl2, 0.1 mM 
EDTA acid, 0.15 mM spermine, 0.5 mM spermidine, 0.5 mM phenylmethyl sulfonyl 
fluoride). 2.5, 5, and 10 units of DNase I (Worthington Biochemical Corporation) 
diluted in 25 µL of nuclei digestion buffer was prepared separately and supplemented 
with 5 µL of 100mM CaCl2. 220 µL of the resuspended nuclei were added to DNase 
I-containing mixtures and gently pipetted.  Samples were then moved from ice to 





mM Tris-HCl, pH 8.0, 20 mM EDTA, 1% SDS, 500 µg/mL proteinase K) to quench 
the reaction. Chromatin was incubated at 65oC for 5 hours to reverse crosslinking 
and eliminate protein followed by 1 hour incubation with RNase A (100 units, Qiagen) 
at 37oC to remove RNA. DNA was extracted with phenol-chloroform-isoamyl alcohol 
extraction followed by isopropanol precipitation. DNA was resuspended in Tris-
EDTA-buffered water, and DNA concentration was determined by NanoDrop 
Spectrophotometer (Thermo Scientific).  
1 µg of DNA was prepared for single-step primer extension with Footprinting 
Primer 1 using an annealing temperature of 59 oC to generate blunt-ended double 
stranded DNA using VentR (exo-) DNA polymerase (M0257, New England Biolabs) 
with primers listed in Table 3.S1. Deoxynucleotide triphosphates used in PCR steps 
were purchased from Roche Applied Science (#11969064001). A linker was ligated 
to these variable length DNAs using T4 DNA Ligase (Promega M1794) 
supplemented with ATP (P0759, New England Biolabs) for 12 hours at 16oC to 
generate DNA fragments of lengths that correspond to the DNase I cleavage site. 
DNA was purified by ethanol precipitation. A second PCR step using nested 
Promoter Footprinting Primer 2 (Forward primer) and Footprint Linker Primer 
(Reverse primer) was utilized to amplify the genomic DNA using PfuTurbo Hotstart 
DNA Polymerase (#600320, Agilent Technologies) for 30 cycles using a 64.5oC 
annealing temperature. The Footprint Linker Primer anneals to the variable site in the 
genomic DNA where DNase I cut and the linker was ligated, allowing the 
amplification of variably sized products from the genomic DNA. A third nested primer, 





polynucleotide kinase (New England Biolabs) and purified from excess [γ-32P]-ATP 
using microspin G-25 beads (GE Healthcare). PCR was performed at 72oC annealing 
temperature for 6 cycles with radiolabeled primer 3, which generates linear 
amplification (because there is no reverse primer) of the in vivo footprint sample. 
Note that Footprinting Primer 3 is nested within Footprinting Primer 2 and has a 
higher melting temperature and that Footprinting Primer 2 is nested within Primer 1 
and has a higher melting temperature; these considerations offer additional 
specificity to the genomic amplicon.  
Single stranded radiolabeled DNA was resolved by denaturing 8M urea 
polyacrylamide gel electrophoresis (6% polyacrylamide) and quantitated via 
phosphorimager exposure. Images were obtained with a Typhoon FLA7000 scanner 
(GE Healthcare Life Sciences). DNase I hypersensitivity signal represents γ-32P 
decay detection by phosphorimager-based quantitation that was plotted using 
densitometry analysis in ImageQuant version 5.2 software (Molecular Dynamics). 
Primers were individually designed and PAGE-purified (listed in Table 3.S1). Optimal 
PCR conditions were determined empirically. A GC acyclonucleotide ladder, shown 
in Figure S3.1E, was used to confirm that the LM-PCR specifically amplifies the 
VEGFR2 proximal promoter region depicted in Figure 3.1C. Acyclonucleotides were 
purchased from New England Biolabs (N0460). Procedure was designed with input 
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Figure 3.1 Mutant p53 Associates with the VEGFR2 Promoter and Leads to 
Promoter Remodeling 
MDA-468.shp53 cells were cultured for 8 days in 3D culture in the presence (-Mut 
p53, black) and absence (+Mut p53, red) of doxycycline. Cells were treated with 
formaldehyde to crosslink chromatin and subjected to the indicated procedures.  
 
(A) Scanning chromatin immunoprecipitation (ChIP) for mutant p53 was performed 
along 4 kilobases surrounding the VEGFR2 transcriptional start site (TSS). ChIP was 
performed in the presence and absence of doxycycline for mutant p53 and also in the 
absence of antibodies to p53 using primers corresponding to the indicated data 
points. Immunoprecipitated chromatin was subjected to qPCR and percent input-
normalized signal between -DOX and +DOX samples were plotted relative to the 
peak binding signal at the -150 bp VEGFR2 site. Error bars represent standard error 
of the three independent experiments shown in Figure S3.1A-C.  
 
(B) For micrococcal nuclease (MNase) PCR chromatin was digested with MNase and 
mononucleosome-sized DNA fragments were isolated. qPCR was performed for six 
amplicons averaging 66 bp along 446 bp of the VEGFR2 promoter from -390 bp to 
+56 bp relative to the TSS, with signal normalized to Amplicon 1. Error bars 







(C) In vivo DNase I footprinting by ligation-mediated PCR was performed at the 
VEGFR2 promoter between approximately -160bp to +5 bp of the TSS. Densitometry 
analysis of the relative DNase I hypersensitivity signal is represented by a histogram 
(+Mut p53, red, -Mut p53, black). 
	  
	  
Figure 3.2 Mutant p53 is Found in Protein Complexes with Members of the 
SWI/SNF Chromatin Remodeling Complex at the VEGFR2 Promoter 
Extracts of MDA-468 (A and C), SK-BR-3 (B), or MDA-231 (D) cells were subjected 
to immunoprecipitation (IP) with anti-p53 antibodies (mAb DO-1; A and B) or anti-
BAF155 antibody (C and D) followed by immunoblotting (IB) with anti-p53 (mAbs DO-
1; A and B or DO-1 and 1801; C and D), anti-BAF53A (A and B) or anti-BAF155 (C 
and D) antibodies. Inputs represent 5% (A, B and D) or 3.3% (C) of total extract.  
 
(E) ChIP-re-ChIP was performed in MDA-468.shp53 cells by performing initial ChIP 
for IgG or mutant p53 followed by re-ChIP with BAF170 or IgG antibodies. qPCR was 
performed at the VEGFR2 promoter at site -150 bp from the TSS. Signal is shown as 
percent input of input material. Error bars represent standard error of two 
independent experiments.  
 
(F-H) Immunodepletion ChIP was performed in MDA-468.shp53 by 
immunoprecipitating cross-linked cell extract with IgG or anti-p53 mAbs (DO-
1/1801/PAb421). ChIP was then performed on the immunodepleted extracts with 





promoter as in E. Signal is shown as fold signal over ChIP for IgG. Error bars 
represent standard error of two independent experiments.  
 
(H) Immunoblot for mutant p53 with histone 2A as loading control corresponds to 
panels F and G.  
	  
Figure 3.3 SWI/SNF is Required for Maximal VEGFR2 Expression, Nucleosomal 
Remodeling and Expression of Other Mutant p53-Dependent Genes 
A and B. MDA-468.shp53 cells were grown for 5 days in 2D cell culture in the 
presence (-Mut p53, black) and absence (+Mut p53, red) of doxycycline and then 
treated  with formaldehyde and prepared for scanning ChIP to detect occupancy of 
BAF155 (A) or  BAF170 (B). IgG was used as a control in either case. 
Immunoprecipitated chromatin was subjected to qRT-PCR using primers that 
spanned the length of the VEGFR2 gene (from -2.35 kb to +30 kb downstream of the 
coding and the 3’-untranslated region (UTR)). Percent input-normalized signal 
between -DOX and +DOX samples were plotted relative to the peak binding signal at 
the -150 bp VEGFR2 site. Error bars represent standard error of three independent 
experiments.  
 






(D) ChIP for mutant p53 in MDA-468.shp53 cells grown in 2D culture was performed 
in the presence and absence of BRG1 and BRM. Negative site corresponds to +30 
kb downstream of the VEGFR2 3’-UTR. **p < 0.01 by one-tailed t-test.  
 
(E) MNase-assisted ChIP was performed on MDA-468.shp53 cells grown in 2D 
culture with control siRNA or siRNA to BAF170. MNase-digested chromatin was 
incubated with antibodies to histone H3 and IgG, and immunoprecipitated 
mononucleosomal-size DNA was purified by agarose gel electrophoresis. qRT-PCR 
was performed using MNase-PCR primers at the proximal promoter (-78 to -10 bp 
from TSS; Amplicon 6, red) and normalized to the distal promoter (-390 bp to -330bp 
from TSS; Amplicon 1, blue). Error bars represent standard error of three 
independent experiments.  
 
(F-I) MDA-468.shp53 cells grown in 2D culture were transfected with 20 nM of two 
independent siRNAs to deplete BRM (F), BRG1 (G), BAF155 (H) , or BAF170 (I). 
Total VEGFR2 transcript was assayed by qRT-PCR and normalized to control siRNA 
(Ctrl). Error bars represent standard error of three independent experiments. 
Corresponding immunoblots for (E-I) are shown in Figure 3.S3D.  
 
(J-N) MDA-468.shp53 cells grown in 2D culture were transfected with mixture of 50 
nM of siRNA to co-deplete BRM and BRG1 or with control (Ctrl) siRNA. VEGFR2 
protein (J) and RNA (K) are shown. Three other mutant p53 transcriptional targets 





PCR and normalized to RPL32 internal control. Error bars represent standard error of 
three independent experiments. **p < 0.01 by two-tailed t-test. 
 
Figure 3.4 SWI/SNF Complex Mediates Mutant p53-Dependent Transcription at 
Many Mutant p53 Responsive Genes 
(A) RNA-Sequencing was performed on two independent replicates of MDA-
468.shp53 cells grown for 4 days with either control siRNA, siRNA to deplete mutant 
p53 (Mut p53 knockdown, KD), or siRNAs to co-deplete BRG1 and BRM (SWI/SNF 
KD). The 3000 most affected genes in both knockdown conditions, as compared to 
siControl, were analyzed. The total number of upregulated and downregulated genes 
for each knockdown condition are depicted. The number of co-upregulated or co-
downregulated genes in both Mut p53 KD and SWI/SNF KD conditions are 
demonstrated by Venn diagram.  
 
(B) The table lists the number of co-regulated genes (common genes) and 
antagonistically regulated genes (defined as genes up- or down-regulated by mutant 
p53 depletion that were respectively down- or up-regulated by SWI/SNF depletion) 
from the RNA-Seq data. Percent of co-regulated genes was calculated by dividing 
the number of co-regulated genes by the number of genes affected in the KD 
condition.  
 
(C) Proposed model depicting how mutant p53 interacts with SWI/SNF at mutant 





to SWI/SNF regulated genes. Mutant p53 recruits other transcription factors (TF), 
histone acetyltransferases (HATs), or other chromatin modifiers which promote 
SWI/SNF-dependent promoter remodeling. 
	  
	  
Figure 3.S1 Mutant p53 Associates with the VEGFR2 Promoter and Leads to 
Promoter Remodeling, (Related to Figure 3.1) 
(A-C)  MDA-468.shp53 cells were cultured for 8 days in 3D culture in the presence  
(-Mut p53, black) and absence (+Mut p53, red) of doxycycline. Chromatin was 
crosslinked with formaldehyde and subjected to scanning chromatin 
immunoprecipiation (ChIP) analysis. Three biological replicates of the ChIP 
experiment from Figure 3.1A are shown to demonstrate binding patterns of mutant 
p53 to the VEGFR2 promoter along 4 kilobases surrounding the VEGFR2 
transcriptional start site (TSS). ChIP was performed in the presence and absence of 
doxycycline for mutant p53 and also in the absence of antibodies to p53. 
Immunoprecipitated chromatin was subjected to qPCR and percent input-normalized 
signal between -DOX and +DOX samples were plotted relative to the peak binding 
signal at the -150 bp VEGFR2 site.  
 
(D) In vivo DNase I footprinting of VEGFR2 exon 1 in MDA-468.shp53 cells grown in 
the presence (-Mut p53) or absence (+Mut p53) of doxycycline to deplete mutant 
p53. Approximate genomic position is indicated in relation to the transcriptional start 
site. Densitometry analysis of the relative DNase I hypersensitivity signal is 





the same gel in non-adjacent lanes as indicated by dashed line. 
 
(E) In vivo DNase I footprinting acycloCTP and acycloGTP ladder of the VEGFR2 
genomic region represented in Figure 3.1C to demonstrate the specificity of the 
footprinting. Acyclonucleotide ladder primers (Table 3.S1) were used to amplify the 
genomic region representing the VEGFR2 promoter region in Figure 3.1C. 
Radiolabeled VEGFR2 promoter footprinting primer 3 was then used along with 
acycloCTP or acycloGTP-supplemented PCR reaction to perform linear amplification. 
Footprinting products were resolved on a 6% polyacrylamide/8M urea sequencing 
gel. The position relative to the VEGFR2 TSS (+1 site) is indicated. Genome 
sequence is from the UCSC Genome Browser hg19 assembly. 
	  
	  
Figure 3.S2 Mutant p53 Forms a Protein Complex with Members of the SWI/SNF 
Chromatin Remodeling Complex, (Related to Figure 3.2) 
(A) Mutant p53 was immunoprecipitated from MDA-468.shp53 cells following 
chromatin IP procedure. Input represents 3.3% of input material.  
 
(B) Mutant p53 was immunoprecipitated from MDA-231.shp53 cells following 
chromatin IP procedure. Input represents 5% of input material.  
 
(C) Mutant p53 was immunoprecipitated from HT29 cells following chromatin IP 
procedure. Input represents 25% of input material. Black lines adjoin lanes from the 





(D) ChIP-re-ChIP workflow.  
 
(E) Immunodepletion ChIP workflow.  
 
(F) Immunodepletion ChIP for mutant p53 was performed in MDA-468.shp53 cells by 
immunodepleting cross-linked cell extract with p53 or IgG antibodies. ChIP was then 
performed on the immunodepleted extracts with antibodies to mutant p53 (FL-393 
polyclonal p53 antibody) or rabbit IgG control. qPCR was performed at the VEGFR2 
promoter at the site -150 bp from the transcriptional start site. ChIP signal is shown 




Figure 3.S3 SWI/SNF is Required for VEGFR2 Expression and Nucleosomal 
Remodeling and for the Expression of Select Mutant p53-Dependent Genes, 
(Related to Figure 3.3) 
MDA-468.shp53 cells were grown for 5 days in cell culture under the listed 
experimental conditions.  
 
(A) Cells grown in the presence (-Mut p53, black) and absence (+Mut p53, red) of 
doxycycline were fixed with formaldehyde and prepared for scanning chromatin 
immunoprecipitation. Cell extracts were incubated with anti-p53 antibody FL-393 or a 
control rabbit IgG. Immunoprecipitated chromatin was subjected to qPCR using 





VEGFR2 transcriptional start site along with exon position are indicated. Percent 
input-normalized signal between -DOX and +DOX samples were plotted relative to 
the peak binding signal at the -150 bp VEGFR2 site. Error bars represent standard 
error of three independent experiments. The same samples were used for 
experiments in Figure 3.3A-B with immunoblot shown in Figure 3.3C.  
 
(B-C) Cells were transfected with 20 nM of two independent siRNAs to deplete (B) 
BRM (red) or (C) BRG1 (grey). Expression of three novel mutant p53 transcriptional 
targets are shown: IGFBP5, ceruloplasmin, and mammaglobin-A. RNA expression 
was assayed by qRT-PCR and normalized to control siRNA condition. Error bars 
represent standard error of three independent experiments.  
 
(D) Immunoblots for the experiments in (B), (C), and Figure 3.3E-I.  
 
(E) MDA-468.shp53 cells were grown with and without doxycycline to deplete 
endogenous mutant p53. RNA expression was assayed by qRT-PCR and normalized 
to control siRNA condition for IGFBP5, ceruloplasmin, and mammaglobin-A genes.  
 
(F) MDA-468.shp53 cells were transfected with mixture of 50 nM of siRNA to BRM 
and BRG1 as well as with control siRNA. HMGCR and HMGCS1 RNA expression 
was assayed by qRT-PCR and normalized to control. Error bars represent standard 





Figure 3.S4 SWI/SNF Complex Mediates Mutant p53-Dependent Transcription at 
Many Mutant p53 Responsive Genes, (Related to Figure 3.4) 
In two independent experiments (A-B and C-D), RNA-Sequencing was performed on 
MDA-468.shp53 cells grown for 4 days with control siRNA, siRNA to deplete mutant 
p53 (Mut p53 knockdown, KD), and siRNA to co-deplete BRG1 and BRM (SWI/SNF 
KD). At least 68 million reads per sample were acquired using 100 bp single end 
reads. Genes with a GFOLD change of at least 40% (1.667-fold) compared to control 
were categorized as either upregulated or downregulated.  
	  
	  
(A) Genes that were co-upregulated or co-downregulated by mutant p53 or SWI/SNF 
were examined and overlapping expression patterns were determined for the first 
replicate of this experiment.  
	  
	  
(B) Table lists number of co-regulated genes (defined as genes that were 
upregulated in both conditions or downregulated in both conditions) and 
antagonistically regulated genes (defined as genes up- or down-regulated by mutant 
p53 depletion that were respectively down- or up-regulated by SWI/SNF depletion) 
from the RNA-Seq data for the first replicate.  
 
(C) Genes that were co-upregulated or co-downregulated by mutant p53 or SWI/SNF 
were examined and overlapping expression patterns were determined for the second 






(D) Table lists number of co-regulated genes and antagonistically regulated genes 
from the RNA-Seq data for the second replicate. The combined data for these two 
replicates using FDR criteria are presented in Figure 3.4A-B. 
 
Table 3.S1 Primer, Oligonucleotide, and siRNA List 
Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
primers, scanning chromatin immunoprecipitation (ChIP) primers, micrococcal 
nuclease (MNase) PCR and MNase-ChIP primers, in vivo DNase I footprinting by 
ligation-mediated PCR primers and ligation linker sequence, RNA sequencing library 
primers, and siRNA sequences are shown. For the ChIP primers, base pair position 
is approximate and based on UCSC hg19 genome assembly. For microccocal 
nuclease primers, total amplicon length was calculated. For the RNA sequencing 
index primer, the barcode location, which was variable, is indicated. 
	  
	  
Table 3.S2 SILAC Mass Spectrometry List of Mutant p53 Interactors 
H1299-p53-R282W cells with inducible mutant p53 R282W were grown with and 
without induction of p53 R282W using stable isotope labeling by amino acids in cell 
culture (SILAC) and immunoprecipitation was performed as described in the Methods 
section. Immunoprecipitated material was processed and analyzed by mass 
spectrometric analysis as described in the Methods section. Genes corresponding to 
mass spectra peptides with H/L normalized ratio > 2.0 are listed along with the official 
full name and NCBI gene alias. SWI/SNF components are listed in bold. BRM and 





Table 3.S3 BioGRID Analysis of p53 and SWI/SNF Interaction Networks 
BioGRID release 3.2.118 (Stark et al., 2006) was utilized to compile lists of TP53 and 
SWI/SNF interactors based on published protein-protein or genetic interactions from 
human samples. Gene List 1 included TP53, for which there were 798 published p53 
interactors (not shown). Gene List 2 included the listed SWI/SNF components 
(SWI/SNF gene aliases are listed) for which there were a total of 417 published 
SWI/SNF interactors (not shown). From the 798 TP53 and 417 SWI/SNF interactors, 
there were 115 genes that overlapped between TP53 and SWI/SNF groups 
(Common Interacting Partners). The 115 genes are separated into three columns and 
listed in alphabetical order. Note that SWI/SNF components and TP53 are on the list 
(bolded and underlined), as different SWI/SNF components have been shown to 
interact with wild-type p53 (see main text). Nine proteins (bolded in red) that have 
been reported to interact with mutant p53 that are on the list are shown separately 
with the indicated references. 
 (Adorno et al., 2009; Chicas et al., 2000; Di Agostino et al., 2006; Frazier et al., 
1998; Gaiddon et al., 2001; Haupt et al., 2013; Lee et al., 2000; Ragimov et al., 1993; 








































































































PERSPECTIVES AND FUTURE DIRECTIONS 
We have reported two aspects of mutant p53 function that could lead to clinical 
interventions: (1) classifying breast tumors by TP53 mutational status could improve 
response to anti-VEGF therapy due to the combined effect of inhibiting mutant p53-
induced pro-proliferative VEGFR2 signaling compounded with antagonistic effects on 
tumor vasculature (Chapter 2) and (2) targeting the SWI/SNF complex in mutant p53 
tumors could impede mutant p53 transcriptional gain of function effects (Chapter 3).  
We investigated how mutant p53 impacts transcription of VEGFR2 (which we 
identified as one of its strongest target genes; see Chapter 2). Mutant p53 was found to 
bind near the VEGFR2 transcriptional start site, causing the promoter to adopt a 
transcriptionally active conformation. We identified subunits of the SWI/SNF chromatin 
remodeling complex as mutant p53 interactors that co-occupy the VEGFR2 promoter 
along with mutant p53. SWI/SNF is required for maximal mutant p53 promoter 
occupancy, as depletion of SWI/SNF both reduces mutant p53 association with the 
VEGFR2 promoter and results in significantly reduced VEGFR2 expression. Using RNA 
sequencing, we report that approximately half of all mutant p53-dependent gene 
alteration requires the SWI/SNF complex. We surmise that mutant p53 impacts 
transcription of VEGFR2 as well as myriad other target genes by promoter remodeling 
through interaction with the SWI/SNF chromatin remodeling complex. 
 
Mutant p53 Transcriptional Plasticity 
Mutant p53 mediates pro-oncogenic transcriptional profiles (Brosh and Rotter, 




transcriptional changes by SWI/SNF-mediated nucleosomal remodeling. This is 
important as mutant p53 has been proposed to facilitate transcriptional plasticity 
(Quante et al., 2012). Because nucleosomal positioning is a critical factor in gene 
regulation, promoting or inhibiting transcription by regulating access to DNA, mutant p53 
may co-opt SWI/SNF activity to mediate both gene activation and repression. It is 
possible that mutant p53 may stimulate the activity of the SWI/SNF complex by 
recruiting additional factors such as p300. We are currently investigating this possibility 
to further define how mutant p53 cooperates with the SWI/SNF complex. 
What we know is that mutant p53 and SWI/SNF both regulate largely overlapping 
sets of genes in cells expressing endogenous mutant p53. We also know that mutant 
p53 depletion leads to promoter closure at the VEGFR2 locus (Figure 3.1). SWI/SNF 
and mutant p53 co-occupy the VEGFR2 promoter (Figure 3.2). SWI/SNF depletion (in 
the presence of mutant p53) also leads to promoter closure and correlates with 
decreased VEGFR2 expression (Figure 3.3). Knockdown of mutant p53 does not affect 
SWI/SNF promoter recruitment, but SWI/SNF knockdown leads to decreased mutant 
p53 recruitment to the VEGFR2 promoter (Figure 3.3). These data suggest a model 
whereby mutant p53 may amplify expression of genes which are primed by the 
presence of SWI/SNF. SWI/SNF enhances mutant p53 promoter occupancy, and then 
mutant p53 (likely through its transactivation subdomains or C-terminal domain) recruits 
additional factors that promote SWI/SNF-dependent promoter recruitment. Remember 
that in the absence of mutant p53, the VEGFR2 promoter is closed and the gene is not 




The SWI/SNF complex associates genome-wide with transcription regulatory 
elements (Euskirchen et al., 2011) to regulate nucleosome occupancy (Tolstorukov et 
al., 2013). Interestingly, BRG1 and BRM both impact VEGFR2 expression and 
independently affect the expression of three other mutant p53 target genes. This 
suggests the at least in this cell line, BRG1 and BRM can co-substitute for each other in 
promoting mutant p53 gain of function. 
SWI/SNF proteins are tumor suppressive in some contexts. For instance, PBAF 
subunit BAF180 mediates p21 expression in breast tumor cells to suppress 
tumorigenesis (Xia et al., 2008), BRG1 is necessary for efficient RB-mediated cell cycle 
arrest (Strobeck et al., 2000), and BRG1 cooperates with ATM to promote the DNA 
damage response (Kwon et al., 2014). Moreover, mutations in SWI/SNF subunits and 
TP53 have a tendency toward mutual exclusivity in multiple cancer types including 
breast cancer, suggesting that loss of SWI/SNF function may phenocopy p53 loss to 
mediate oncogenesis (Kadoch et al., 2013).  
It is interesting to consider that the tumor suppressive functions of SWI/SNF may 
be counterbalanced by the dependence of a cancer cell to utilize SWI/SNF function for 
its own pro-survival purposes. It is conceivable that alteration of SWI/SNF function 
through interaction with mutant p53 may obviate SWI/SNF tumor suppressor function 
and allow the complex to function as an oncogene. This may explain, for instance, why 
SWI/SNF components are frequently amplified in multiple tumor types (see Figure 1.4). 
Interestingly, in tumors with mutated SWI/SNF residues, other functional SWI/SNF 
components can retain oncogenic potential for the cell. This has been described for 




intact SWI/SNF complex is still present in tumor cells (Wilson et al., 2014). This is 
thought to be because BRM may substitute for BRG1 (Wilson et al., 2014). As 
mentioned in Chapter 1, this hypothesis led to the discovery using an shRNA screen 
that in BRG1 mutant tumors, BRM is the most important genetic vulnerability that can 
be targeted (Hoffman et al., 2014; Wilson et al., 2014). The authors describe the 
concept of cancer-selective paralog dependency, whereby loss of one genetic paralog 
(BRG1) reveals a dependence to the paralogous gene (BRM)(Hoffman et al., 2014). It is 
interesting to consider that such genetic vulnerabilities could be harnessed to 
antagonize the growth of mutant p53-expressing tumors. 
 Wild-type p53 interacts with SWI/SNF, which is important in mediating 
expression of p53 target gene p21 (Lee et al., 2002). Multiple components of the 
SWI/SNF complex have been identified as wild-type p53 binding partners including 
BRG1 (Lee et al., 2002; Naidu et al., 2009), SNF5 (Lee et al., 2002), BAF60A and 
BAF155 (Oh et al., 2008), ARID1A (Guan et al., 2011), and BRD7 (Burrows et al., 
2010). At the p21 promoter, which both distal and proximal p53 response elements 
contain high levels of nucleosomal occupancy (Laptenko et al., 2011). Upon p53 
activation, nucleosomal occupancy is rapidly lost (Laptenko et al., 2011). Nucleosomal 
displacement is most likely to occur subsequent to p53 DNA binding as it is unlikely that 
the alternative - that nucleosomes and p53 compete for the same site - occurs, 
especially considering that p53 can bind to its response element while the response 
element is engaged by a nucleosome (Laptenko et al., 2011). Furthermore, p53 recruits 
p300 in order to acetylate nucleosomal histones to mediate transcriptional activation 




element, recruits p300 which acetylates key histone residues, which stimulates 
SWI/SNF recruitment and subsequent nucleosomal repositioning to facilitate the 
recruitment of other transcriptional components that culminate in the formation of the 
RNA pol II pre-initiation complex. SWI/SNF may be stably present throughout these 
processes or be recruited following p53 response element binding, and SWI/SNF could 
dissociate from the promoter once remodeling occurs. SWI/SNF dissociation from the 
p21 promoter following promoter remodeling (subsequent to p53 response element 
binding) could explain the observation that BRG1 promoter occupancy decreases 
following p53 recruitment (Naidu et al., 2009). 
In this work, we describe mutant p53 interaction with BRG1, BRM, BAF155, 
BAF170, and BAF53A (Chapter 3). As mutant p53 and wild-type p53 often mediate 
opposing effects on their interacting partners, in theory mutant p53 could dysregulate 
normal SWI/SNF complex function that wild-type 53 requires for transcriptional activities 
(Lee et al., 2002; Xu et al., 2007) by affecting its activity, interaction with other proteins, 
or chromosomal positioning. Mutant p53 has been proposed to facilitate transcriptional 
plasticity (Quante et al., 2012), and functional interaction of mutant p53 with a chromatin 
remodeling complex like SWI/SNF that has broad genomic distribution (Euskirchen et 
al., 2011) may explain the ability of mutant p53 to mediate gene expression at multiple 
loci. Because nucleosomal positioning is a critical factor in gene regulation, promoting 
or inhibiting transcription by regulating access to DNA-binding proteins (Wilson and 
Roberts, 2011), mutant p53 could theoretically co-opt SWI/SNF activity to mediate both 





Mutant p53 Gain of Function         
 It is well established that mutant p53 promotes metastasis in mouse models, 
which is consistent with the observations that mutant p53 expression correlates with 
worse survival in human cancers (Alsner et al., 2008; Elledge et al., 1993; Langerod et 
al., 2007; Olivier et al., 2006; Petitjean et al., 2007). Hotspot mutations of p53 lead to 
increased cell proliferation, (Bossi et al., 2006; Bossi et al., 2008; Freed-Pastor et al., 
2012; Haupt et al., 2009; Preuss et al., 2000; Scian et al., 2004; Strano et al., 2002; Yan 
and Chen, 2009; Yan et al., 2008), resistance to apoptosis (Bossi et al., 2008; Lim et al., 
2009) which can be mediated through mutant p53 interaction with Ets-2 (Do et al., 
2012), increased migration (Adorno et al., 2009; Weissmueller et al., 2014), and 
increased cellular invasion through Matrigel (Muller et al., 2009; Muller et al., 2013). The 
weight of these studies cannot be ignored. The contributions of specific missense 
mutations to cancer formation - and how different missense mutations correlate with 
other mutations or gene expression patterns - is essential to making significant strides 
in the understanding and treatment mutant p53-expressing cancers. 
These studies identify a variety of mechanisms through which mutant p53 
promotes oncogenesis. As each tumor is unique in its development, it should be 
considered at this point that mutant p53 may be a promiscuous transcription factor that 
is utilized by the tumor cell - based on its specific mutations, dominant signaling 
pathways, and interaction with the microenvironment - in a manner that is selectively 
advantageous. Mutant p53 has been reported to stimulate multiple receptor tyrosine 
kinases, including EGFR (Ludes-Meyers et al., 1996), IGF1R (Werner et al., 1996), 




with VEGFR2, promote pro-proliferative signaling. As a tumor forms, acquisition of a 
hotspot mutation in TP53 may facilitate transcriptional plasticity, whereby tumor cells 
increase capacity for gene expression changes and therefore undergo selection for the 
greatest pro-proliferative transcriptional program for the particular tumor context. This 
hypothesis explains, for instance, why such a wide array of genes and pathways has 
been reported to mediate mutant p53 gain of function.  
 One example from this work involves VEGF pathway signaling. TP53 mutation 
facilitates the angiogenic switch by de-repressing HIF1A and VEGFA expression 
(Mukhopadhyay et al., 1995; Ravi et al., 2000), promoting expression of pro-angiogenic 
factors that enhance tumor angiogenesis, growth, and metastatic potential (Folkman, 
2002). Our data suggest that p53 hotspot mutants may be selected over loss of function 
p53 mutants during the progression of breast cancer in part due to the advantages 
conferred by cell-autonomous VEGFR2 signaling. SWI/SNF activity is required for 
mutant p53-mediated VEGFR2 expression, and our data also suggest that TP53 
mutated tumors may respond to anti-VEGF pathway drugs.  
Specific mutant p53 domains are either required or dispensible to mutant p53 
target gene activation, and the mechanisms of this regulation are incompletely defined 
(Table 1.1). It is imperative to investigate domain-specific p53 interactions in order to 
understand mechanistically how p53 regulates various genes as well as to integrate 
new findings in the context of previous literature. Mutant p53 likely mediates 
transcription by co-opting sets of transcription factors to initiate gene activation at the 
transcription factor’s location. Co-activators recruited by the transcription factor or 




individual transcription factors for target gene activation is unclear and likely dependent 
on the specific mutation in p53 and the active cell signaling pathways leading to subsets 
of active transcription factors in the cell. It is also possible that mutant p53, following 
recruitment by a transcription factor or chromatin modulator, recruits additional factors 
that can stimulate the function of the initial recruiting factor. 
Wild-type p53 is known to direct transcription through interaction with the 
Mediator complex (Meyer et al., 2010; Zhang et al., 2005). The pre-initiation complex is 
composed of the Mediator complex, the general transcription factors TFII-A, -B, -D, -E, -
F, and -H, and RNA polymerase II (Esnault et al., 2008; Roeder, 1996). The human 
Mediator complex interacts directly with TFIID in the process of forming the pre-initiation 
complex (Johnson et al., 2002). p53 has been reported to interact with various Mediator 
components (Gu et al., 1999), including Med17 (TRAP80)(Ito et al., 1999) and Med1 
(RB18A)(Drane et al., 1997; Meyer et al., 2010). Med17 interacts with p53 TAD1 (Ito et 
al., 1999) and Med1 interacts with the p53 CTD (mapped to residues 363-393) (Meyer 
et al., 2010). Interestingly, increasing titrations of Med1 lead to decreased p53-
dependent p21 expression and increased p53-dependent Bax expression (Frade et al., 
2000) and increased MDM2 expression (Frade et al., 2002). Notably, the D5 domain of 
Med1 has been reported to interact with mutant p53 in Raji lymphoma cells (R213Q, 
Y234H), although this interaction has not been reviewed by the mutant p53 literature 
nor subsequently reported on through this point in time (Lottin-Divoux et al., 2005).  
Further studies should investigate the role of the Mediator complex in mediating 
mutant p53 gain of function. It is likely that the Mediator complex is necessary to 




The extent that mutant p53 may interact with and regulate the Mediator complex will be 
the basis for many further studies. The reason this is critically important is that protein-
protein interactions with mutant p53 do not exist in cells that do not have mutant p53. If 
a protein is found that is required for mutant p53 gene transactivation, then an 
intervention could be developed for the mutant p53-protein complex that would only 
exist in cells expressing mutant p53 gain of function mutants. 
 
Anti-VEGF Therapy in TP53 Mutant Breast Cancer 
It is an exciting observation that TP53 status may predict response to anti-VEGF 
therapies in breast cancer (Chapter 2). Needless to say, larger and more 
comprehensive clinical trials must be conducted in order to define an effect. 
Furthermore, these data must be stratified by TP53 mutation types, which will require 
large patient cohorts. To improve the confidence in this hypothesis, mouse models 
should be considered. It would be optimal to generate breast tissue-specific conditional 
VEGFR2 knockout mice to study in different p53 genetic backgrounds. A more feasible 
alternative would be to study the extent that in vivo knockdown of VEGFR2 affects 
tumor growth, metastasis, and survival in xenotransplants of breast tumor cells 
expressing inducible short hairpin RNAs to deplete VEGFR2. Other models of VEGFR2 
inhibition such as pharmacological inhibition or VEGF antagonism affect the tumor 
vasculature, so the impact of autocrine VEGFR2 signaling on tumorigenesis can be 
isolated. Tumor cell-specific depletion of VEGFR2 on the other hand would be restricted 
to the tumor cells. This could be compared to mutant p53 depleted cells. The proposed 




implication that cancers with enhanced autocrine VEGFR2 signaling will respond more 
favorably to anti-VEGF treatments than cancers that do not have high epithelial 
VEGFR2 expression. 
It is also possible to investigate the mechanisms in which VEGFR2 affects cell 
growth. We observed that VEGFR2 knockdown prevents optimal cell growth, and this 
could occur through decreased cellular proliferation, increased apoptosis, increased 
cellular senescence, or a combination of these mechanisms. Interestingly, withdrawal of 
VEGF has been shown to shift tumor cells into a senescent state (Hasan et al., 2011). It 
is also important to examine the cell signaling changes mediated by mutant p53 and 
VEGFR2. Such experiments could include extensive immunoblotting for the PI3K, 
MAPK, FAK, and PKC signal cascades in the presence and absence of mutant p53 and 
VEGFR2. It is always important to consider expressing a potential phenotype-mediating 
gene in a rescue model to have more confidence in an observation, so VEGFR2 could 
be re-introduced in the absence of mutant p53 (as in Figure 2.3A-C).  
It would be informative to analyze the gene expression changes that occur upon 
VEGFR2 inhibition (or other mutant p53 implicated receptor tyrosine kinases) and 
compare these to mutant p53 depletion. It is likely that VEGFR2 signaling mediates 
some of the oncogenic gene expression changes mediated by mutant p53. Because 
VEGFR2 inhibition by itself is enough to restrict growth of mutant p53-expressing breast 
cancer cells, it is important to identify any coordinating factors that may mediate this 
effect. Such a factor may be common in multiple mutant p53-upregulated signaling 
pathways (eg: by EGFR or MET). This potential factor could then be specifically 





 TP53 is among the most important genes in cancer. However, it cannot continue 
to be primarily studied without consideration to other mechanisms taking place in the 
cell. New hypotheses regarding mutant p53 function should be derived from large 
databases of mutations in human cancer. Synthetic lethal shRNA screens will be 
increasingly important in identifying proteins that cooperate with mutant p53 or other 
oncogenes. Cell biological studies should take account what exists in the clinical 
literature so that the time from bench to bedside is reduced. The goal is that selection 
criteria for therapeutics may be pre-selected for an individual with specific alterations in 
certain genes. Clinical trials must increasingly obtain genetic information from patients 
and consult the scientific literature to understand which subsets of patients could most 
benefit from a particular drug and then adjust the clinical trial criteria for those genetic 
subtypes. There is much to be said about increasing collaboration between these areas. 
Oncology is headed toward highly adaptable treatment regimens based on the 
particular genetic alterations of a tumor. Defining the contributions of mutant p53 and 
VEGFR2 to breast cancer tumorigenicity are likely to be critical steps toward identifying 
specific tumor alterations that can be therapeutically harnessed. Outstanding questions 
include how SWI/SNF and mutant p53 positively regulate each other via recruitment of 
p53 to promoters and how the ensuing functional activation of promoter remodeling 
occurs. Future directions also include testing the feasibility of development of small 
molecules to interrupt the mutant p53-SWI/SNF interaction to impede mutant p53 gain 
of function activities. Finally, whether patients with mutant p53-expressing breast tumors 















































Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., 
Bobisse, S., Rondina, M.B., Guzzardo, V., et al. (2009). A Mutant-p53/Smad complex 
opposes p63 to empower TGFbeta-induced metastasis. Cell 137, 87-98. 
 
Alsner, J., Jensen, V., Kyndi, M., Offersen, B.V., Vu, P., Borresen-Dale, A.L., and 
Overgaard, J. (2008). A comparison between p53 accumulation determined by 
immunohistochemistry and TP53 mutations as prognostic variables in tumours from 
breast cancer patients. Acta Oncol 47, 600-607. 
 
Bossi, G., Lapi, E., Strano, S., Rinaldo, C., Blandino, G., and Sacchi, A. (2006). Mutant 
p53 gain of function: reduction of tumor malignancy of human cancer cell lines through 
abrogation of mutant p53 expression. Oncogene 25, 304-309. 
 
Bossi, G., Marampon, F., Maor-Aloni, R., Zani, B., Rotter, V., Oren, M., Strano, S., 
Blandino, G., and Sacchi, A. (2008). Conditional RNA interference in vivo to study 
mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle 7, 1870-1879. 
 
Brosh, R., and Rotter, V. (2009). When mutants gain new powers: news from the 
mutant p53 field. Nat Rev Cancer 9, 701-713. 
 
Burrows, A.E., Smogorzewska, A., and Elledge, S.J. (2010). Polybromo-associated 
BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 
required for induction of replicative senescence. Proc Natl Acad Sci U S A 107, 14280-
14285. 
 
Do, P.M., Varanasi, L., Fan, S., Li, C., Kubacka, I., Newman, V., Chauhan, K., Daniels, 
S.R., Boccetta, M., Garrett, M.R., et al. (2012). Mutant p53 cooperates with ETS2 to 
promote etoposide resistance. Genes Dev 26, 830-845. 
 
Drane, P., Barel, M., Balbo, M., and Frade, R. (1997). Identification of RB18A, a 205 
kDa new p53 regulatory protein which shares antigenic and functional properties with 
p53. Oncogene 15, 3013-3024. 
 
Elledge, R.M., Fuqua, S.A., Clark, G.M., Pujol, P., Allred, D.C., and McGuire, W.L. 
(1993). Prognostic significance of p53 gene alterations in node-negative breast cancer. 
Breast Cancer Res Treat 26, 225-235. 
 
Esnault, C., Ghavi-Helm, Y., Brun, S., Soutourina, J., Van Berkum, N., Boschiero, C., 
Holstege, F., and Werner, M. (2008). Mediator-dependent recruitment of TFIIH modules 







Espinosa, J.M., and Emerson, B.M. (2001). Transcriptional regulation by p53 through 
intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 8, 57-
69. 
 
Euskirchen, G.M., Auerbach, R.K., Davidov, E., Gianoulis, T.A., Zhong, G., Rozowsky, 
J., Bhardwaj, N., Gerstein, M.B., and Snyder, M. (2011). Diverse roles and interactions 
of the SWI/SNF chromatin remodeling complex revealed using global approaches. 
PLoS Genet 7, e1002008. 
 
Folkman, J. (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol 
29, 15-18. 
 
Frade, R., Balbo, M., and Barel, M. (2000). RB18A, whose gene is localized on 
chromosome 17q12-q21.1, regulates in vivo p53 transactivating activity. Cancer Res 60, 
6585-6589. 
 
Frade, R., Balbo, M., and Barel, M. (2002). RB18A regulates p53-dependent apoptosis. 
Oncogene 21, 861-866. 
 
Freed-Pastor, W.A., Mizuno, H., Zhao, X., Langerod, A., Moon, S.H., Rodriguez-
Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012). Mutant p53 
disrupts mammary tissue architecture via the mevalonate pathway. Cell 148, 244-258. 
 
Gu, W., Malik, S., Ito, M., Yuan, C.X., Fondell, J.D., Zhang, X., Martinez, E., Qin, J., and 
Roeder, R.G. (1999). A novel human SRB/MED-containing cofactor complex, SMCC, 
involved in transcription regulation. Mol Cell 3, 97-108. 
 
Guan, B., Wang, T.L., and Shih Ie, M. (2011). ARID1A, a factor that promotes formation 
of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic 
cancers. Cancer Res 71, 6718-6727. 
 
Hasan, M.R., Ho, S.H., Owen, D.A., and Tai, I.T. (2011). Inhibition of VEGF induces 
cellular senescence in colorectal cancer cells. Int J Cancer. 
 
Haupt, S., di Agostino, S., Mizrahi, I., Alsheich-Bartok, O., Voorhoeve, M., Damalas, A., 
Blandino, G., and Haupt, Y. (2009). Promyelocytic leukemia protein is required for gain 
of function by mutant p53. Cancer Res 69, 4818-4826. 
 
Hoffman, G.R., Rahal, R., Buxton, F., Xiang, K., McAllister, G., Frias, E., Bagdasarian, 
L., Huber, J., Lindeman, A., Chen, D., et al. (2014). Functional epigenetics approach 
identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. 







Ito, M., Yuan, C.X., Malik, S., Gu, W., Fondell, J.D., Yamamura, S., Fu, Z.Y., Zhang, X., 
Qin, J., and Roeder, R.G. (1999). Identity between TRAP and SMCC complexes 
indicates novel pathways for the function of nuclear receptors and diverse mammalian 
activators. Mol Cell 3, 361-370. 
 
Johnson, K.M., Wang, J., Smallwood, A., Arayata, C., and Carey, M. (2002). TFIID and 
human mediator coactivator complexes assemble cooperatively on promoter DNA. 
Genes Dev 16, 1852-1863. 
 
Kadoch, C., Hargreaves, D.C., Hodges, C., Elias, L., Ho, L., Ranish, J., and Crabtree, 
G.R. (2013). Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes 
identifies extensive roles in human malignancy. Nat Genet 45, 592-601. 
 
Kwon, S.J., Park, J.H., Park, E.J., Lee, S.A., Lee, H.S., Kang, S.W., and Kwon, J. 
(2014). ATM-mediated phosphorylation of the chromatin remodeling enzyme BRG1 
modulates DNA double-strand break repair. Oncogene. 
 
Langerod, A., Zhao, H., Borgan, O., Nesland, J.M., Bukholm, I.R., Ikdahl, T., Karesen, 
R., Borresen-Dale, A.L., and Jeffrey, S.S. (2007). TP53 mutation status and gene 
expression profiles are powerful prognostic markers of breast cancer. Breast Cancer 
Res 9, R30. 
 
Laptenko, O., Beckerman, R., Freulich, E., and Prives, C. (2011). p53 binding to 
nucleosomes within the p21 promoter in vivo leads to nucleosome loss and 
transcriptional activation. Proc Natl Acad Sci U S A 108, 10385-10390. 
 
Lee, D., Kim, J.W., Seo, T., Hwang, S.G., Choi, E.J., and Choe, J. (2002). SWI/SNF 
complex interacts with tumor suppressor p53 and is necessary for the activation of p53-
mediated transcription. J Biol Chem 277, 22330-22337. 
 
Lim, L.Y., Vidnovic, N., Ellisen, L.W., and Leong, C.O. (2009). Mutant p53 mediates 
survival of breast cancer cells. Br J Cancer 101, 1606-1612. 
 
Lottin-Divoux, S., Barel, M., and Frade, R. (2005). RB18A enhances expression of 
mutant p53 protein in human cells. FEBS Lett 579, 2323-2326. 
 
Ludes-Meyers, J.H., Subler, M.A., Shivakumar, C.V., Munoz, R.M., Jiang, P., Bigger, 
J.E., Brown, D.R., Deb, S.P., and Deb, S. (1996). Transcriptional activation of the 
human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 16, 
6009-6019. 
 
Meyer, K.D., Lin, S.C., Bernecky, C., Gao, Y., and Taatjes, D.J. (2010). p53 activates 
transcription by directing structural shifts in Mediator. Nature structural & molecular 





Mukhopadhyay, D., Tsiokas, L., and Sukhatme, V.P. (1995). Wild-type p53 and v-Src 
exert opposing influences on human vascular endothelial growth factor gene 
expression. Cancer Res 55, 6161-6165. 
 
Muller, P.A., Caswell, P.T., Doyle, B., Iwanicki, M.P., Tan, E.H., Karim, S., Lukashchuk, 
N., Gillespie, D.A., Ludwig, R.L., Gosselin, P., et al. (2009). Mutant p53 drives invasion 
by promoting integrin recycling. Cell 139, 1327-1341. 
 
Muller, P.A., Trinidad, A.G., Timpson, P., Morton, J.P., Zanivan, S., van den Berghe, 
P.V., Nixon, C., Karim, S.A., Caswell, P.T., Noll, J.E., et al. (2013). Mutant p53 
enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 
32, 1252-1265. 
 
Naidu, S.R., Love, I.M., Imbalzano, A.N., Grossman, S.R., and Androphy, E.J. (2009). 
The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 
necessary for proliferation of malignant cells. Oncogene 28, 2492-2501. 
 
Oh, J., Sohn, D.H., Ko, M., Chung, H., Jeon, S.H., and Seong, R.H. (2008). BAF60a 
interacts with p53 to recruit the SWI/SNF complex. J Biol Chem 283, 11924-11934. 
 
Olivier, M., Langerod, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., 
Rodriguez, C., Lidereau, R., Bieche, I., et al. (2006). The clinical value of somatic TP53 
gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12, 1157-1167. 
 
Petitjean, A., Achatz, M.I., Borresen-Dale, A.L., Hainaut, P., and Olivier, M. (2007). 
TP53 mutations in human cancers: functional selection and impact on cancer prognosis 
and outcomes. Oncogene 26, 2157-2165. 
 
Preuss, U., Kreutzfeld, R., and Scheidtmann, K.H. (2000). Tumor-derived p53 mutant 
C174Y is a gain-of-function mutant which activates the fos promoter and enhances 
colony formation. Int J Cancer 88, 162-171. 
 
Quante, T., Otto, B., Brazdova, M., Kejnovska, I., Deppert, W., and Tolstonog, G.V. 
(2012). Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions 
of active genes and generates transcriptional plasticity. Cell Cycle 11, 3290-3303. 
 
Ravi, R., Mookerjee, B., Bhujwalla, Z.M., Sutter, C.H., Artemov, D., Zeng, Q., Dillehay, 
L.E., Madan, A., Semenza, G.L., and Bedi, A. (2000). Regulation of tumor angiogenesis 
by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14, 34-44. 
 
Roeder, R.G. (1996). Nuclear RNA polymerases: role of general initiation factors and 
cofactors in eukaryotic transcription. Methods Enzymol 273, 165-171. 
 
Scian, M.J., Stagliano, K.E., Deb, D., Ellis, M.A., Carchman, E.H., Das, A., Valerie, K., 
Deb, S.P., and Deb, S. (2004). Tumor-derived p53 mutants induce oncogenesis by 




Strano, S., Fontemaggi, G., Costanzo, A., Rizzo, M.G., Monti, O., Baccarini, A., Del Sal, 
G., Levrero, M., Sacchi, A., Oren, M., et al. (2002). Physical interaction with human 
tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277, 18817-18826. 
 
Strobeck, M.W., Knudsen, K.E., Fribourg, A.F., DeCristofaro, M.F., Weissman, B.E., 
Imbalzano, A.N., and Knudsen, E.S. (2000). BRG-1 is required for RB-mediated cell 
cycle arrest. Proc Natl Acad Sci U S A 97, 7748-7753. 
 
Tolstorukov, M.Y., Sansam, C.G., Lu, P., Koellhoffer, E.C., Helming, K.C., Alver, B.H., 
Tillman, E.J., Evans, J.A., Wilson, B.G., Park, P.J., et al. (2013). Swi/Snf chromatin 
remodeling/tumor suppressor complex establishes nucleosome occupancy at target 
promoters. Proc Natl Acad Sci U S A 110, 10165-10170. 
 
Weissmueller, S., Manchado, E., Saborowski, M., Morris, J.P., Wagenblast, E., Davis, 
C.A., Moon, S.H., Pfister, N.T., Tschaharganeh, D.F., Kitzing, T., et al. (2014). Mutant 
p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor 
beta Signaling. Cell 157, 382-394. 
 
Werner, H., Karnieli, E., Rauscher, F.J., and LeRoith, D. (1996). Wild-type and mutant 
p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. 
Proc Natl Acad Sci U S A 93, 8318-8323. 
 
Wilson, B.G., Helming, K.C., Wang, X., Kim, Y., Vazquez, F., Jagani, Z., Hahn, W.C., 
and Roberts, C.W. (2014). Residual complexes containing SMARCA2 (BRM) underlie 
the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol 34, 1136-1144. 
 
Wilson, B.G., and Roberts, C.W. (2011). SWI/SNF nucleosome remodellers and cancer. 
Nat Rev Cancer 11, 481-492. 
 
Xia, W., Nagase, S., Montia, A.G., Kalachikov, S.M., Keniry, M., Su, T., Memeo, L., 
Hibshoosh, H., and Parsons, R. (2008). BAF180 is a critical regulator of p21 induction 
and a tumor suppressor mutated in breast cancer. Cancer Res 68, 1667-1674. 
 
Xu, Y., Zhang, J., and Chen, X. (2007). The activity of p53 is differentially regulated by 
Brm- and Brg1-containing SWI/SNF chromatin remodeling complexes. J Biol Chem 282, 
37429-37435. 
 
Yan, W., and Chen, X. (2009). Identification of GRO1 as a critical determinant for 
mutant p53 gain of function. J Biol Chem 284, 12178-12187. 
 
Yan, W., Liu, G., Scoumanne, A., and Chen, X. (2008). Suppression of inhibitor of 
differentiation 2, a target of mutant p53, is required for gain-of-function mutations. 






Zhang, X., Krutchinsky, A., Fukuda, A., Chen, W., Yamamura, S., Chait, B.T., and 
Roeder, R.G. (2005). MED1/TRAP220 exists predominantly in a TRAP/ Mediator 
subpopulation enriched in RNA polymerase II and is required for ER-mediated 
transcription. Mol Cell 19, 89-100. 
 
